Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED]
26-Feb-2018 Document Date:  A Study to Assess the Pharmacokinetics of Midazolam, Dabigatran, 
Pi[INVESTIGATOR_2830], Atorvastatin, and Rosuvastatin Administered as 
Microdoses in Subjects With Varying Degrees of Renal 
Insufficiency in the Presence and Absence of Rifampin
  
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202894] No.:  CA21 005 
 
[COMPANY_006] Protocol No.:  MK-0000-386-02 
 
  
A Study  to Assess the Pharmacokinetics of Midazolam, Dabigatran, Pi[INVESTIGATOR_2830], 
Atorvastatin, and Rosuvastatin Administered as Microdoses in Subjects With Varying 
Degrees of Renal Insufficiency in the Presence and Absence of Rifampin  
  
 
  
 
 
 
  
 
 
 
  
 
 
Compliance Statement  
[COMPANY_006] clinical studies will be conducted in compliance with local and/or national 
regulations and in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki.  
 
Confidentiality Statement 
This document is confidential. It contains proprietary information of [COMPANY_006]. Any 
viewing or disclosure of such infor mation that is not authorized in writing by [CONTACT_173588]. Such information may be used solely for the purpose of reviewing 
or performing this study.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202895] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 2 
CONFIDENTIAL  
1 PROTOCOL REVISION HISTORY  
Date/Name  [CONTACT_62578]  
26Feb2018 
 Amendment 2, Final Protocol for review 
This protocol amendment is being written because changes or 
corrections are required to the biomarker and pharmacokinetic 
blood sampling and processing and urine collection as described in 
the protocol.  
As a result of the amendment, the following sections of the protocol 
were updated (in bold  for addition and strikethrough for deletion):  
1. Appendix 6, Sample Handling Instructions for Midazolam and Dabigatran Samples: Updated  instructions. 
2. Appendix 9: Specimen Collection Procedures – 
Plasma and 
Serum Biomarkers: Added or updated procedures . 
3. Appendix 10: Sample Handling Instructions for Urine 
Collection (Biomarkers): Added or updated instructions. 
19Dec2017 
 Amendment 1, Final Protocol for review  
This protocol amendment is being written because changes or 
corrections are required to the biomarker and pharmacokinetic 
blood sampling and processing and urine collection as described in 
protocol.  
In addition, a few other clarifications to the st udy conduct were 
incorporated into the protocol. As a result of the amendment, the following sections of the protocol 
were updated (in bold  for addition and strikethrough for deletion):  
1. Section 6, Flow Chart, the row “Blood for Plasma Total and 
Direct Bilirubin (P1 & P2)” changed to : “Blood for Serum  
Total and Direct Bilirubin (P1 & P2) (Central Lab) .” 
2. Section 6, Flow Chart, the row “Blood for Serum Creatinine 
(P1 & P2)” changed to : “Blood for Serum Creatinine  (P1 & 
P2) (Central Lab) .” 
3. Section 6, Flow Chart, footer g changed to: “To be performed 
in Period 1 only. Note: For protein binding, it will be analysed  
  04VMX7
[COMPANY_003]
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202896] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 3 
CONFIDENTIAL  
as part of the biomarker sample. ” 
4. Section 8.1.3, Exploratory Objectives, Section 8.2, Analysis 
Endpoints, Biomarkers, and c orresponding sections in the 
synopsis (Exploratory Objectives and Key Assessments, 
Biomarkers): In these sections, reference to “plasma 
biomarkers” or “plasma and urinary biomarkers” was changed 
to include reference to plasma , serum and urine  biomarkers, 
and Appendix  9: Specimen Collection Procedure – “Plasma 
Biomarkers” changed to:   “…Plasma and Serum  Biomarkers.”  
5. Section 5, Synopsis, Biomarkers, Section 6, Study Events Flow 
Chart, Footer ‘t”, Section 8.2, Analysis Endpoints, Biomarkers, 
and Section 10.2.2, Urine Collection: Urine creatinine as a 
biomarker has been removed from the urine sample analysis, 
thus these sections changed to  remove urine creatinine: “ Urine 
creatinine will also be measured [central lab] in addition to 
coproporhyrin I and III, p- cresol sulfate, indoxyl sulfate, and 
CMPF. ” or “urine creatinine  (clinical laboratory) ” or 
“creatinine ”, as appriopriate.   
6. Section [IP_ADDRESS], Inclusion Criteria, Subjects with Renal 
Impairment, Inclusion Criterion #2:  updated to include note: 
“A female must be non -pregnant, non- breast feeding and if she 
is of reproductive potential: must demonstrate a serum β-human chor ionic gonadotropin (β –
hCG) level consistent with 
the nongravid state at screening (Note: if a subject has a β –
hCG level that is not consistent with the non- gravid state 
due to disease or medication, the investigators may consult 
with the sponsor to obtai n approval to enroll the subject in 
the study)  and…”  
7. Section [IP_ADDRESS], Exclusion Criteria, Subjects with Renal 
Impairment, Exclusion Criterion #7:  updated to allow 
cholecystectomy : “Subject with a history of significant 
endocrine (other than T2DM), gastro intestinal, cardiovascular, 
hematological, immunological, respi[INVESTIGATOR_696], or genitourinary 
diseases whose current condition is considered clinically 
unstable in the opi[INVESTIGATOR_66678] .  
Subjects who have had a cholecystectomy may be allowed.” 
8. Section 9.4.1, Treatments Administered: Added records: 
“Treatment A will be supplied as microdose cocktail. See 
Table 2. Oral solutions for Treatment  A will be prepared and 
stored according to the Method of Preparation Manual and 
Master Batch Records provided separately,” and c larified the 
water given with dosing: “Subjects will drink one container of 
approximately 240 mL of water after each complete  dosing  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202897] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 4 
CONFIDENTIAL  
completion .”  
9. Section 10.5, Blood Volume Drawn for Study Assessments, 
Table 4: The following changes were made: 
1. corrected the number of on- study hematology and serum 
chemistry from “6” to “4” timepoints during the study , 
2. biomarker blood samples for total and direct bili rubin and 
creatinine will be processed for serum (instructions 
added/updated in revised Appendix 9),  
3. blood samples for other plasma biomarkers and uremic 
toxins are now detailed in the table  (instructions 
added/updated in revised Appendix 9), 
4. a separate  sample will now be collected for biomarker 
plasma coproporhyrin I and III ( instructions added/updated 
in revised Appendix 9),  
5. the blood collected for most pharmacokinetic samples will 
be reduced,  
6. a separate sample will now be collected for protein bindi ng 
(and footer was updated ; instructions added in revised 
Appendix 9),  
7. an additional column was added to the table to identify the 
“Handling Instructions” and relevant appendix, and 
8. the volume per timepoint  and sample volume over the 
course of the study were updated. 
10. Appendix 3, Sample Handling Instructions for Midazolam and 
Dabigatran Samples : Updated.  
11. Appendix 4, Sample Handling Instructions for Pi[INVESTIGATOR_2830], 
Atorvastatin (and metabolites), and Rosuvastati n Samples: 
Updated. 
12. Appendix 5, Sample Handling Instructions for Rifampin 
Samples: Updated.  
13. Appendix 6, Sample Handling Instructions for Midazolam and Dabigatran Samples: Updated.  
14. Appendix 8: Medications allowed as per protocol  
and Section 
9.3.1, Prohibitions and Concomitant Therapy: Added: “ Proton 
Pump inhibitors: Note:  Proton pump inhibitors must be 
withheld [ADDRESS_202898] 
dosing.” Corrected to be consistent with medications 
contraindicated for this study to remove “glyburide” from the 
medications allowed as per protocol: “Medications for 
treatment of diabetes such as insulin, sulfonylureas (e.g., 
tolbutamide, glipi[INVESTIGATOR_7130], glyburide,  glimepi[INVESTIGATOR_14956], metformin,  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202899] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 5 
CONFIDENTIAL  
saxagliptin, sitagliptin), meglitinides (e.g., repaglinide, 
nateglinide ), thiazolidinediones, dipeptidyl peptidase -4 
inhibitors, and glucagon-like peptide- 1 analogs.”  
15. Appendix 9: Specimen Collection Procedures – Plasma and 
Serum Biomarkers: Added or updated  instructions for serum 
total and direct bilirubin , serum creatinine, other biomarkers 
and uremic toxins, and  for plasma coproporhyrin I and III . 
16. Appendix 10: Sample Handling Instructions for Urine 
Collection (Biomarkers): Added clarification for urine 
collection for pharmacokinetic and biomarker samples  and 
updated instructions.  
08Sep2017 
 Final  Protocol 
    
  04VMX7
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202900] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 6 
CONFIDENTIAL  
2 PRINCIPAL INVESTIGATOR [INVESTIGATOR_78411] – SIGNATORIES  
A Study to Assess the Pharmacokinetics of Midazolam, Dabigatran, Pi[INVESTIGATOR_2830], 
Atorvastatin, and Rosuvastatin Administered as Microdoses in Subjects With Varying 
Degrees of Renal Insufficiency in the Presence and Absence of Rifampin  
 
SPONSOR:  [COMPANY_006] Sharp & Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. 
(hereafter referred to as the Sponsor or [COMPANY_006]) 
One [COMPANY_006] Drive  
[PO_BOX] 
Whitehouse Station, N ew Jersey , [ZIP_CODE] -0100 , [LOCATION_003]  
 
SPONSOR’S  
REPRESENTATIVE:  
 
Merc
k & Co., Inc.  
RY34 -A500 
[ADDRESS_202901], New Jersey [ZIP_CODE], [LOCATION_003] Tel.:   
E-mail:    
   
 Signature   [CONTACT_121313] S 
AND CLINICAL S 
  
Orlando Clinical Research Center  
[ADDRESS_202902] Orlando, [LOCATION_012] [ZIP_CODE], [LOCATION_003] Tel.:   
E-mail:   
   
 Signature  
  [CONTACT_173634], Inc.  
[ADDRESS_202903]  
Miami, [LOCATION_012] [ZIP_CODE], [LOCATION_003] Tel.:   
E-mail:     
    
 Signature   [CONTACT_1782]     
  04VMX7
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202904] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202905] 
Montreal, Quebec H4M 2N8, Canada  
Tel.:  
 
E-mail:   
 
Certified Clinical Laboratory  Reliable Research Laboratory  
[ADDRESS_202906]:    
Tel.:   
E-mail:   
 
Pharmacokinetic and Statistical Analyses  Celerion  
[ADDRESS_202907] Montreal, Quebec H4M 2N8, Canada  
Tel.:  
 
 and/or  Celerion  
[ADDRESS_202908], Nebraska [ZIP_CODE], [LOCATION_003] Tel.:  
 
 
    
  04VMX7
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202909] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 8 
CONFIDENTIAL  
4 TABLE OF CONTENTS  
1 PROTOCOL REVISION HISTORY  .......................................................................................... 2 
2 PRINCIPAL INVESTIGATOR [INVESTIGATOR_78411] – SIGNATORIES  ...................................... 6 
3 ADDITIONAL KEY CONTACTS FOR THE STUDY ............................................................. 7 
4 TABLE OF CONTENTS  .............................................................................................................. 8 
5 SYNOPSIS .................................................................................................................................... 12 
6 STUDY EVENTS FLOW CHART  ............................................................................................ 20 
7 BACKGROUND AND RATIONALE  ....................................................................................... 23 
7.1 Background .......................................................................................................................... 23 
7.1.1  Midazolam  ............................................................................................................ 23 
7.1.2  Dabiga tran ............................................................................................................. 24 
7.1.3  Atorvastatin  ........................................................................................................... 25 
7.1.4  Pi[INVESTIGATOR_2830]  ............................................................................................................ 26 
7.1.5  Rosuvastatin  .......................................................................................................... 27 
7.1.6  Rifampin  ................................................................................................................ 28 
7.2 Rationale  ............................................................................................................................... 29 
7.2.1  Rationale for this Study and Study Design ........................................................... 29 
7.2.2  Rationale for the Dose Selection  ........................................................................... 29 
7.2.3  Rationale for Endpoints ......................................................................................... 31 
7.2.4  Rationale for Planned Exploratory Biomarker Research  ...................................... 31 
7.2.5  Rationale for Future Biomedical Research  ........................................................... 31 
8 STUDY OBJECTIVES, ESTIMATIONS, AND ENDPOINTS  ............................................... 32 
8.1 Objectives and Estimations  .................................................................................................. 32 
8.1.1  Primary  .................................................................................................................. 32 
8.1.2  Secondary Objectives  ............................................................................................ 34 
8.1.3  Exploratory Objectives .......................................................................................... 35 
8.1.4  Planned Exploratory Biomarker ............................................................................ 35 
8.2 Analysis Endpoints ............................................................................................................... 35 
9 INVESTIGATIONAL PLAN ..................................................................................................... 37 
9.1 Overall Study Design and Plan  ............................................................................................. 37 
9.1.1  Confinement, Return Visit, and Follow -up ........................................................... 38 
9.1.2  Study Duration ...................................................................................................... 38 
9.2 Selection of Study Population .............................................................................................. 39 
9.2.1  Inclusion Criteria ................................................................................................... 39 
[IP_ADDRESS]  Subjects with Renal Impairment  ........................................................... 39 
[IP_ADDRESS]  Healthy Subjects  .................................................................................... 41 
9.2.2  Exclusion Criteria ................................................................................................. 42  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202910] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 9 
CONFIDENTIAL  
[IP_ADDRESS]  Subjects with Renal Impairment  ........................................................... 42 
[IP_ADDRESS]  Healthy Subjects  .................................................................................... [ADDRESS_202911] Withdrawal/Discontinuation Criteria  ....................................................... 46 
[IP_ADDRESS]  Withdrawal/Discontinuation  .................................................................. 46 
[IP_ADDRESS].1  Withdrawal from Future Biomedical Research  ........................ 47 
9.3 Study Restrictions ................................................................................................................. 47 
9.3.1  Prohibitions and Concomitant Therapy................................................................. 47 
9.3.2  Meals  ..................................................................................................................... 49 
9.3.3  Activity  .................................................................................................................. 49 
9.4 Treatments  ............................................................................................................................ 50 
9.4.1  Treatments Administered  ...................................................................................... 50 
9.4.2  Method of Assigning Subjects to Treatment Groups ............................................ 51 
9.4.3  Blinding  ................................................................................................................. 51 
9.4.4  Treatment Compliance .......................................................................................... 51 
9.4.5  Study Design or Procedure Modifications Permitted within Protocol 
Parameters  ............................................................................................................. 51 
10 STUDY PROCEDURES  ............................................................................................................. 52 
10.1  Safety Assessment  ................................................................................................................ 52 
10.1.1  Screening ............................................................................................................... 52 
10.1.2  Physical Examination  ............................................................................................ 52 
10.1.3  Vital Signs  ............................................................................................................. 52 
10.1.4  ECG Monitoring ................................................................................................... 53 
10.1.5  Pulse Oximetry  ...................................................................................................... 53 
10.1.6  Rescue Medication  ................................................................................................ 53 
10.1.7  Clinical Laboratory Tests  ...................................................................................... 54 
10.1.8  Assessing and Recording Adverse Events  ............................................................ 55 
[IP_ADDRESS]  Definition of an Overdose for This Protocol and Reporting of Overdose to the Sponsor ........................................................................ 55 
[IP_ADDRESS]  Reporting of Pregnancy and Lactation to the Sponsor .......................... 56 
[IP_ADDRESS]  Immediate Reporting of Adverse Events ............................................... 56 
[IP_ADDRESS].1  Serious Adverse Events  ............................................................ 56 
[IP_ADDRESS].[ADDRESS_202912]  ........................................................ 58 
[IP_ADDRESS]  Evaluating Adverse Events  .................................................................... 58 
[IP_ADDRESS]  Sponsor Responsibility for Reporting Adverse Events ......................... 61 
10.2  Pharmacokinetic and Biomarker Assessments  ..................................................................... 61 
10.2.1  Blood Sampling and Processing ............................................................................ 61 
10.2.2  Urine Collection  .................................................................................................... 61 
10.3  Planned Genetic Analysis Sample Collection ...................................................................... 62 
10.4  Future Biomedical Research Samples  .................................................................................. 62 
10.5  Blood Volume Drawn for Study Assessments ..................................................................... 63  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202913] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 10 
CONFIDENTIAL  
11 DATA ANALYSIS  ....................................................................................................................... 65 
11.1  Pharmacokinetic Parameters ................................................................................................ 65 
11.1.1  Plasma ................................................................................................................... 65 
11.1.2  Urine ...................................................................................................................... 65 
11.2  Statistical Methods  ............................................................................................................... 66 
11.2.1  Determination of Sample Size  .............................................................................. 66 
11.2.2  Subjects to Analyze  ............................................................................................... 68 
11.2.3  Descriptive Statistics  ............................................................................................. 69 
11.2.4  Analysis Overview  ................................................................................................ 69 
[IP_ADDRESS]  Primary Analyses ................................................................................... 69 
[IP_ADDRESS]  Secondary Analyses ............................................................................... 70 
[IP_ADDRESS]  Exploratory Analyses for Biomarkers ................................................... [ADDRESS_202914] Access to Source Data/Documents  ............................................................................ [ADDRESS_202915] OF APPENDICES  
Appendix 1:  [COMPANY_006]* Code of Conduct for Clinical Trials .......................................................... 79 
Appendix 2:  Collection and Management of Specimens for Future Biomedical Research  ........ 83 
Appendix 3:  Sample Handling Instructions for Midazolam and Dabigatran Samples ................ 88 
Appendix 4:  Sample Handling Instructions for Pi[INVESTIGATOR_2830], Atorvastatin (and 
metabolites), and Rosuvastatin Samples ................................................................ 91  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202916] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 11 
CONFIDENTIAL  
Appendix 5:  Sample Handling Instructions for Rifampin Samples ............................................ 94 
Appendix 6:  Sample Handling Instructions for Urine Collection ( Dabigatran  and 
Rosuvastatin ) .......................................................................................................... 96 
Appendix 7:  PAXgeneTM Blood for DNA Analysis .................................................................... 99 
Appendix 8:  Prohibited and Allowed Medications for Subjects with RI .................................. 103 
Appendix 9:  Specimen Collection Procedure – Plasma and Serum Biomarkers ...................... 105 
Appendix 10:  Sample Handling Instructions for Urine Collection (Biomarkers) ....................... [ADDRESS_202917] OF TABLES  
Table 1:  Study Microdose Cocktail Component Doses: ....................................................... 31 
Table 2:  Study Microdose Cocktail Component Doses ........................................................ 50 
Table 3:  Evaluating Adverse Events ..................................................................................... 59 
Table 4:  Blood Volume Drawn During the Study ................................................................ 63 
Table 5:  Power Calculations for True Fold Increases by [CONTACT_173589]  ...................... 68 
   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202918] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 12 
CONFIDENTIAL  
5 SYNOPSIS 
Compound: Midazolam, dabigatran, pi[INVESTIGATOR_2830], atorvastatin, rosuvastatin, and 
rifampin  
Clinical Indication: N/A 
Study Phase and Type:  Phase I – Other Clinical Study Reports  
Study Objectives and 
Estimation : Primary (Period 1):  
Objective 1:  To characterize the plasma pharmacokinetic profiles of midazolam, dabigatran, 
pi[INVESTIGATOR_2830] (and its metabolite, 
pi[INVESTIGATOR_173507]), atorvastatin (and its metabolites, ortho -
hydroxyatorvastatin [2- OH atorvastatin] and para -
hydroxyatorvastatin [4- OH atorvastatin]), and rosuvastatin 
following a single oral dose administration of a microdose cocktail in healthy subjects , in subjects with mild, moderate, severe ( not on 
dialysis) renal impairment, and in subjects with  end-
stage renal 
disease (ESRD; on dialysis) . 
Estimation 1:  The plasma pharmacokinetic parameters (e.g., 
AUC0 -24, AUC0 -last, AUC0 -∞, Cmax, C24, Tmax, and apparent 
terminal t½) of midazolam, dabigatran, pi[INVESTIGATOR_2830] (and its 
metabolite, pi[INVESTIGATOR_173507]), atorvastatin (and its metabolites, 
2-OH atorvastatin and 4 -OH atorvastatin), and rosuvastatin 
following a single oral dose administration of a microdose cocktail will be estimated in 
healthy subjects, in subjects with mild, 
moderate,  severe (not on dialysis) renal impairment, and in subjects 
with ESRD (on dialysis). 
Primary Objective for Midazolam:  
Objective 2:  To evaluate the effect of a single oral dose of rifampin 
on the single -dose pharmacokinetics of midazolam administered as 
part of a microdose cocktail in each subject population separately 
(except for ESRD subjects). 
Estimation 2:  Plasma AUC0 -∞ of midazolam following a single 
oral dose administration of a microdose cocktail containing 
midazolam, dabigatran etexilate, pi[INVESTIGATOR_2830], atorvastatin, and 
rosuvastatin with a single oral dose of rifampin will be estimated 
and compared to the plasma AUC0- ∞ of midazolam following a 
single oral dose administration of the microdose cocktail alone, in 
each subject population separa tely ( except for ESRD subjects; i.e., 
healthy  subjects and subjects with  mild, moderate, or severe renal 
impairment).   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202919] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 13 
CONFIDENTIAL  
Primary Objective for Dabigatran:  
Objective 3:  To evaluate the effect of a single oral dose of rifampin 
on the single -dose pharmacokinet ics of dabigatran administered as 
part of a microdose cocktail in each subject population separately 
(except for ESRD subjects).  
Estimation 3:  Plasma AUC0 -∞ of dabigatran following a single 
oral dose administration of a microdose cocktail containing  
midazolam, dabigatran etexilate, pi[INVESTIGATOR_2830], atorvastatin, and 
rosuvastatin with a single oral dose of rifampin will be estimated 
and compared to the plasma AUC0- ∞ of dabigatran following a 
single oral dose administration of the microdose cocktail alone,  in 
each subject population separately (except for ESRD subjects; i.e., healthy  subjects and subjects with  mild, moderate, or severe renal 
impairment).  
Primary Objective for Pi[INVESTIGATOR_2830]: 
Objective 4:  To evaluate the effect of a single oral dose of rifampin 
on the single -dose pharmacokinetics of  
pi[INVESTIGATOR_2830] (and its 
metabolite, pi[INVESTIGATOR_173507]) administered as part of a microdose 
cocktail in each subject population separately (except for ESRD 
subjects).  
Estimation 4:  Plasma AUC0 -∞ of pi[INVESTIGATOR_2830] (and its metabolite 
pi[INVESTIGATOR_173507]) following a single oral dose administration of a 
microdose cocktail containing midazolam, dabigatran etexilate, 
pi[INVESTIGATOR_2830], atorvastatin, and rosuvastatin with a single oral dose of 
rifampin will be e stimated and compared to the plasma AUC0- ∞ of 
pi[INVESTIGATOR_2830] (and its metabolite, pi[INVESTIGATOR_173507]) following a 
single dose administration of the microdose cocktail alone, in each 
subject population separately ( except for ESRD subjects; i.e., 
healthy  subjects and subjects with  mild, moderate, or severe renal 
impairment).  
Primary Objective for Atorvastatin: 
Objective 5:  To evaluate the effect of a single oral dose of rifampin 
on the single -dose pharmacokinetics of  atorvastatin (and its 
metabolites, 2 -OH atorvastatin and 4- OH atorvastatin) administered 
as part of a microdose cocktail in each subject population separately 
(except for ESRD subjects).   
Estimation 5:  Plasma AUC0 -∞ of atorvastatin (and its metabolites, 
2-OH atorvastatin and 4 -OH atorvastatin) following a single oral 
dose administration of a microdose cocktail containing midazolam, 
dabigatran etexilate, pi[INVESTIGATOR_2830], atorvastatin, and rosuvastatin with 
a single oral dose of rifampin will be estimated and co mpared to the  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202920] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 14 
CONFIDENTIAL  
plasma AUC0 -∞ of atorvastatin (and its metabolites, 2 -OH 
atorvastatin and 4- OH atorvastatin) following a single oral dose 
administration of the microdose cocktail alone, in each subject 
population separately (except for ESRD subjects; i.e., healthy  
subjects and subjects with  mild, moderate, or severe renal 
impairment).  
Primary Objective for Rosuvastatin: 
Objective 6:  To evaluate the effect of a single oral dose of rifampin  
on the single -dose pharmacokinetics of rosuvastatin administered as 
part of a microdose cocktail in each subject population separately 
(except for ESRD subjects).  
Estimation 6:  Plasma AUC0 -∞ of rosuvastatin following a single 
oral dose administration of a microdose cocktail containing 
midazolam, dabigatran etexilate, pi[INVESTIGATOR_2830], atorvastatin, and 
rosuvastatin with a single oral dose of rifampin will be estimated 
and compared to the plasma AUC0- ∞ of rosuvastatin following a 
single oral dose administration of the microdose cocktail alone, in 
each subject population separately ( except for ESRD subjects; i.e., 
healthy  subjects and subjects with  mild, moderate, or severe renal 
impairment).  
Secondary  Objectives : 
Objective 1:  To estimate the effect of a single oral dose of rifampin 
on the single oral dose pharmacokinetics ( AUC0 -24, AUC0 -last, 
Cmax, C24, Tmax, apparent terminal t½, CL/F, and Vz/F) of 
midazolam  administered as part of a microdose cocktail in each 
subject population separately (except for ESRD subjects). 
Objective 2:  To estimate the effect of a single oral dos e of rifampin 
on the single oral dose pharmacokinetics ( AUC0 -24, AUC0 -last, 
Cmax, C24, Tmax, apparent terminal t½, CL/F, and Vz/F) of 
dabigatran  administered as part of a microdose cocktail in each 
subject population separately (except for ESRD subjects). Objective 3:  To estimate the effect of a single oral dose of rifampin 
on the single oral dose pharmacokinetics ( AUC0 -24, AUC0 -last, 
Cmax, C24, Tmax, apparent terminal t½, CL/F, and Vz/F) of 
pi[INVESTIGATOR_2830]  (and its metabolite, pi[INVESTIGATOR_173507]) when 
pi[INVESTIGATOR_173508] a microdose cocktail in each 
subject population separately (except for ESRD subjects). Objective 4:  To estimate the effect of a single oral dose of rifampin 
on the single dose pharmacokinetics ( AUC0 -24, AUC0 -last, Cmax,  
C24, Tmax, apparent terminal t½, CL/F, and Vz/F) of atorvastatin  
(and its metabolites, ortho -hydroxyatorvastatin [2 -OH atorvastatin] 
and para -hydroxyatorvastatin [4 -OH atorvastatin]) when  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202921] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202922] population separately (except for ESRD subjects). 
Objective 5:  To estimate the effect of a single oral dose of rifampin 
on the single oral dose pharmacokinetics ( AUC0 -24, AUC0 -last, 
Cmax, C24, Tmax, apparent terminal t½, CL/F, and Vz/F) of 
rosuv astatin  administered as part of a microdose cocktail in each 
subject population separately (except for ESRD subjects). Objective 6:  To compare the magnitude of the drug -drug 
interaction (DDI) between rifampin and each of the 5 substrates in 
the microdose cocktail between h ealthy subjects and each cate gory 
of RI subjects (mild, moderate, severe RI). 
Objective 7:  To estimate the plasma pharmacokinetic parameters 
(e.g., AUC0 -24, AUC0 -last, AUC0 -∞
, Cmax, C24, Tmax, and 
apparent terminal t½) of dabigatran, atorvastatin (and its 
metabolites, 2 -OH atorvastatin and 4 -OH atorvastatin), pi[INVESTIGATOR_2830] 
(and its metabolite, pi[INVESTIGATOR_173507]), rosuvastatin, and 
midazolam following a single oral dose administration of a 
microdose cocktail in ESRD subjects  on dialys is when the 
microdose cocktail is administered at different times relative to 
dialysis . 
Objective 8:  To estimate the plasma pharmacokinetic parameters (e.g., AUC0 -24, AUC0 -last, AUC0 -∞
, Cmax, C24, Tmax, and 
apparent terminal t½) of rifampin  following a si ngle oral dose 
administration with a single oral dose of a microdose cocktail in 
each subject population separately (except for ESRD subjects).  
Exploratory Objectives : 
Objective  1:  To evaluate plasma , serum, and urinary biomarkers to 
assess the impact of renal impairment on functions such as organic 
anion transporting polypeptide ( OATP )1B inhibition. 
Objective  2:  To evaluate the urinary pharmacokinetics (e.g., CLr, 
Ae0-24, and fe) of dabigatran and rosuvastatin in each population. 
Planned Exploratory Biomarker:  
Objective:   To explore the relationship between genetic variation 
and response to the treatment(s) administered, and mechanisms of 
disease. Variation across the human genome may be analy zed for 
association with clinical data collected in this study.  
Summary of Study 
Design:  This is an open label, 2 -period, fixed sequence study in 24 RI 
subjects (6 subjects with mild  renal impairment; 6  subjects with 
moderate renal impairment; 6 subjects with severe renal impairment  
who are not on dialysis; [ADDRESS_202923] subjects) , and 6 healthy control 
subjects.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202924] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202925] 
dosing. Assignment to a renal function group will be as follows: 
Group N eGFR (mL/min/1.73m
2) or CLcr 
(mL/min)*  
ESRD  requiring 
hemodialysis 6 Requiring hemodialysis 
Severe impairment  6 < 30 not on hemodialysis** 
Moderate impairment  6 30 – < 60 *** 
Mild impairment 6 60 - < 90  
Healthy control 6 ≥ 90 **** 
* Estimated glomerular filtration rate (eGFR) based on 
Modification of Diet in Renal Disease (MDRD) equation at 
screening.  Baseline eGFR will be obtained twice during the 
screening period, and the mean of the two values will be used for 
group assignment. The second ba seline eGFR sample may be 
obtained at the time of check -in in Period 1. Creatinine clearance 
(CLcr ) by [CONTACT_3158] -Gault equation will be used for healthy 
control assignment (normal renal function). 
** Reasonable efforts will be made to enroll at least 2 subjects 
with eGFR values of < 20 mL/min/1.73m2. 
*** Reasonable efforts will be made to ensure a broad 
representation across the range of eGFR values of 
30 - < 60 mL/min/1.73m2. 
**** For healthy subje cts a creatinine clearance computed over a 
24 hour urine collection for subjects that do not qualify with 
≥ 90 mL/min CLcr  may be done for confirmation purposes.  
In Period 1, subjects will receive Treatment A, a single oral dose of the microdose  cocktail (i.e., midazolam oral solution, dabigatran 
etexilate and pi[INVESTIGATOR_173509], atorvastatin and rosuvastatin oral solution) on Day 1 followed by [CONTACT_173590] 
72 hours. The microdose cocktail will be dosed  approximately  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202926] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202927] subjects.  
In Period 2, subjects (except ESRD subjects) will receive Treatment 
B, a single oral dose of rifampin capsules with a single oral dose of the microdose cocktail, coadministered on Day 1. 
In Period 2, ESRD subjects will receive only Treatment A, a single 
oral dose of the microdose cocktail on Day 1. The microdose 
cocktail will be dosed as soon as possible within 24 hours after the 
completion of dialysis. In each period, pharmacokinetic samples for plasma midazolam, 
dabigatran (as free dabigatran), pi[INVESTIGATOR_2830], 
pi[INVESTIGATOR_173507], 
atorvastatin, 2- OH atorvastatin, [ADDRESS_202928] subjects (including subjects who 
terminate the study early) using their standard procedures 
approximately [ADDRESS_202929] visit. 
Blinding: This is an open- label study.  
Number of Subjects: Twenty -four (24) RI subjects between 18 and 78 years of age 
(inclusive) will be enrolled; 6 subjects with mild renal impairment; 6 subjects with moderate renal impairment; 6 subjects with severe renal impairment 
who are not on dialysis; and [ADDRESS_202930]  on 
dialysis . A cohort of 6 healthy control subjects will also be enrolled.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202931] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 18 
CONFIDENTIAL  
Dosage, Dosage Form, 
Route, and Dose 
Regimen:  Subjects will receive the following treatments in a fixed -sequence:  
Treatment A (Period 1):   Single oral dose of the microdose 
cocktail at Hour [ADDRESS_202932]. The 
microdose cocktail will contain: 
• 10 μg midazolam (1 mL of 10 μg/mL oral solution), 
administered orally as midazolam hydrochloride (HCl); 
• 375/10 μg dabigatran etexilate and pi[INVESTIGATOR_2830] (1 mL of 375/10 μg/mL oral solution), administered as dabigatran 
etexilate mesylate and pi[INVESTIGATOR_173510]; and  
• 100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 
μg/mL oral solution, dosed as 2 x 1 
mL dosing syringes), 
administered as atorvastatin calcium trihydrate and 
rosuvastatin calcium . 
Each oral solution will be administered using 1 mL  amber 
dosing s yringe s.  
Treatment B (Period 2):   600 mg (2 x 300 mg capsules) single 
oral dose  rifampin  coadministered with a single oral dose 
microdose cocktail (as described in Treatment A) at Hour [ADDRESS_202933].  
NOTE: Subjects with ESRD will not receive rifampin in Period 2; 
they will receive Treatment A in Period 2, instead of Treatment B.  
Key Assessments:  Pharmacokinetics:  
The following plasma pharmacokinetic parameters will be 
calculated for all plasma analytes (rifampin  [Period 2 only] , 
midazolam, dabigatran, pi[INVESTIGATOR_2830], pi[INVESTIGATOR_173511], 
atorvastatin, 4- OH atorvastatin, 2- OH atorvastatin, and 
rosuvastatin) on Day 1 of each treatment period, as appropriate :  
AUC0 -24, AUC0- last, AUC0 -∞, Cmax, C24, Tmax, apparent 
terminal t½, CL/F  (parent only), and Vz/F (parent only).  
The following urine pharmacokinetic parameters may also be 
calculated for rosuvastatin and dabigatran: CLr, Ae0 -24, and fe . 
Protein binding (plasma) assays will be performed on predose 
samples from Period 1. Non-model based descriptive statistics 
of pharmacokinetic 
parameters will be provided by [CONTACT_173591] (midazolam, dabigatran, pi[INVESTIGATOR_2830], pi[INVESTIGATOR_173507], 
atorvastatin, 4- OH atorvastatin, 2- OH atorvastatin, rosuvastatin, 
and rifamp in,) and urine analytes ( dabigatran and rosuvastatin 
only). Separate ANOVA models will be constructed for each 
substrate in the microdose cocktail. AUC0 -∞ will be compared  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202934] No.:  CA21005 
[COMPANY_006]   
 
 CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 19 
CONFIDENTIAL  
between the different groups (except subjects with ESRD) by 
[CONTACT_173592] 95% confidence intervals. 
Similar analyses will be conducted for the following 
pharmacokinetic parameters: AUC0 -24, AUC0- last, Cmax, and 
C24. 
Similar statistical analyses describe above  will be used to compare 
Period [ADDRESS_202935].  
Safety: 
Safety will be monitored through physical examination, vital signs, 
pulse oximetry, 12- lead electrocardiograms (ECGs), adverse events 
and clinical laboratory tests. Summary statistics for the laboratory 
safety tests, 12 -lead ECGs, and/or vital signs may be computed and 
provided, as deemed clinically appropriate. 
Biomarkers:  
The following biomarkers and also uremic toxins will be measured 
to assess OATP1B inhibition: serum total/direct bilirubin , plasma 
coproporhyrin I and III , p-cresol sulfate, indoxyl sulfate, 3-carboxy-
4-methyl-5-propyl-2- furanpropanoic acid  (CMPF) , 
glycodeochycholate- sulfate (GDCA -S), glycochenodeoxycholate-
sulfate (GCDCA -S), deoxycholate -sulfate (DCA -S), 
Taurochenodeoxycholate- sulfate (TCDC -S), and 
Taurodeoxycholate- sulfate (TCDA -S) concentrations and urine 
coproporhyrin I and III, p- cresol sulfate, indoxyl sulfate, and CMPF  
concentrations. 
To evaluate the concentration -time ef fects of perpetrator -mediated 
inhibition of OATP1B, the following parameters will be calculated  
for the biomarkers and uremic toxins  on Day 1 following 
Treatments  A and B:  AUC0 -last, Cmax , Tmax  for plasma 
parameters , and Ae0-24 and fe  for urine  parameters . Measurements 
to assess renal clearance will be performed after a 24 -hour interval 
urine collection .   
A p redose sample will also include measurement of serum 
creatinine (central lab) and may also be used to measure uremic 
toxins/biomarkers (exploratory). 
The exploratory objectives will be evaluated using the same 
statistical models that were used to address the primary objectives. 
Although no formal hypotheses will be tested, these models will be used to estimate the between -group differences amongst each  
substrate/perpetrator combination within a substrate.  
  
  04VMX7
MK-0000    [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202936] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018  Page 20 
CONFIDENTIAL  
6 STUDY EVENTS FLOW CHART  
Study Procedures a Screening b Study Days in Periods 1 (Treatment A) and 2 (Treatment B)  c  FU d 
Days →  -2 or -1  1 2 3 4  
Hours →   (C-I) e P 0 0.25 0.5 1 1.5 2 3 4 6 8 12 16 f 24 32 48 72  
Administrative Procedures                      
Informed Consent  X                    
Informed Consent for Future Biomedical Research  X                    
Inclusion/Exclusion Criteria  X X g                   
Medical History  X                    
Safety Evaluations                      
Full Physical Examination  h X                  X i  
Height  X                    
Weight  X X g                   
Assessment of Renal Function j X                   
12-Lead Electrocardiogram  X  X k                X i  
Vital Signs (heart rate , blood pressure , & respi[INVESTIGATOR_862]) X  X k     X           X i  
Vital Signs (temperature  only) X                    
Pulse Oximetry  l X  X   X X  X  X X         
Hematology, Serum Chemistry m, and Urinalysis  X X                 X i  
Serum Pregnancy Test (female subjects only)  X X                   
Serum FSH (postmenopausal females only)  X                    
Urine or Saliva Drug Screen  X X                   
Urine or Breath Alcohol Screen  X X                   
HIV/Hepatitis Screen  X                    
Adverse Events Monitoring  X X 
Concomitant Medication Monitoring  X  
Study Drug Administration / Pharmacokinetics                      
Microdose Cocktail  Administration  (P1 & P2)     X                 
Rifampin Administration (P2) n    X                 
Blood for Microdose  Pharmacokinetics  (P1 & P2)  o   X  X X X X X X X X X X X X X X X  
Blood for Protein Binding (P1)    X g                  
Blood for Rifampin  Pharmacokinetics  (P2) n   X   X X X X X X X  X  X     
Blood for Serum Total and Direct Bilirubin (P1 & P2)  
(Central Lab)    X   X X  X  X X  X  X      
  04VMX7
MK-0000    [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202937] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018  Page 21 
CONFIDENTIAL  
Study Procedures a Screening b Study Days in Periods 1 (Treatment A) and 2 (Treatment B)  c  FU d 
Days →  -2 or -1  1 2 3 4  
Hours →   (C-I) e P 0 0.25 0.5 1 1.5 2 3 4 6 8 12 16 f 24 32 48 72  
Blood for Serum Creatinine (P1 & P2)  (Central Lab)    X   X X  X  X X  X  X     
Blood for other Biomarkers  (P1 & P2)  p   X q   X X  X  X X  X  X     
Urine Collection for Pharmacokinetics r, s   X X     
Urine Collection for Biomarkers  s, t   X X     
Other Procedures                      
Blood for Genetic Analysis u    X                 
Confinement in the CRU   X  
Visit  X                    
 
a. For details on Procedures, refer to Section  10 and/or corresponding appendices.  
b. Within [ADDRESS_202938] subjects (including subjects who terminate the study early) using their standard procedures approximately [ADDRESS_202939]  visit.  
e. Subjects will be admitted to the CRU  on Day -2 (Orlando clinical site) or Day -1 (Miami clinical site), at the time indicated by [CONTACT_47365] . 
f. The 16 -hour time point following dosing on Day  1 will be either on Day  1 or Day  2, depending on the time of dosing on Day  1. 
g. To be performed in Period 1 only . 
h. A symptom -driven physical examination may be performed at other times, at the Investigator’s discretion.  
i. To be performed on Day [ADDRESS_202940] equation; prior to Period 1, baseline eGFR will be obtained twice (at least [ADDRESS_202941] screening) and averaged. The second baseline eGFR sample may be obtained at the time of check -in in Period 1 . CLcr  by [CONTACT_3158] -Gault equation 
will be used for healthy control assignment (normal renal function).  
k. To be performed w ithin 24  hours prior to  dosing.  
l. Pulse oximetry: oxygen levels and heart rate readings will be performed at screening and prior to dosing (baseline) and will be monitored continuously with a 
pulse oximeter for approximately 6  hours postdose (with the exception of restroom use), with readings taken at approximately the scheduled time points.  
m. Samples for serum chemistry will be obtained follow ing a fast of at least 8 hours; however, in case of dropout s or rechecks, subjects may not have fasted for  
  04VMX7
MK-0000    [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202942] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018  Page [ADDRESS_202943]  will not receive rifampin.  
o. Samples collected for pharmacokinetic measurements of plasma analytes (midazolam, dabigatran, pi[INVESTIGATOR_2830], pi[INVESTIGATOR_173507], atorvastatin, 4 -OH 
atorvastatin, 2 -OH atorvastatin, and rosuvastatin).  
p. Samples collected for the measurement of the following plasma biomarkers  and uremic toxins :  coproporhyrin I and III, p -cresol sulfate, indoxyl sulfate, 
CMPF , GDCA- S, GCDCA -S, DCA -S, TCDC -S, and TCDA -S. Additional biomarkers /uremic toxins may also be measu red.  
q. Predose samples may also be used to measure uremic toxins/biomarkers (exploratory).  
r. Urine collection for pharmacokinetic measurements of dabigatran and rosuvastatin.  
s. Urine collection intervals are: predose (spot collection), 0  - 4 hours, 4 - 8 hours , 8 – [ADDRESS_202944]-dose. For subjects with renal 
impairment , urine samples will be collected whenever possible, as they may not be able to produce urine at each interval.  Note: For subjects who are anuric, 
urine samples will not be collected .  
t. Samples collected for the m easur ement of the following biomarkers and uremic toxins in urine:  coproporhyrin I and III , p-cresol sulfate, indoxyl sulfate, and 
CMPF . Additional biomarkers /uremic toxins may also be measured. 
u. This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. This s ample will not be collected at 
the site if there is either a local law or regulation prohibiting collection, or if the IRB/IEC does  not approve the collection of the sample for these purposes.  If 
the sample is collected, leftover extracted DNA will be stored for future biomedical research if the subject signs the FBR consent. If the planned genetic 
analysis is not approved, but FBR is  approved and consent is given, this sample will be collected for the purpose of FBR.  
Abbreviations:  C-I = Check -in, CLcr = Creatinine clearance, CMPF  = 3- carboxy -4-methyl -5-propyl -2-furanpropanoic acid , CRU  = Clinical research unit, 
DCA-S = D eoxycholate -sulfate , DNA  = Deoxyribonucleic acid, eGFR =  Estimated glomerular filtration rate, ESRD  = End-stage renal disease, FBR  = Future 
biomarker research, FSH = Follicle -stimulating hormone, FU = Follow -Up, GCDCA -S = G lycochenodeoxycholate -sulfate , GDCA-S = G lycodeochycholate -
sulfate , HIV = Human immunodeficiency virus , IRB/IEC  = Institutional Research Board/Independent Ethics Committee, MDRD  = Modification of Diet in Renal 
Disease , OH = Hydroxy, P = Predose , P1 = Period 1, P2 = Period 2 , TCDA -S = T aurodeoxych olate -sulfate , TCDC-S = T aurochenodeoxycholate -sulfate . 
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202945] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 23 
CONFIDENTIAL  
7 BACKGROUND AND RATIONALE  
7.1 Background 
Renal impairment is a well- recognized influence on drug clearance. Both chronic renal 
failure (CRF) and ESRD have been shown to not only reduce the systemic  clearance of drugs 
but also impact protein and tissue binding. 1 While this is to be anticipated with drugs 
typi[INVESTIGATOR_173512], it is also appreciated that CRF can modify non -renal disposition, 
including those typi[INVESTIGATOR_897] ‘handled’ hepatically. Over the years, data has emerged suggesting 
the influence of renal failure on the cytochrome P450 (CYP450) family, but also on transporter function, including hepatic and renal uptake transporters. Alterations in these transporters a s well as drug metabolism pathways may have a meaningful impact on 
predictions and decision- making in drug development. The underlying mechanisms 
responsible for alterations in drug disposition (transporter and enzyme activity) in the setting of renal fail ure remain poorly characterized. While plausible through direct inhibition or 
indirect mediation, tighter predictions remain critical in patients with CRF and ESRD. Current predictive physiologically based pharmacokinetic ( PBPK ) modeling in this setting 
with an array of pathways and substrates remains rudimentary and will be strengthened 
through clinical investigation and subsequent iterative modeling. 
The current study takes advantage of a [COMPANY_006] -characterized cocktail 
[ADDRESS_202946] of dedicated studies in this more at -risk and potentially frail population. 
The present study will probe three pathways of disposition: CYP3A using midazolam, P-glycoprotein ( P-gp) using dabigatran, OATP1B1/1B3 using rosuvastatin, pi[INVESTIGATOR_173513], and breast cancer  resistance protein ( BCRP ) using rosuvastatin. The relative 
contribution of renal impairment to substrate disposition will be examined across the spectrum of renal impairment (mild, moderate, severe, and ESRD). This will provide a 
holistic framework to bet ter appreciate the influencing of renal clearance of such pathways 
with comparison to normal healthy kidney function ( glomeluar filtration rate [ GFR ] ≥ 90 
mL/min). Rifampin, a designated probe inhibitor of OATP1B1/1B3 will be included to examine hepatic up take in the setting of renal impairment across the spectrum of renal 
function.  
Recently, there is an increased interest in the identification of selective endogenous 
biomarkers which are substrates of OATP1B and could be used early in clinical development  
to assess the potential of drug candidates to inhibit these transporters. In the current study, bilirubin, conjugated bilirubins, and coproporhyrins I and III will be measured as candidate biomarkers in pharmacokinetic samples from patients and healthy subject s treated with 
rifampin.  
7.1.[ADDRESS_202947] of 
γ-aminobutyric acid (GABA) -A receptors in the central nervous system. Midazolam is  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202948] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 24 
CONFIDENTIAL  
routinely used in clinical medicine as a sedative  and is specifically indicated for pediatric 
pre-procedural sedation. It has been used in the [LOCATION_002] as a parenteral sedative and as 
an oral syrup formulation for pediatric use. Midazolam provides a safe and effective sedation 
and anxiolysis prior t o surgical procedures that require anesthesia as well as before other 
procedures that require sedation but may not require anesthesia. The sedative effects of midazolam are dependent on the dose administered, the route of administration, and the presence or absence of other medications. Onset time of sedative effects after oral administration is approximately 10 -20 minutes depending on the dose administered. 
Sedation after intravenous injection is more rapid and is usually achieved within 5 minutes.  Rare s ide effects (occurring in less than 1% of subjects) have been reported following 
administration of midazolam and include partial or complete impairment of recall, epi[INVESTIGATOR_173514], respi[INVESTIGATOR_2341], apnea, and airway obstruction.
[ADDRESS_202949] completely absorbed with 90% of a radiolabeled dose excreted in the urine within 24 hours; less than 10% is excreted in the feces within 5 days. The mean Tmax values across dose groups  (0.25, 0.5, and 1.0 mg/kg) range from 0.17 to 
2.65 hours. Midazolam exhibits linear pharmacokinetics between oral doses of 0.25 to 1.0 mg/kg (up to a maximum dose of 40 mg).
[ADDRESS_202950] -pass metabolism by [CONTACT_173593]3A4 and is rapi[INVESTIGATOR_173515], 1’ -hydroxymidazolam, which 
subsequently undergoes conjugation. Because midazolam is primarily metabolized by [CONTACT_097]3A4, it is subject to pharmacokinetic interactions with in hibitors and inducers of this 
isozyme. Decreases in plasma midazolam concentrations after administration of known inducers of CYP3A4- mediated metabolism all occur to a similar extent: carbamazepi[INVESTIGATOR_050] 
(94%), phenytoin (94%) and rifampin (96%).
[ADDRESS_202951] thrombin inhibitors indicated to reduce the risk of stroke and systemic embolism in patients with non -valvular atrial fibrillation. Because thrombin (serine 
protease) enables the co nversion of fibrinogen into fibrin during the coagulation cascade, its 
inhibition prevents the development of a thrombus. Both free and clot -bound thrombin, and 
thrombin- induced platelet aggregation are inhibited by [CONTACT_173594].  
4, 5 
Following oral administration, dabigatran etexilate  is rapi[INVESTIGATOR_173516]- catalyzed hydrolysis to dabigatran in the gut, plasma and 
liver. Peak plasma concentrations of dabigatran occur 1- 2 hours after drug administration.  
Bioconversion of dabigatran etexilate is completed in the liver, and approximately 20% is conjugated with glucuronic acid to pharmacologically active acyl glucuronides and excreted in the bile. Due to its isomerisation, several positional dabigatran glucuronides isomers occur in plasma. The dabigatran glucuronide isomers represent about 20% of the total dabigatran after oral dosing (comparison of the AUC values). The pro -drug, dabigatran etexilate, is not  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202952] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 25 
CONFIDENTIAL  
metabolized by [CONTACT_173595] a substrate of the efflux transporter P -gp. Dabiga tran 
is not a substrate of P- gp. 4, 5, 6 
The major route of dabigatran elimination is via kidneys. Following intravenous 
administration of [14C] -labeled dabigatran, a mean of 85% of the administered dose was 
recovered in urine and 6% in feces over 168 h postdose. Following oral administration of [14C]- labeled dabigatran etexilate, a mean of 7% of the administered dose was recovered in 
urine and 86% in feces over [ADDRESS_202953] likely due to unabsorbed dabigatran etexilate. Renal clearance represented 80% of total dabigatran clearance. 
6 
No dose adjustment of dabigatran is recommended in patients with mild or moderate renal impairment. A reduced dose of dabigatran (75 mg twice a day [BID] vs. 150 mg BID) is 
recommended in patients with severe renal impairment (CrCl 15 -30 mL/min). Dosing 
recommendations for patients with CrCl <15 mL/min or on dialysis are not provided in the label.  
7.1.3 Atorvastatin 
Atorvastatin is a synthetic lipid -lowering agent that inhibits 3 -hydroxy -3-
methylglutarylcoenzyme A (HMG -CoA) reductase, the rat e-limiting enzyme in cholesterol 
biosynthesis.  This enzyme catalyzes the conversion of HMG -CoA to mevalonic acid, a 
precursor of sterols, including cholesterol. 
Atorvastatin calcium is indicated as an adjunct to diet to: 
• Reduce the risk of myocardial infarction (MI), stroke, revascularization procedures, 
and angina in patients without coronary heart disease (CHD), but with multiple risk 
factors;  
• Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors.  
• Reduce the risk of non- fatal MI, fatal and non -fatal stroke, revascularization 
procedures, hospi[INVESTIGATOR_173517] (CHF), and angina in patients with CHD.  
• Reduce elevated total cholesterol (total -C), low -density cholesterol (LDL -C), 
apolipoprotein B (apo B), and triglyceride (TG) levels and increase high- density 
cholesterol (HDL -C) in adult patients with primary hyperlipi[INVESTIGATOR_035] (heterozygous 
familial and nonfamilial) and mixed dyslipi[INVESTIGATOR_035].  
• Reduce elevated TG in patients with hypertriglycer idemia and primary 
dysbetalipoproteinemia. 
• Reduce total -C and LDL -C in patients with homozygous familial 
hypercholesterolemia.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202954] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 26 
CONFIDENTIAL  
• Reduce elevated total -C, LDL -C, and apo B levels in boys and postmenarchal girls, 
[ADDRESS_202955], within 1 hour. Atorvastatin has an absolute bioavailability of approximately 14% and is approximately 98% bound to plasma 
protein. Atorvastatin is extensively metabolized in the gut wall and liver with 2 main 
metabolites: ortho -hydroxyatorvastatin and para -hydroxyatorvastatin. These metabolites have 
HMG- CoA reductase inhibitory activity equal to that of atorvastatin; and approximately 70% 
of atorvastatin’s pharmacological activity is attributed to active metabolites. Atorvastatin is metabolized in part by [CONTACT_097]3A4 enzymes and is transported into the liver via OATP1B1 transporters.  
7, 8 
Atorvastatin’s bioavailability is reduced when the drug is administered with food, or when it is given in the evening rather than the morning. However, as LDL -C reduction is similar 
under fed and fasted conditions, and after morning or evening administration, atorvastatin may be administered without regard to meals or time of day. Atorvastatin and its metabolites are excreted mainly in the bile. Less than 2% of an oral dose of atorvastatin is excreted in the urine. The  pharmacokinetic half -life of atorvastatin is approximately [ADDRESS_202956] persists for longer than the half -life of atorvastatin in 
plasma, due to the longer half- life of the active metabolites.  
7 
Renal disease has no influence on the plasma concentrations or LDL -C reduction of 
atorvastatin; thus, dose adjustment in patients with renal dysfunction is not  necessary. While 
studies have not been conducted in patients with ESRD , hemodialysis is not expected to 
significantly enhance clearance of atorvastatin since the drug is extensively bound to plasma proteins. 
7.1.[ADDRESS_202957] if needed the dosage. 
9 
Pi[INVESTIGATOR_173518] 1 hour in the small intestine and has an absolute 
bioavailability of an oral solution is approximately 51%. Pi[INVESTIGATOR_173519] 99% bound to plasma protein, mainly albumin and alpha 1- glycoportein. Pi[INVESTIGATOR_173520]1B1 transporters where it is metabolized by  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202958] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 27 
CONFIDENTIAL  
glucuronidation via UGTs (UGT1A3 and UGT2B7) to pi[INVESTIGATOR_173507]. Pi[INVESTIGATOR_173521]; CYP2C9 and to a lesser extent CYP2C8.  8, 9 
Administering pi[INVESTIGATOR_173522] a high fat meal decrease s Cmax by 43% but does not affect 
the extent of exposure. Pi[INVESTIGATOR_173523]; about 15% is eliminated in urine and about 79% in feces. 
8, 9 
In patients with moderate renal impairment (glomerular filtration rate of 30 to <60 mL/min/1.73 m
2) and end stage renal disease receiving hemodialysis, pi[INVESTIGATOR_173524]0 -∞ is 79 and 86% higher than those of healthy subject s, respectively, while pi[INVESTIGATOR_173525] 60 and 40% higher than those of healthy subject s, respectively. Patients received 
hemodialysis immediately before pi[INVESTIGATOR_173526]. Hemodialysis patients have 33 and 36% increases in the mean unbound fraction of pi[INVESTIGATOR_173527] s and patients with 
moderate renal impairment, respectively. The effect of mild and severe renal impairment on pi[INVESTIGATOR_173528]. 
7.1.[ADDRESS_202959] to diet in adult patients: 
• with primary hyperlipi[INVESTIGATOR_173529], to reduce elevated total-C, 
LDL-C, ApoB, non- HDL -C, and TG levels, and to increase HDL -C. 
• with hypertriglyceridemia.  
• with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia).  
• with homozygous familial hypercholesterolemia to reduce LDL -C, total -C, and 
ApoB. 
• with atherosclerosis as part of a treatment strategy to slow the progression of the 
disease by [CONTACT_173596] -C and LDL- C. 
• without clinically evident coronary heart disease, but with multiple risk factors for 
myocardial infarction, stroke, and arterial revascularization procedures. 
Rosuvastatin is also indicated in pediatric patients, 10 to 17 years of age, with heterozygous familial hypercholesterolemia to reduce elevated total -C, LDL -C and ApoB after failing an 
adequate trial of diet therapy.  
10 
Peak plasma concentrations of rosuvastatin are reached between 3 to 5 hours following oral administration under both fed and fasting conditions. Both Cmax and AUC  increased in 
approximate proportion to rosuvastatin dose and the absolute bioavailability of rosuvastatin  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202960] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 28 
CONFIDENTIAL  
is approximately 20%. Administration of rosuvastatin with food did not affect the extent of 
absorption. BCRP plays a key role in the absorption and hepatic clearance of rosuvastatin. Rosuvastatin is primarily eliminated via the liver; however it is not extensively metabolized with approximately 10% of a radiolabeled dose recovered as metabolite. CYP2C9 appears to the principal enzyme involved in the formation of the major metabolite, N -desmethyl 
rosuvastatin, after rosuvastatin is rapi[INVESTIGATOR_173530]1B1. Rosuvastatin is also a substrate for BCRP. Rosuvastatin is mainly excreted via bile and feces (90%). 
10, 12, 13 
Rosuvastatin exposure is not influenced by [CONTACT_173597] (eGFR  ≥ 30 mL/min/1.73 m
2); however, exposure to rosuvastatin is increased to a clinically 
significant exten t in patients with severe renal impairment who are not receiving 
hemodialysis. CRESTOR dosing should be adjusted in patients with severe renal impairment (CLcr <  30 mL/min). 
10 
7.1.6 Rifampi n 
Rifampin is a semi- synthetic antibiotic derivative of rifamycin SV which acts by [CONTACT_173598] (DNA) -dependent ribonucleic acid (RNA) polymerase activity in 
susceptible species of Mycobacterium tuberculosis. Its activity does not impede mammalian enzyme RNA polymerase, therefore it is an effective treatment for both tuberculosis and meningococcus infections. Rifampin can be administered by [CONTACT_173599] [ADDRESS_202961] and is considered to be a highly variable drug in healthy adults and pediatric populations. A single oral dose of 600 mg of rifampin in healthy adults has an average peak serum concentration of 7 μg/mL ranging from 
4 to 32 μg/mL with an average half- life of 3.35 ±  0.66 hours. Gastric absorption with food 
reduces the bioavailability of rifampin by [CONTACT_2902] 30%. Rifampin is widely distributed throughout the body and can reach effective concentrations in various organs and cerebrospi[INVESTIGATOR_872]. Rifampin is 80% protein bound in the blood while the remaining unbound fraction is not ionized and can readily diffuses into tissues. 
[ADDRESS_202962] shown that an acute single dose of rifampin inhibits OATP1B1/1B3 as well as P-gp transport enzymes. 
Rifampin is rapi[INVESTIGATOR_173531]; during 
this process, gradual deacetylation of the drug occurs so that nearly all the drug in the bile is in this form 6 hours postdose. The deacetylated form of rifampin is active and exhibits antibacterial properties. Moreover, intestinal rea bsorption is reduced by [CONTACT_173600].  
While label data for rifampi[INVESTIGATOR_173532], data exis ts in 
the clinical literature. While there may be a reduction in urine excretion of rifampi[INVESTIGATOR_37180] n and  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202963] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202964] on plasma concentrations of rifampi[INVESTIGATOR_2513]. 15 Rifampi[INVESTIGATOR_173533]- biliary  excretion 16 with renal elimination playing a 
relatively minor role . 17 The general recommendation is not to reduce rifampi[INVESTIGATOR_173534] 15 and to also administer at  the usual dose of 600 mg in 
patents on hemodialysis. 18 
7.2 Rationale  
7.2.1 Rationale for this Study  and Study Design  
This study is intended to evaluate the pharmacokinetic performance of a cocktail of five probe substrates (i.e., dabigatran etexilate, atorvastatin, pi[INVESTIGATOR_2830], rosuvastatin, and midazolam) in the setting of renal impairment and healthy subjects orally as microdoses. A 
probe inhibitor, rifampin will be included to assess the influence of transporter function in this setting.  
The effect of timing of dosing relative to dialysis will be explored by [CONTACT_173601].  
7.2.2 Rationale for the Dose Selection  
Midazolam : 
A midazolam dose of 10 μg has been chosen for administration in the microdose cocktail.  The dose of midazolam that is typi[INVESTIGATOR_173535] 0.5 mg/kg (to a maximum of 20 mg). A 2 mg midazolam dose is frequently selected for evaluation of midazolam as a probe substrate in DDI studies. The 10 μg dose selected for use in this study is therefore 1/200th of the standard dose used in DDI studies and is not expected to generate any clinically apparent pharmacodynamic ef fects. The plasma pharmacokinetic profile of 
midazolam arising from administration of this microdose is expected to be measurable using the bioanalytical procedures specified for this study. 
Dabigatran : 
A dabigatran etexilate dose of 375 μg has been chosen for administration in the microdose 
cocktail. The clinically approved doses of dabigatran etexilate are 75 mg and 150 mg, 
administered twice daily. The dose selected for this study is therefore 1/200th of the lowest clinically approved dose, and is not ex pected to generate any clinically apparent 
pharmacodynamic effects. The plasma pharmacokinetic profile of dabigatran arising from administration of this microdose is expected to be measurable using the bioanalytical procedures specified for this study.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202965] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 30 
CONFIDENTIAL  
Pi[INVESTIGATOR_2830] : 
A pi[INVESTIGATOR_173536] 10 μg has been chosen for administration in the microdose cocktail.  
The clinically approved dose range of pi[INVESTIGATOR_173537] 1 -4 mg, administered once daily. The 
usual recommended starting dose is 2 mg. The dose selected for  this study is therefore 
1/200th of the usual clinical starting dose, and is not expected to generate any clinically apparent pharmacodynamic effects. The plasma pharmacokinetic profile of pi[INVESTIGATOR_173538]. 
Atorvastatin : 
An atorvastatin dose of 100 μg has been chosen for administration in the microdose cocktail. 
The clinically approved dose range of atorvastatin is 10 -80 mg, administered once daily. The 
usual recommended starting dose is 10- 20 mg. The dose selected for this study is therefore 
1/100th of the lowest clinically approved dose, and is not ex pected to generate any clinically 
apparent pharmacodynamic effects. The plasma pharmacokinetic profile of atorvastatin 
arising from administration of this microdose is expected to be measurable using the bioanalytical procedures specified for this study. 
Rosuvastatin : 
A rosuvastatin dose of 50 μg has been chosen for administration in the microdose cocktail. 
The clinically approved dose range of rosuvastatin is 5- 40 mg, administered once daily. The 
dose selected for this study is therefore 1/100th of the lowest clinically approved dose, and is not expected to generate any clinically apparent pharmacodynamic effects. The plasma pharmacokinetic profile of rosuvastatin arising from administration of this microdose is expected to be measurable using the bioanalyt ical procedures specified for this study. 
Rifampin : 
The single 600 mg rifampin dose has been selected based on the use of this dose in previous DDI studies, and the intent to use this dose in subsequent DDI studies. While 600 mg per day is the maximum dail y dose used in the treatment of tuberculosis (typi[INVESTIGATOR_173539]), higher daily doses are used in other settings (e.g., 600 mg BID for meningococcal prophylaxis and 300 mg three time s a day for prosthetic valve endocarditis), and single doses 
of 600 mg are expected to be well -tolerated.  
   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202966] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 31 
CONFIDENTIAL  
Table 1: Study Microdose Cocktail Component Doses: 
Probe Compound  Cocktail Microdose  Therapeutic Dose  
Midazolam  10 μg  1 – 5 mg/dose 
Dabigatran  375 μg  75 – 150 mg BID 
Pi[INVESTIGATOR_2830]  10 μg  1 – 4 mg once a day [ QD] 
Atorvastatin  100 μg  10 – 80 mg QD 
Rosuvastatin  50 μg  5 – [ADDRESS_202967] representative pharmacokinetic parameter for the assessment of inhibition of 
metabolic elimination of single oral dos e of dabigatran etexilate, atorvastatin, pi[INVESTIGATOR_2830], 
rosuvastatin, and midazolam is AUC0-∞. Thus, the primary pharmacokinetic measure of the study is the true GMR of AUC0 -∞ of each substrate with and without probe DDI 
perpetrators.  
7.2.4 Rationale for Planned Exploratory Biomarker Research 
Planned Genetic Analysis  
Understanding genetic determinants of drug response and the molecular basis of disease is an important endeavor during medical research. This research will evaluate whether genetic variation within a clinical trial population correlates with response to the treatment(s) under evaluation and/or disease. If genetic variation is found to predict efficacy or adverse events, the data might inform optimal use of therapi[INVESTIGATOR_90030]. Knowledge  of the 
molecular basis of disease contributes to the development of novel biomarkers and the identification of new drug targets. This research contributes to understanding molecular basis of disease and the genetic determinants of efficacy and safety asso ciated with the treatments 
in this study.  
7.2.[ADDRESS_202968] Future Biomedical Research on DNA specimens consented for 
future biomedical research during this clinical trial.  
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting /retaining  specimens for Future 
Biomedical R esearch is to explore and identify biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs/vaccines, and/or to ensure that subjects receive the correct dose of the correct drug/vaccine at the correct time. The details of 
this Future Biomedical Research sub -trial are presented in Appendix 2 - Collection and 
Management of Specimens for Future Biomedical Research.    
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202969] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 32 
CONFIDENTIAL  
8 STUDY OBJECTIVES, ESTIMATION S, AND ENDPOINTS  
8.1 Objectives and Estimation s 
8.1.1 Primary  
Primary (Period 1) : 
Objective 1:  To characterize the plasma pharmacokinetic profiles of midazolam, dabigatran, 
pi[INVESTIGATOR_2830] (and its metabolite, pi[INVESTIGATOR_173507]), atorvastatin (and its metabolites, 2 -OH 
atorvastatin and 4- OH atorvastatin), and rosuvastatin following a single oral dose 
administration of a microdose cocktail in healthy subjects, in subjects with mild, moderate, severe (not on dialysis) renal impairment, and in subjects with ESRD  (on dialysis). 
Estimation 1:  The plasma pharmacokinetic parameters (e.g., AUC 0-24, AUC0- last, 
AUC0 -∞, Cmax, C24, Tmax, and apparent terminal t½) of midazolam, dabigatran, 
pi[INVESTIGATOR_2830] (and its metabolite, pi[INVESTIGATOR_173507]), atorvastatin (and its metabolites, 2 -OH 
atorvastatin and 4- OH atorvastatin), and rosuvastatin following a  single oral dose 
administration of a microdose cocktail will be estimated in healthy subjects, in subjects with mild, moderate, severe (not on dialysis) renal impairment, and in subjects with ESRD (on dialysis).  
Primary Objective for Midazolam:  
Objective 2:  To evaluate the effect of a single oral dose of rifampin on the single -dose 
pharmacokinetics of midazolam administered as part of a microdose cocktail in each subject population separately (except for ESRD subjects). 
Estimation 2:  Plasma AUC 0-∞ of midazolam following a single oral dose administration of 
a microdose cocktail containing midazolam, dabigatran etexilate, pi[INVESTIGATOR_2830], atorvastatin, 
and rosuvastatin with a single oral dose of rifampin will be estimated and compared to the 
plasma A UC0 -∞ of midazolam following a single oral dose administration of the microdose 
cocktail alone, in each subject population separately (except for ESRD subjects; i.e., healthy 
subjects and subjects with mild, moderate, or severe renal impairment).  
Primary Objective for Dabigatran: 
Objective 3:  To evaluate the effect of a single oral dose of rifampin on the single -dose 
pharmacokinetics of dabigatran administered as part of a microdose cocktail in each subject 
population separately (except for ESRD subjects). 
Estimation 3:  Plasma AUC0 -∞  of dabigatran following a single oral dose administration of 
a microdose cocktail containing  midazolam, dabigatran etexilate, pi[INVESTIGATOR_2830], atorvastatin, 
and rosuvastatin with a single oral dose of rifampin will be estimate d and compared to the 
plasma AUC0 -∞ of dabigatran following a single oral dose administration of the microdose  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202970] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202971] population separately (except for ESRD subjects; i.e., healthy 
subjects and subjects with mild, moderate, or seve re renal impairment).  
Primary Objective for Pi[INVESTIGATOR_2830]: 
Objective 4:  To evaluate the effect of a single oral dose of rifampin on the single -dose 
pharmacokinetics of pi[INVESTIGATOR_2830] (and its metabolite, pi[INVESTIGATOR_173507]) administered as 
part of a microdose cocktail in each subject population separately (except for ESRD subjects).  
Estimation 4:  Plasma AUC0 -∞ of pi[INVESTIGATOR_2830] (and its metabolite pi[INVESTIGATOR_173507]) 
following a single oral dose administration of a microdosecocktail containing midazolam, dabigatran etexilate, pi[INVESTIGATOR_2830], atorvastatin, and rosuvastatin with a single oral dose of 
rifampin will be estimated and compared to the plasma AUC0 -∞ of pi[INVESTIGATOR_2830] (and its 
metabolite, pi[INVESTIGATOR_173507]) following a single dose administration of the microdose 
cocktail alone, in each subject population separately (except for ESRD subjects; i.e., healthy 
subjects and subjects with mild, moderate, or severe renal impairment).  
Primary Objective for Atorvastatin: 
Objective 5:  To evaluate the effect o f a single oral dose of rifampin on the single -dose 
pharmacokinetics of atorvastatin (and its metabolites, 2- OH atorvastatin and 4- OH 
atorvastatin) administered as part of a microdose cocktail in each subject population 
separately (except for ESRD subjects ).  
Estimation 5:  Plasma AUC0 -∞ of atorvastatin (and its metabolites, 2 -OH atorvastatin and 
4-OH atorvastatin) following a single oral dose administration of a microdose cocktail 
containing midazolam, dabigatran etexilate, pi[INVESTIGATOR_2830], atorvastatin, and rosuvastatin with a 
single oral dose of rifampin will be estimated and compared to the plasma AUC0- ∞ of 
atorvastatin (and its metabolites, 2 -OH atorvastatin and 4- OH atorvastatin) following a single 
oral dose administration of the microdose cocktail alone, in each subject population 
separately (except for ESRD subjects; i.e., healthy subjects and subjects with mild, moderate, or severe renal impairment).  
Primary Objective for Rosuvastatin: 
Objective 6:  To evaluate the effect of a single oral dose of rifampin on the single -dose 
pharmacokinetics of rosuvastatin administered as part of a microdose cocktail in each subject 
population separately (except for ESRD subjects). 
Estimation 6:  Plasma AUC0 -∞ of rosuvastatin following a single oral dose administration of 
a microdose cocktail containing midazolam, dabigatran etexilate, pi[INVESTIGATOR_2830], atorvastatin, 
and rosuvastatin with a single oral dose of rifampin will be estimated and compared to the 
plasma AUC0 -∞ of rosuvas tatin following a single oral dose administration of the microdose 
cocktail alone, in each subject population separately (except for ESRD subjects; i.e., healthy subjects and subjects with mild, moderate, or severe renal impairment).  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202972] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 34 
CONFIDENTIAL  
8.1.2 Secondary  Objectives  
Objective 1:  To estimate the effect of a single oral dose of rifampin on the single oral dose 
pharmacokinetics (AUC0 -24, AUC0- last, Cmax, C24, Tmax, apparent terminal t½, CL/F, 
and Vz/F) of midazolam  administered as part of a microdose cocktail in each sub ject 
population separately (except for ESRD subjects). 
Objective 2:  To estimate the effect of a single oral dose of rifampin on the single oral dose 
pharmacokinetics (AUC0 -24, AUC0- last, Cmax, C24, Tmax, apparent terminal t½, CL/F, 
and Vz/F) of dabigatran  administered as part of a microdose cocktail in each subject 
population separately (except for ESRD subjects). 
Objective 3:  To estimate the effect of a single oral dose of rifampin on the single oral dose 
pharmacokinetics (AUC0 -24, AUC0- last, Cmax, C24, Tmax, apparent terminal t½, CL/F, 
and Vz/F) of pi[INVESTIGATOR_2830]  (and its metabolite, pi[INVESTIGATOR_173507]) when pi[INVESTIGATOR_173540] a microdose cocktail in each subject population separately (except for ESRD subjects).  
Objective 4:  To estimate the effect of a single oral dose of rifampin on the single dose pharmacokinetics (AUC0 -24, AUC0- last, Cmax, C24, Tmax, apparent terminal t½, CL/F, 
and Vz/F) of atorvastatin  (and its metabolites, ortho -hydroxyatorvastatin [2- OH 
atorvastatin] and para -hydroxyatorvastatin [4- OH atorvastatin]) when atorvastatin is 
administered as part of a microdose cocktail in each subject population separately (except for ESRD subjects).  
Objective 5:  To estimate the effect of a single oral dose of rifampin on the single  oral dose 
pharmacokinetics (AUC0 -24, AUC0- last, Cmax, C24, Tmax, apparent terminal t½, CL/F, 
and Vz/F) of rosuvastatin  administered as part of a microdose cocktail in each subject 
population separately (except for ESRD subjects). 
Objective 6:  To compare the magnitude of the drug- drug interaction (DDI) between rifampin 
and each of the 5 substrates in the microdose cocktail between healthy subjects and each 
category of RI subjects (mild, moderate, severe RI ).  
Objective 7:  To estimate the plasma pharmacokinetic parameters (e.g., AUC0 -24, 
AUC0 -last, AUC0 -∞, Cmax, C24, Tmax, and apparent terminal t½) of dabigatran, 
atorvastatin (and its metabolites, 2 -OH atorvastatin and 4- OH atorvastatin), pi[INVESTIGATOR_2830] (and 
its metabolite, pi[INVESTIGATOR_173507]), rosuvastatin , and midazolam following a single oral dose 
administration of a microdose cocktail in ESRD subjects on dialysis when the microdose cocktail is administered at different times relative to dialysis . 
Objective 8:  To estimate the plasma pharmacokinetic parameters (e.g., AUC0 -24, 
AUC0 -last, AUC0 -∞, Cmax, C24, Tmax, and apparent terminal t½) of rifampin  following a 
single oral dose administration with a single oral dose of a microdose cocktail in each subject population separately (except for ESRD subjects).  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202973] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 35 
CONFIDENTIAL  
8.1.3 Exploratory Objectives  
Objective  1:  To evaluate plasma, serum, and urinary biomarkers to assess the impact of renal 
impairment on functions such as organic anion transporting polypeptide ( OATP)1B 
inhibition. 
Objective  2:  To evaluate the urinary pharmacokinetics (e.g., CLr, Ae0 -24, and fe) of 
dabigatran and rosuvastatin in each population. 
8.1.4 Planned Exploratory Biomarker 
Objective:   To explore the relationship between genetic variation and response to the 
treatment(s) administered, and mechanisms of disease.  Variation across the human genome 
may be analyzed for association with clinical data collected in this study.  
8.2 Analysis Endpoints  
Pharmacokinetics:  
The following plasma pharmacokinetic parameters will be calculated for all plasma analytes 
(rifampin  [Period 2 only], midazolam, dabigatran, pi[INVESTIGATOR_2830], pi[INVESTIGATOR_173541], 
atorvastatin, 2- OH atorvastatin, 4-OH atorvastatin, and rosuvastatin) on Day 1 of each 
treatment period , as appropriate :  AUC0 -24, AUC0- last, AUC0 -∞, Cmax, C24, Tmax, 
apparent ter minal t½, CL/F (parent only), and Vz/F (parent only).  
The following urine pharmacokinetic parameters may also be calculated for dabigatran and rosuvastatin: CLr , Ae0 -24, and fe .  
Protein binding (plasma) assays will be performed on predose samples from Period 1. 
Safety: 
Safety endpoints will include adverse events, physical examinations, vital signs, 12- lead 
ECGs, pulse oximetry, and clinical laboratory tests.  
Biomarkers : 
The following  biomarkers  and also uremic toxins will be measured to assess OATP1B 
inhibition : serum total/direct bilirubin , plasma coproporhyrin I and III , p-cresol sulfate, 
indoxyl sulfate, CMPF, GDCA -S, GCDCA- S, DCA- S, TCDC -S, and TCDA -S 
concentrations, and urine coproporhyrin I and III, p- cresol sulfate, indoxyl sulfate, and 
CMPF concentrations. 
To evaluate the concentration -time effects of perpetrator -mediated inhibition of OATP1B, 
the following parameters will be calculated for the biomarkers and uremic toxins on Day 1 
following Treatment s A and B:  AUC0 -last, Cmax, Tmax for plasma parameters, and Ae0 -24 
and fe for urine parameters. Measurements to assess renal clearance will be performed after a  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202974] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 36 
CONFIDENTIAL  
24-hour interval urine collection (urine will be collected in intervals 0 -4 hr, 4- 8 hr, 8 -12 hr, 
and 12-24 hr.    
A predose sample will also include measurement of serum creatinine (central lab) and may 
also be used to measure uremic toxins/biomarkers (exploratory). 
   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202975] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 37 
CONFIDENTIAL  
9 INVESTIGATIONAL PLAN  
9.1 Overall Study Design and Plan 
This is an open label, 2 period, fixed sequence study in 24 renal impairment subjects and 
6 healthy control subjects.   
Twenty -four (24) RI subjects between 18 and 78 years of age (inclusive) will be enrolled; 
6 subjects with mild renal impairment; 6  subje cts with moderate renal impairment; 6 subjects 
with severe renal impairment who are not on dialysis; and [ADDRESS_202976]  dosing. 
Assignment to a renal function group will be as follows: 
Group N eGFR (mL/min/1.73m2) or CLcr (mL/min)* 
ESRD requiring hemodialysis 6 Requiring hemodialysis 
Severe impairment  6 < 30 not on hemodialysis ** 
Moderate impairment  6 30 – < 60 *** 
Mild impairment  6 60 - < 90 
Healthy  control  6 ≥ 90 **** 
* eGFR based on MDRD equation at screening.  Baseline eGFR will be obtained twice during the 
screening period, and the mean of the two values will be used for group assignment. The second 
baseline eGFR  sample may be obtained at the time of check -in in Period 1. CLcr by [CONTACT_3158] -Gault 
equation will be used for healthy control assignment (normal renal function). 
** Reasonable efforts will be made to enroll at least 2 subjects with eGFR values of 
< 20 mL/ min/1.73m2  
*** Reasonable efforts will be made to ensure a broad representation across the range of eGFR values 
of 30 - <  60 mL/min/1.73m2 
**** . For healthy subjects a creatinine clearance computed over a 24 hour urine collection for 
subjects that do not qualify with >90 mL/min  CLcr  may be done for confirmation purposes. 
In Period 1, subjects will receive Treatment A, a single oral dose of the microdose cocktail 
(i.e., midazolam oral solution , dabigatran etexilate and pi[INVESTIGATOR_173509], atorvast atin 
and rosuvastatin oral solution) on Day 1 followed by [CONTACT_121265] 72 hours.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202977] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202978] subjects . 
In Period 2, subjects (except ESRD subjects) will  receive Treatment B, a single oral dose of 
rifampin capsules with a single oral dose of the microdose cocktail, coadministered on Day 1. 
In Period 2, ESRD subjects will receive only Treatment A, a single oral dose of the 
microdose cocktail on Day 1. The microdose cocktail will be dosed as soon as possible  
within 24 hours after the completion of dialysis . 
In each period, pharmacokinetic samples for plasma midazolam, dabigatran (as free 
dabigatran), pi[INVESTIGATOR_2830], pi[INVESTIGATOR_173507], atorvastatin, [ADDRESS_202979] 14 days washout between dosing in Period 1 and dosing in  Period 2. 
Subjects may be replaced at the discretion of the Sponsor. 
9.1.1 Confinement , Return Visit , and Follow- up 
Subjects will be housed from Day -2 (Orlando c linical site) or Day – 1 (Miami clinical site)  
at the time indicated by [CONTACT_173602] (CRU), until after the 72-hour blood 
draw. At all times, a subject may be required to remain at the CRU for longer at the 
discretion of the Investigator. 
The clinic will attempt to contact [CONTACT_1766] (including subjects who terminate the study early) 
using their standard procedures approximately [ADDRESS_202980] visit. 
9.1.2 Study Duration  
The duration of the study from screening to Day  4 of Period 2 is approximately 6.5 weeks. 
The duration of the study from screening to follow-up is approximately 8 weeks.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202981] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 39 
CONFIDENTIAL  
9.2 Selection of Study Population 
9.2.1 Inclusion Criteria  
[IP_ADDRESS] Subjects with Renal Impairment  
Subjects must fulfill all of the following inclusion criteria to be eligible for participation in 
the study, unl ess otherwise specified:  
1. Adult male or female subject, 18-[ADDRESS_202982] feeding and if she is of reproductive 
potential: must demonstrate a serum β -human chorionic gonadotropin (β –hCG ) level 
consistent with the nongravid state at screening (Note: if a subject has a β – hCG level that 
is not consistent with the non- gravid state due to disease or medication, the investigators 
may consult with the sponsor to obtain approval to enroll the subject in the study ) and 
agree to use (and/or have their partner use) two (2) acceptable methods of birth control beginning at screening, throughout the study and until [ADDRESS_202983] dosing of study drug: 
• diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide and contraceptive sponge)  
• cervical cap with spermicide (nulliparous women only) 
• contraceptive sponge with spermicide (nulliparous women only)  
• male condom or female condom with spermicide (cannot be used together ) 
3. A female of non -childbearing potential:  must have undergone one of the following 
sterilization procedures at least [ADDRESS_202984] dose: 
• hysteroscopic sterilization; 
• bilateral tubal ligation or bilateral salpi[INVESTIGATOR_1656];  
• hysterectomy;  
• bilateral oophorectomy. 
or be postmenopausal with amenorrhea for at least [ADDRESS_202985] follow the same restrictions as 
a non- vasectomized male.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202986] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202987] agree not to donate sperm from dosing until 90 days after dosing/the 
last dose of study drug.  
6. Subject has a body mass index (BMI) ≤ 40.0 kg/m2, at screening.  
7. With the exception of renal impairment, subject is judged to be in good health based on 
medical history, physical examination, vital signs, pulse oximetry, and laboratory safety 
tests. Subject has no clinically significant ECG abnorm ality, as deemed by [CONTACT_25309]. Subjects who do not qualify based on a reversible condition or 
mild intercurrent illness may be re -screened after the underlying condition is resolved. 
8. Subject is a non-smoker or moderate smoker (≤ 20 cigarettes/day or the  equivalent). 
Subject must agree to consume no more than 10 cigarettes or equivalent/day from the 
time of screening and throughout the period of sample collection. 
9. Subject has a clinical diagnosis of renal impairment and meets the renal impairment  
function qualifications listed below at the prestudy visit (screening):  
Group eGFR (mL/min/1.73m2)* 
ESRD requiring hemodialysis Requiring hemodialysis 
Severe impairment  < 30 not on hemodialysis ** 
Moderate impairment  30 – < 60 *** 
Mild impairment  60 - < 90 
* eGFR based on MDRD equation at screening. Baseline eGFR will be obtained twice as part of 
subject screening and the mean of the two values will be used for renal impairment  
assignment. The second baseline eGFR  sample may be obtained at the time of check -in in 
Period 1.  
** Reasonable efforts will be made to enroll at least 2 subjects with eGFR values of 
< 20 mL/min/1.73m2  
*** Reasonable efforts will be made to ensure a broad representation across the range of eGFR 
values of 30 - < 60 mL/min/1.73m2 
Based on eGFR from the MDRD equation at screening as defined as follows (for females 
multiply result by 0.742, if African American multiply result by 1.212):  
The MDRD equation is: 
eGFR  = 175 x (S cr,std)-1.154 x (Age )-0.203 
Scr, std:  serum creatinine (mg/dL) measured with a standardized assay.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202988] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 41 
CONFIDENTIAL  
10. For mild, moderate, and severe RI subjects:   Has a stable renal function with no clinically 
significant change in renal status at least [ADDRESS_202989]:  Is maintained on a stable regimen of HD within [ADDRESS_202990] dose. 
12. Subjects u nderstands the study procedures in the informed consent form s (ICFs), is 
willing and able to comply with the protocol, and provides written informed consent for 
the trial, including for Future Biomedical Research. Future Biomedical Research will be conducted as a voluntary part of the trial. 
[IP_ADDRESS] Healthy Subjects  
Subjec ts must fulfill all of the following inclusion criteria to be eligible for participation in 
the study, unless otherwise specified: 
1. Adult male or female subject, [ADDRESS_202991] feeding and if she is of reproductive 
potential: must demonstrate a serum β -human chorionic gonadotropin (β –hCG) level 
consistent with the nongravid state at screening and agree to use (and/or have their 
partner use) two (2) acceptable methods of birth control beginning at screening, throughout the study and until [ADDRESS_202992] dosing of study drug: 
• diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide and contraceptive sponge)  
• cervical cap with spermicide (nulliparous women only)  
• contraceptive sponge with spermicide (nulliparous women only)  
• male condom or female condom with spermicide (cannot be used together)  
3. A female of non -childbearing potential:  must have undergone one of the following 
sterilization procedures at least [ADDRESS_202993] dose: 
• hysteroscopic sterilization; 
• bilateral tubal ligation or bilateral salpi[INVESTIGATOR_1656];  
• hysterectomy;  
• bilateral oophorectomy. 
or be postmenopausal with amenorrhea for at least [ADDRESS_202994] dose. No  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202995] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202996] has a BMI ≤ 40.0 kg/m
2, at screening.  
6. Subject is judged to be in good health based on medical history, physical examination, vital signs, pulse oximetry, and laboratory safety tests. Subject has no clinically 
significant ECG abnormality, as deemed by t he Investigator  or designee. Subjects who do 
not qualify based on a reversible condition or mild intercurrent illness may be re- screened 
after the underlying condition is resolved. 
7. Subject is a non-smoker or moderate smoker (≤ 20 cigarettes/day or the  equi valent). 
Subject must agree to consume no more than 10 cigarettes or equivalent/day from the 
time of screening and throughout the period of sample collection. 
9. Subject has b aseline CLcr ≥  90 mL/min based on Cockcroft -Gault equation at screening 
defined as follows (for females multiply result by 0.85)*: 
The Cockcroft -Gault equation is:  
CLcr  = [140- age (years)]  + weight (kg) / 72 S
cr, std 
Scr, std:  serum creatinine (mg/dL) measured with a standardized assay.  
*For healthy subjects a creatinine clearance comp uted over a 24 hour urine collection for 
subjects that do not qualify with ≥ 90 mL/min CLcr may be done for confirmation 
purposes. 
8. Subject understands  the study procedures in the ICFs, is willing and able to comply with 
the protocol, and provides written informed consent for the trial, including for Future Biomedical Research. Future Biomedical Research will be conducted as a voluntary part 
of the trial.  
9.2.2 Exclusion Criteria  
[IP_ADDRESS] Subjects with Renal Impairment  
Subjects must not be enrolled in the study if they meet any of the following criteria:  
1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study. 
2. Subject has a h istory or presence of clinically significant medical or psychiatric condition 
or disease in the opi[INVESTIGATOR_25279].   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_202997] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_202998] has rapi[INVESTIGATOR_173542]; or subject has demonstrated or suspected renal stenosis. Rapid fluctuation in renal 
function is defined as creatinine clearance that differs by [CONTACT_726] 30% within 3 months of the screening eGFR determination. If historical measurements are not available, then the 2 screening measurements will be used to demonstrate stability.  Subjects with CrCL 
≤ 24 mL/min with renal fluctuation of more than 30% within [ADDRESS_202999] has uncontrolled type 2 diabetes mellitus (T2DM), a history of Type [ADDRESS_203000] with a history of significant endocrine (other than T2DM), gastrointestinal, cardiovascular, hematological, immunological, respi[INVESTIGATOR_696], or genitourinary diseases whose current condition is considered clinically unstable in the opi[INVESTIGATOR_173543]. Subjects who have had a 
cholecystectomy may be allowed.   
8. Subject has a history of malignant neoplastic disease . Exceptions: (1) Subjects with 
adequately treated non -melanomatous skin carcinoma or carcinoma in situ of the cervix 
may participate in the study; (2) Subjects with other malignancies which have been successfully treated ≥10 years prior to screening  where, in the judgment of both the 
Investigator and treating physician, appropriate follow -up has revealed no evidence of 
recurrence from the time of treatment through the time of the screening; or, (3) Subjects, who, in the opi[INVESTIGATOR_173544], are highly unlikely to sustain a 
recurrence for the duration of the study. 
9. For mild, moderate, and severe RI subjects: Subject has had a renal transplant or has had nephrectomy. 
10. For subjects with ESRD: Had a failed renal allograft within the last [ADDRESS_203001] is unable to refrain from or anticipates the use of any medication or substance (including prescription or over -the- counter, vitamin supplements, natural or herbal 
supplements) as indicated in Section 9.3.[ADDRESS_203002] has a history  or presence of hypersensitivity or idiosyncratic reaction to the study 
drug(s) or related compounds.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203003] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203004] has positive results for the urine or saliva drug and/or urine or breath alcohol 
screen at screening or check -in, unless the positive drug screen is due to prescription drug 
use that is approved by [CONTACT_10552]’s Clinical Monitor. 
16. Positive results at screening for human immunodeficiency virus ( HIV), hepatitis  B 
surface antigen ( HBsAg ), or hepatitis C antibodies. Subject s who are hepatitis  C antibody 
positive may be enrolled, if they are confirmed with negative viral load at screening. 
17. Subject has  been on a diet incompatible with the on- study diet, in the opi[INVESTIGATOR_47338], within the [ADDRESS_203005] is or has an immediate family member (e.g., spouse, parent/legal guardian, 
sibling or child) who is a member of the investigational site or sponsor staff directly 
involved with this trial.  
21. Subject participated  in another clinical trial within [ADDRESS_203006] dose. The 
4-week window will be derived from dosing  in the previous study to Day  1 of Period 1 of 
the current study. 
[IP_ADDRESS] Healthy Subjects  
Subjects must not be enrolled in the study if they meet any of the following criteria:  
1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study. 
2. Subject has a history  or presence of clinically significant medical or psychiatric condition 
or disease in the opi[INVESTIGATOR_25279].  
3. Subject has a history  of any illness that, in the opi[INVESTIGATOR_173545] , 
might confound the results of the study or poses an additional risk to the subject by [CONTACT_173603]. 
4. Subject has a history of stroke, chronic seizures, or major neurological disorders. 
5. Subject has history of hypoglycemia, glucose intolerance, T2DM, or ketoacidosis. 
6. Subject has a history of clinically significant endocrine, gastrointestinal, cardiovasc ular, 
hematological, hepatic, immunological, renal, respi[INVESTIGATOR_696], or genitourinary abnormalities  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203007] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203008] has a history of malignant neoplastic disease. Exceptions: (1) Subjects with adequately treated non -melanomatous skin carcinoma or carcinoma in situ of the cervix 
may participate in the study; (2) Subjects with other malignancies whic h have been 
successfully treated ≥10 years prior to screening  where, in the judgment of both the 
investigator and treating physician, appropriate follow -up has revealed no evidence of 
recurrence from the time of treatment through the time of screening ; or, (3) Subjects, 
who, in the opi[INVESTIGATOR_25279], are highly unlikely to sustain a 
recurrence for the duration of the study. 
8. Subject has had a renal transplant or has had nephrectomy. 
9. Subject is unable to refrain from or anticipates the use of any medication or substance (including prescription or over -the- counter, vitamin supplements, natural or herbal 
supplements) as indicated in Section 9.3.[ADDRESS_203009] has a history  or presence of hypersensitivity or idiosyncratic reaction to the study 
drug(s) or related compounds. 
12. A female subject who is pregnant or lactating.  
13. Subject has positive results for the urine or saliva drug and/or urine or breath alcohol screen at screenin g or check- in of Period 1. Unless the positive drug screen is due to 
prescription drug use that is approved by [CONTACT_10552]’s Clinical Monitor. 
14. Subject has positive results at screening for HIV, HBsAg, or HCV.  
15. Subject has  been on a diet incompatible with the on- study diet, in the opi[INVESTIGATOR_47338], within the [ADDRESS_203010] is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is a member of the investigational site or sponsor staff directly involved with this trial.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203011] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203012] Withdrawal/Discontinuation Criteria  
Subjects may withdraw consent at any time for any reason or be dropped from the trial at the 
discretion of the Investigator should any untoward effect occur. In addition, a subject may be 
withdrawn by [CONTACT_173604], the 
trial plan is violated, or for administrative and/or other safety reasons. Specific details regarding discontinuation or withdrawal procedures, including specific details regarding withdrawal from Future Biomedical Research, are provided in Section  [IP_ADDRESS]. 
Discontinuation is “permanent”. Once a subject is discontinued, he/she shall not be allowed to enroll again. 
Subjects may be replaced at the discretion of the Sponsor. 
A subject must be discontinued from the study for any of the following reasons: 
• The subject withdraws consent. 
• The subject has a confirmed positive serum pregnancy test. 
• The subject has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_173546]/or Sponsor, places the subject at unnecessary risk through 
continued participation in the trial or does not allow the subject to adhere to the 
requirements of the protocol. 
A subject may be discontinued from the study for any of the following reasons: 
• Adverse events.  
• Difficulties in blood collection.  
• Protocol violation. 
[IP_ADDRESS] Withdrawal/Discontinuation 
The Investigator or designee must notify the Sponsor whe n a subject has been 
discontinued/withdrawn from the study. If a subject discontinues for any reason at any time during the course of the study, the procedures scheduled at early termination (as outlined in Section  6) will be performed. Furthermore, the subject will be asked to return to the clinic or 
be contact[INVESTIGATOR_530], if the Investigator deems necessary, for a follow -up (approximately [ADDRESS_203013] dose of study drug), to determine if any adverse events have occurred since the last visit. Any adverse events which are present at the time of discontinuation/withdrawal should be followed in accordance with the safety requirements outlined in Section  10.1.8.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203014] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 47 
CONFIDENTIAL  
[IP_ADDRESS].[ADDRESS_203015] the Sponsor using the designated mailbox ([EMAIL_1250]). Subsequently, the subject's consent for Future Biomedical Research will be withdrawn. A letter will be sent from the Sponsor to the Investigator confirming the withdrawal. It is the responsibility of the Investigator to inform the subject of completion of wit hdrawal. Any analyses in progress at 
the time of request for withdrawal or already performed prior to the request being received by [CONTACT_90070]. No new analyses would be genera ted after the request is received . 
In the event that the medical records for the main trial are no longer available (e.g., if the Investigator is no longer required by [CONTACT_121275]) or the specimens have been comp letely anonymized, there will no longer be a link between the 
subject’s personal information and their specimens. In this situation, the request for specimen withdrawal cannot be processed .  
9.3 Study Restrictions  
9.3.1 Prohibitions and Concomitant Therapy  
Consumpti on of foods and beverages containing the following substances will be prohibited 
as indicated:  
• Xanthines /Caffeine: 24  hours before dosing and throughout the period of 
pharmacokinetic sample collection in each period ; 
• Alcohol: 48 hours before dosing and throughout the period of pharmacokinetic 
sample collection in each period ; 
• Grapefruit/Seville orange: [ADDRESS_203016] 
pharmacokinetic sample collection  in Period 2. 
• Fruit Juice:  72  hours before dosing until the las t pharmacokinetic sample collection 
in each period; 
• Vegetables from the mustard green family (e.g.,  kale, broccoli, watercress, collard 
greens, kohlrabi, Brussels sprouts, mustard), and charbroiled meats:  [ADDRESS_203017] is prescribed prohibited medication, upon discussion between the Sponsor and the Investigator, the Investigator may substitute the previously prescribed medication to an  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203018] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 48 
CONFIDENTIAL  
allowed one for the purpose of this study. During the study, acetaminophen (up to 2 g per 
24 hours) may be administered at the discretion of the Investigator. 
Appropriate sources will be consulted by [CONTACT_173605]/pharmacodynamic interaction with drug. If deviations occur, the 
Investigator will decide on a case -by-case basis whether the subject may continue 
participation in the study based on the time the study drug was administered and its pharmacology.  
Also refer to Appendix 8 for additional details on allowable and prohibited concomitant 
therapy.  
All medications taken by [CONTACT_25300]. 
For Renal Impaired Subjects:  
All prescription or non -prescription medications (including St. John’s Wort) that are strong 
or moderate inhibitors or strong or modera te inducers of CYP 3A and CYP2C9 enzymes or P-
gp transporters will be prohibited. These metabolizing enzyme inhibitors and inducers will 
not be allowed for at least [ADDRESS_203019] dose and 
throughout the study. Medications of particular concern include, but are not limited to azole 
antifungals (ketoconazole, itraconazole), macrolide antibiotics (erythromycin, clarithromycin), HIV protease inhibitors, nefazodone, rifampin (except when administered as 
part of Treatment B) , dexamethasone, troglitazone, barbiturates, and any drug or supplement 
(e.g., St. John’s Wort) that inhibits or induces P -gp transporters. Weak P -gp inhibitors or 
inducers may be deemed acceptable following consultation with the Sponsor Clinical Monitor and the Investigator. 
Subjects who are taking certain prescription medications to treat manifestations of renal 
disease or medications needed to treat stable diseases (e.g.,  angiotensin converting enzyme 
inhibitors, angiotensin II receptor antagonists, beta -blockers, diuretics) will be allowed to 
participate in the study at the discretion of the Investigator and following consultation with 
the Sponsor Clinical Monitor. Subjects must be on a stable regimen for at least 1 month  (or 
5 half -lives of the study drug, whichever is longer) prior to the first study drug administration 
and is able to withhold the use within 4 hours prior to administration of the study drug.  
Any medication (including over -the- counter) that would signifi cantly alter eGFR, which, by 
[CONTACT_111952], might interfere with the study (e.g., cimetidine) must be 
discontinued at least 2 weeks (or 5 half -lives of the compound, whichever is longer) prior to 
the first dosing of study drug.  
Note:  Proton pump inhibitors must be withheld [ADDRESS_203020] dosing.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203021] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 49 
CONFIDENTIAL  
Phosphate binders containing aluminum, calcium, or lanthanum salts; iron supplements or 
other metal cations; H2RAs [except cimetidine]) ; vitamin D, or multivitamins containing iron 
or zinc must be withheld [ADDRESS_203022] dosing.  
For Healthy Subjects:  
Any medication or substance (including prescription or over -the- counter, vitamin 
supplements, natural or herbal supplements) are to be discontinued at least 14 days prior to 
dosing and throughout the study are prohibited. All prescription or non- prescripti on 
medications (including St. John’s Wort) that are moderate/ strong inhibitors or 
moderate/ strong inducers of CYP 3A and CYP2C9 enzymes or P-gp transporters will be 
prohibited for at least [ADDRESS_203023] dose and throughout 
the study. Certain medications may be deemed acceptable following consultation with the Sponsor Clinical Monitor and the Investigator. Appropriate sources will be consulted by [CONTACT_121277]/ pharmacodynamic 
interaction with study drug. 
9.3.2 Meals  
Water (except water provided with dosing) will be restricted [ADDRESS_203024] meals and/or snacks, but will be restricted at all other times 
throughout the confinement period. 
Subjects will fast overnight for at least [ADDRESS_203025] from all food and 
drink except water between meals and snacks.  
Each meal and/or snacks served at the CRU will be standardized , and will be similar in 
caloric content and composition. 
9.3.[ADDRESS_203026] sports at any time from screening until completion of the study.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203027] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 50 
CONFIDENTIAL  
Depending on the CRU rules and regulations, subjects may be prohibited from smoking 
during their confinement or during portions of their confinement. 
9.4 Treatments  
9.4.1 Treatments Administered  
Treatment A will be supplied as microdose cocktail.  See Table 2. Oral solutions for 
Treatment  A will be prepared and stored according to the Method of Preparation Manual  and 
Master Batch Records  provided separately. 
Treatment B will be supplied as microdose cocktail and rifampin as 3 00 mg oral capsules . 
Table 2: Study Microdose Cocktail Component Doses 
Probe Compound  Cocktail Microdose  Therapeutic Dose  
Midazolam  10 μg  1 – 5 mg/dose 
Dabigatran  375 μg  75 – 150 mg BID 
Pi[INVESTIGATOR_2830]  10 μg  1 – 4 mg QD  
Atorvastatin  100 μg  10 – 80 mg QD 
Rosuvastatin  50 μg  5 – 40 mg QD 
Subjects  will receive the following treatments  in a fixed -sequence: 
Treatment A (Period 1):   Single oral dose of the microdose  cocktail at Hour [ADDRESS_203028]. The microdose cocktail will contain: 
• 10 μg midazolam (1 mL of 10 μg/mL oral solution), administered orally as midazolam 
hydrochloride (HCl); 
• 375/10 μg dabigatran etexilate and pi[INVESTIGATOR_2830] (1 mL of 375/10 μg/mL oral solution), administered as dabigatran etexilate mesylate and pi[INVESTIGATOR_173510];  and 
• 100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution, dosed as 
2 x 1 mL dosing syringes), administered as atorvastatin calcium tr ihydrate and 
rosuvastatin calcium . 
Each oral solution will be administered using 1  mL amber dosing syringes .  
Treatment B (Period 2):   600 mg oral single dose rifampin (2 x 300 mg capsule s) 
coadministered with a single oral dose microdose cocktail (as described in Treatment A) at 
Hour [ADDRESS_203029].  
NOTE:  Subjects with ESRD  will not receive rifampin in Period 2 ; they will receive 
Treatment  A in Period 2, instead of Treatment B . In Period 1, dosing will occur  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203030] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 51 
CONFIDENTIAL  
approximately 24 hours prior to dialysis. In Period 2, dosing will occur as soon as possible 
within 24 hours after completion of the dialysis.  
Subjects will drink one container of approximately 240 mL of water after each complete 
dosing completion .  
The pharmacy at the CRU will provide each dose in individual syringes  (microdose cocktail) 
or unit dose containers (rifampin) for each subject. 
The exact clock time of dosing will be recorded.  
9.4.[ADDRESS_203031] who will not receive rifampin in Period 2; they will receive Treatment A in Period  2, instead of Treatment B. 
If replacement subjects are used, the replacement subject number will be 100 more than the original (e.g., allocation  number [ADDRESS_203032] allocation number 0001). 
9.4.[ADDRESS_203033]’s mouth. Subjects’ hands will 
also be verified to ensure that the study drug  was ingested.  
9.4.[ADDRESS_203034] be discontinued for the reasons described in Section  9.2.3. 
   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203035] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 52 
CONFIDENTIAL  
10 STUDY PROCEDURES  
The Study Events Flow Chart ( Section  6) summarizes the clinical procedures to be 
performed at each visit. Individual clinical procedures are described in detail below. 
Additional evaluations/testing may be deemed necessary by [CONTACT_11219]/or the 
Sponsor for reasons related to subject safety. 
For this study, the blood collection for all plasma analytes (midazolam, dabigatran, 
pi[INVESTIGATOR_2830], pi[INVESTIGATOR_173547], atorvastatin, 2-OH atorvastatin, 4-OH atorvastatin, 
rosuvastatin, and rifampin) is the critical parameter and needs to be collected as close to the 
exact time point as possible. All other procedures should be completed as close to the 
prescribed/ scheduled time as possible, but can be performed prior or after the 
prescribed/scheduled time.  
Any nonscheduled procedures required for urgent evaluation of safety concerns take precedence over all routine scheduled procedures.  
10.[ADDRESS_203036] dosing, medical history and demographic data, including 
name, sex, age, race, ethnicity, body weight (kg), height (cm), and BMI  (kg/m
2), will be 
recorded. Each subject will have a physical examination, vital sign measureme nts (heart rate, 
blood pressure, temperature, and respi[INVESTIGATOR_697]), 12- lead ECG , pulse oximetry, and the 
laboratory tests of hematological, hepatic , and renal function , and additional tests as noted in 
Section  10.1.7. 
10.1.2 Physical Examination 
A physical examination will be performed as per Study Events Flow Chart ( Section  6). 
Symptom- driven physical examinations may be performed at other times, if deemed 
necessary by [CONTACT_18370].  
10.1.3 Vital Signs  
Single measurements of body temperature, respi[INVESTIGATOR_697], blood pressure , and heart rate, 
will be measured as outlined in the Study Events Flow Chart ( Section  6). 
Vital signs may be taken at any other  times, if deemed necessary. Blood pressure and heart 
rate measurements will be performed with subjects in a seated position  for at least 1  minute , 
except when they are supi[INVESTIGATOR_1662] -reclined because of study procedures and/or adverse 
events (e.g.,  nausea, dizziness) or if deemed necessary by [CONTACT_737] . 
Blood pressure ,  heart rate, and respi[INVESTIGATOR_173548] 24  hours prior to 
Day 1 dosing for the predose time point. When scheduled postdose , vital signs will be 
performed within approximately 10 minutes of the scheduled time point.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203037] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 53 
CONFIDENTIAL  
10.1.4 ECG Monitoring  
Single 12- lead ECGs will be performed as outlined in the Study Events Flow Chart 
(Section  6). 
ECGs will be performed with subjects in a supi[INVESTIGATOR_173549] 5 minutes . All ECG 
tracings will be reviewed by [CONTACT_116768]/her designee.  
ECGs will b e measured within [ADDRESS_203038] will be withdrawn from the study by [CONTACT_116768]/her designee if, in 
their medical judgment, ECG findings are present which make continued study participation 
not in the subject’s best interest.  
10.1.[ADDRESS_203039] a baseline pulse oximetry reading done prior to study drug admini stration and will be monitored continuously for approximately 6 hours with a pulse 
oximeter (oxygen levels, as saturation  [%], and heart rate) with readings taken at scheduled 
time points as outlined in the Study Events Flow Chart ( Section  6). 
Where the time of monitoring coincides with a blood sampling time point, the reading will be taken approximately [ADDRESS_203040] obstruction, oxygen desaturation, apnea, and rarely, respi[INVESTIGATOR_69908]/or cardiac arrest. 
Oxygen and/or specific reversal agents (e.g., flumazenil) will be available as a rescue medication in case of any severe midazolam -related events, at the discretion of the Study 
Physician or his/her designee.  
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203041] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 54 
CONFIDENTIAL  
10.1.7 Clinical Laboratory Tests 
All tests listed below will be performed as per Study Events Flow Chart ( Section  6). In 
addition, laboratory safety tests may be performed at various unscheduled time points, if 
deemed necessary by [CONTACT_737]. 
Hematology   Serum Chemistry*  
• Hemoglobin  
• Hematocrit  
• Total  and differential leukocyte count  
• Red blood cell count 
• Platelet count  • Blood urea nitrogen  
• Bilirubin (total and direct) ** 
• Alkaline phosphatase  
• Aspartate aminotransferase (AST)  
• Alanine aminotransferase (ALT)  
• Albumin 
• Sodium 
• Potassium 
• Chloride 
• Glucose (fasting)  
• Creatinine  
• Creatine phosphokinase 
 
Urinalysis    Additional Tests  
• pH 
• Specific gravity  
• Protein*** 
• Glucose 
• Ketones 
• Bilirubin  
• Blood*** 
• Nitrite** * 
• Urobilinogen 
• Leukocyte esterase** *  • HIV test  
• HBsAg  
• HCV  
• Urine  or saliva  drug screen  
 Opi[INVESTIGATOR_858]  
 Amphetamines 
 Cocaine  
 Cannabinoids 
• Urine  or breath  alcohol screen  
• Serum pregnancy test  
(for females only) 
• FSH (for postmenopausal females only) 
 
* Serum chemistry tests will be performed after at least an [ADDRESS_203042]; however, in case of 
dropout or rechecks, subjects may not have fasted for 8  hours before the serum chemistry 
sample is taken.  
** Predose samples for total and direct bilirubin will be obtained following a fast of 
approximately 8 hours; however, all postdose samples collected for the assessment of OATP 
1B inhibition are not required to be performed following a fast of approximately 8 hours. 
** If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic 
examination (red blood cell, white blood cell, bacte ria, casts, and, epi[INVESTIGATOR_1663]) will be 
performed. For subjects who are anuric, urine samples for urinalysis will not be collected.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203043] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203044] a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol- specified procedure, whether or not considered related to the medicinal product or 
protocol- specified procedure. Any worsening (i.e., any cl inically significant adverse change 
in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event. 
Changes resulting from normal growth and development that do not va ry significantly in 
frequency or severity from expected levels are not to be considered adverse events. Examples 
of this may include, but are not limited to, teething, typi[INVESTIGATOR_121254] a p hysiologically appropriate time.  
Sponsor's product includes any pharmaceutical product, biological product, device, diagnostic agent , or protocol -specified procedure  whether investigational (including placebo 
or active comparator medication) or marketed, m anufactured by, licensed by, provided by [CONTACT_26363]. 
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse, and from withdrawal. 
For allocated subjects only, all adverse events that occur after the consent form is signed but 
before allocation  must be reported by [CONTACT_121280] a 
protocol- specified intervention, including but not limited to washout or discontinuation of 
usual therapy, diet, placebo treatment, or a procedure. From the time of allocation  through 
[ADDRESS_203045] be reported by [CONTACT_737]. Such events will be recorded at each examinati on on the Adverse Event case 
report forms/worksheets. The reporting timeframe for adverse events meeting any serious criteria is described in Section  [IP_ADDRESS].1. The Investigator will make every attempt to follow 
all subjects with non -serious adverse events for outcome. Any unexplained drug -related 
hematuria or evidence of triphosphate crystals should be referred to a nephrologist. 
Electronic reportin g procedures can be found in the Electronic Data Capture ( EDC ) data 
entry guidelines. Paper reporting procedures can be found in the Investigator Trial File 
Binder (or equivalent). 
[IP_ADDRESS] Definition of an Overdose for This Protocol and Reporting of Overdose to th e 
Sponsor  
The subject has taken (accidentally or intentionally) any drug administered as part of the 
protocol and exceeding the dose as prescribed by [CONTACT_760]. It is up to the Investigator or  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203046] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 56 
CONFIDENTIAL  
the reporting physician to decide whether a dose is to be considered an overdose, in 
consultation with the Sponsor. 
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or 
vaccine, the adverse event(s) is reported as a serious adverse event, even if no other seriousness criteria are met.  
If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken without any associated clinical symptoms or abnormal laboratory results, the overdose is reported as a non- serious Event of Clinical Interest (ECI), using the terminology “accidental 
or intentional overdose without adverse effect.” 
All reports of overdose with or without an adverse event must be reported by [CONTACT_46698] 24 hours to the Sponsor either by [CONTACT_26365]. Electronic reporting 
procedures can be found in the EDC data entry guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or equivalent). 
[IP_ADDRESS] Reporting of Pregnancy and Lactation to the Sponsor 
Although pregnancy and lactation are not considered adverse events, it is the responsibility of 
Investigators or their designees to report any pregnancy or lactation in a subject (spontaneously reported to them) that occurs during the trial. 
Pregnancies and lactations that occur after the c onsent form is signed but before allocation  
must be reported by [CONTACT_121281], or 
are the result of a protocol -specified intervention, including but not limited to washout or 
discontinuation of usual therapy, diet, placebo treatment or a procedure. Pregnancies and lactations that occur from the time of allocation  through 14 days following cessation of 
Sponsor’s product must be reported by [CONTACT_737]. All reported pregnancies must be followed to the completion/termination of the pregnancy. Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as serious events (Important M edical Events). If the pregnancy continues to term, the outcome (health of 
infant) must also be reported. 
Such events must be reported within 24 hours to the Sponsor either by [CONTACT_90079]. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or equivalent). 
Pregnant partners of male subjects will not be followed. 
[IP_ADDRESS] Immediate Reporting of Adverse Events  
[IP_ADDRESS].1 Serious Adverse Events  
A serious advers e event is any adverse event occurring at any dose or during any use of 
Sponsor's product that has the following outcome:  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203047] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 57 
CONFIDENTIAL  
• Death  
• Immediately life threatening  
• Persistent or significant disability/incapacity  
• Inpatient hospi[INVESTIGATOR_173550]  
• Congenital anomaly/birth defect 
• Other important medical event  
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timefra me 
as serious adverse events to meet certain local requirements. Therefore, these events are considered serious by [CONTACT_90080]. 
• Cancer  
• Overdose 
Refer to Table [ADDRESS_203048] to be excluded from the trial, or is the result of a protocol -specified intervention, 
including but not limited to washout  or discontinuation of usual therapy, diet, placebo 
treatment or a procedure.  
For the time period beginning at treatment allocation  through 14 days following cessation of 
treatment, any serious adverse event, or follow up to a serious adverse event, including death due to any cause, whether or not related to the Sponsor's product, must be reported within 24 hours to the Sponsor either by [CONTACT_26365]. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper reporting  procedures can be found in 
the Investigator Trial File Binder (or equivalent).  
Additionally, any serious adverse event, considered by [CONTACT_121282] a qualified physician to be related to the Sponsor's product that is brought to the attention of t he 
Investigator at any time outside of the time period specified in the previous paragraph also must be reported immediately to the Sponsor. 
All subjects with serious adverse events must be followed up for outcome.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203049] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 58 
CONFIDENTIAL  
[IP_ADDRESS].[ADDRESS_203050] to be excluded from the trial, or is the result of a protocol- specified intervention, including but not limited to washout or discontinuation of 
usual therapy, diet, placebo treatment or a proced ure. 
For the time period beginning at treatment allocation  through 14 days following cessation of 
treatment, any ECI, or follow up to an ECI, whether or not related to the Sponsor’s product, must be reported within 24 hours to the Sponsor, either by [CONTACT_173606]. 
Electronic reporting procedures can be found in the EDC data entry guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or equivalent). 
Events of clinical interest for this trial include: 
• an overdose of Sponsor's product, as defined in Section  [IP_ADDRESS] that is not associated 
with clinical symptoms or abnormal laboratory results.  
• an elevated AST or ALT laboratory value that is greater than or equal to three times 
(3X) the upper limit of normal (ULN) and an elevated total bilirubin laboratory value 
that is greater than or equal to 2X the ULN and, at the same time, an alkaline phosphatase laboratory value that is less than 2X the ULN, as determined by [CONTACT_13149]-specified laboratory testing or unscheduled laboratory testing.*  
*Note:  These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to spe cify a threshold of abnormal hepatic tests that may 
require an additional evaluation for an underlying etiology. The trial site guidance for assessment and follow up of these criteria can be found in the Investigator Trial File Binder or equivalent. 
[IP_ADDRESS] Evaluating Adverse Events  
An Investigator who is a qualified physician will evaluate all adverse events with respect to 
the elements outlined in Table 3. Th e Investigator ’s assessment of causality is required for 
each adverse event. Refer to Table 3 or instructions in evaluating adverse events.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203051] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 59 
CONFIDENTIAL  
Table 3: Evaluating Adverse Events 
Maximum 
Intensity (Severity)  Mild  awareness of sign or symptom, but easily tolerated (for pediatric trials, awareness of symptom, but easily tolerated)  
Moderate  discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)  
Severe  incapacitating with inability to work or do usual activity (for pediatric trials, 
extremely distressed or unable to do us ual activities)  
Seriousness  A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor's 
product that:  
None  
†Death ; or 
†Immediately life threatening ; or places the subject, in the view of the Investigator , at immediate risk 
of death from the event as it occurred [Note:  This does not include an adverse event that, had it 
occurred in a more severe form, might have caused death.]; or  
†Persistent or significant disability/incapacity  (substantial disruption of one’s ability to conduct 
normal life functions); or  
†Inpatient hospi[INVESTIGATOR_318]  (hospi[INVESTIGATOR_121255], regardless of length of stay, even if the hospi[INVESTIGATOR_2138] a precautionary measure 
for continued observation. (Note:  Hospi[INVESTIGATOR_059] [including hospi[INVESTIGATOR_34096]] 
for a preexisting condition which has not worsened does not constitute a serious adverse event.); or  
†Congenital anomaly/birth defect  (in offspring of subject taking the product regardless of time to 
diagnosis); or  
Cancer; or  
Overdose  (whether accidental or in tentional). Any adverse event associated with an overdose is 
considered a serious adverse event. An overdose that is not associated with an adverse event is 
considered a non-serious event of clinical interest and must be reported within [ADDRESS_203052] and may require medi cal or surgical intervention to 
prevent one of the outcomes listed previously (designated above by a †).  
Duration  Record the start and stop dates of the adverse event. If less than 1 day, indicate the appropriate length of 
time and units.  
Action Taken  The action taken is in reference to the either the Sponsor’s Product or the Interacting Drug. Did the 
adverse event cause the Sponsor's product or the Interacting Drug to be:  
None  
Reduced  
Interrupted 
Discontinued  
Increased  
Not Applicable  
Unknown  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203053] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 60 
CONFIDENTIAL  
Relationship 
to Sponsor's 
Product  Did the Sponsor's product cause the adverse event? The determination of the likelihood that the 
Sponsor's product caused the adverse event will be provided by a n Investigator  who is a qualified 
physician. The Investigator ’s signed/dated initials on the source document or worksheet that supports 
the causality noted on the adverse event form, ensures that a medically qualified assessment of causality 
was done. This initialled  document must be retained for the required regulatory time frame. The criteria 
below are intended as reference guidelines to assist the Investigator  in assessing the likelihood of a 
relationship between the test drug and the adverse event based upon the available information.  
Relationship 
to Sponsor's 
Product  
(continued)  The following components are to be used to assess the relationship between the Sponsor's product 
and the adverse event ; the greater the correlation with the components and their respective elements 
(in number and/or intensity), the more likely the Sponsor's product caused the adverse event:  
Exposure  Is there evidence that the subject was actually exposed to the Sponsor's product such 
as:  reliable history, acceptable compliance assessment (pi[INVESTIGATOR_692], diary, etc.), 
expected pharmacologic effect, or measurement of drug/metabolite in bodily 
specimen?  
Time Course  Did the adverse event follow in a reasonable temporal sequence from administration of the Sponsor's product?  
Is the time of onset of the adverse event compatible wit h a drug -induced effect 
(applies to trials with investigational medicinal product)?  
Likely Cause  Is the adverse event not reasonably explained by [CONTACT_173607], other drug(s)/vaccine(s), or other host or environmental factors  
Dechallenge Was the Sponsor's product discontinued or dose/exposure/frequency reduced?  
If yes, did the adverse event resolve or improve?  
If yes, this is a posit ive dechallenge. If no, this is a negative dechallenge.  
(Note:  This criterion is not applicable if:  (1) the adverse event resulted in death or 
permanent disability; (2) the adverse event resolved/improved despi[INVESTIGATOR_121256]'s product; (3) the trial is a single -dose drug trial; or (4) Sponsor's 
product(s) is/are only used one time.)  
Rechallenge Was the subject re-exposed to the Sponsor's product in this trial?  
If yes, did the adverse event recur or worsen? 
If yes, this is a positive rechallenge. If no, this is a negative rechallenge.  
(Note:  This criterion is not applicable if:  (1) the initial adverse event resulted in death or permanent disability, or (2) the trial is a single -
dose drug trial; or (3) 
Sponsor's product(s) is/are used only one time.)  
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT 
WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN CAUSED BY [CONTACT_173608]'S PRODUCT, OR IF RE -EXPOSURE TO THE SPONSOR'S 
PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE SUBJECT THEN T HE RECHALLENGE MUST BE APPROVED IN ADVANCE 
BY [CONTACT_64918] U.S. CLINICAL MONITOR AND THE INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE.  
Consistency 
with Trial 
Treatment Profile  Is the clinical/pathological presentation of the adverse event consistent wi th previous 
knowledge regarding the Sponsor's product or drug class pharmacology or 
toxicology?  
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_121284] a qualified 
physician according to his/her best clinical judgment, including consideration of the above elements.  
Record one of the following:  Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).  
Related (there is a reasonable possibility of Sponsor's product relationship)  There is evidence of exposure to the Sponsor's product. The temporal sequence of 
the adverse event onset relative to the administration of the S ponsor's product is 
reasonable. The adverse event is more likely explained by [CONTACT_1034]'s product than 
by [CONTACT_5748].   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203054] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 61 
CONFIDENTIAL  
Not Related (there is not a 
reasonable possibility of 
Sponsor's product relationship)  Subject did not receive the Sponsor's product OR temporal sequence of the adverse 
event onset relative to administration of the Sponsor's product is not reasonable OR 
there is another obvious cause of the adverse event. (Also entered for a subject with overdose without an associated adverse event.)  
[IP_ADDRESS] Sponsor Responsibility for Reporting Adverse Events  
All adverse events will be reported to regulatory authorities, IRB or independent ethics 
committees (IECs), and Investigator s in accordance with all applicable global laws and 
regulations i.e., per ICH Topic E6 (R1) Guidelines for Good Clinical Practice. 
10.2 Pharmacokinetic and Biomarker Assessment s 
10.2.1 Blood Sampling and Processing  
For all subjects, blood samples for the determination of all plasma pharmacokinetic analytes 
(rifampin, midazolam, dabigatran, pi[INVESTIGATOR_173551], pi[INVESTIGATOR_173507], atorvastatin, 2-OH 
atorvastatin, 4- OH atorvastatin, and rosuvastatin) will be collected and processed according 
to Appendix 3, Appendix 4, and Appendix 5 at scheduled time points as delineated in the 
Study Events Flow Chart ( Section  6). 
The following windows will be used for pharmacokinetic blood collection and biomarker 
samples time points: 
Sample collection time  Allowed deviation  
0.0 – 8.0 hour ≤± 2 minutes 
>8.0 – 24.0 hour ≤± 5 minutes 
>24.0 – 72.0 hour ≤± 10 minutes 
For all subjects, blood samples for the determination of  all biomarkers in serum and plasma, 
as appropriate, ( serum total and direct bilirubin, serum creatinine, plasma coproporhyrin I 
and III , p-cresol sulfate, indoxyl sulfate, CMPF , GDCA- S, GCDCA- S, DCA- S, TCDC -S, 
and TCDA -S) will be collected and processed according to Appendix 9 at scheduled time 
points as delineated in the Study Events Flow Chart ( Section  6). Additional biomarkers may 
be evaluated to measure uremic toxins/biomarkers.  
10.2.[ADDRESS_203055] will be instructed as to urine collection methods.  
Urine samples for determination of dabigatran  and rosuvastatin concentrations will be 
collected and processed according to Appendix 6 and for the determination of  all biomarkers 
in urine (coproporhyrin I and III , p-cresol sulfate, indoxyl sulfate, and CMPF ) will be 
collected and processed according to Appendix 10 at selected intervals as delineated in the  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203056] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 62 
CONFIDENTIAL  
Study Events Flow Chart ( Section  6).  
For subjects with renal impairment, urine samples will be collected whenever possible, as 
they may not be able to produce urine at each interval. For subjects who are anuric, urine 
samples will not be collected.  
On Day  1, a spot collection will be obtained prior to dosing for the pre -dose sample. Subjects 
will be asked again to empty their bladder within approximately [ADDRESS_203057] ion container and total weight of urine collected during each timed interval will be 
recorded . 
10.3 Planned Genetic Analysis  Sample Collection  
Sample collection, storage and shipment instructions for Planned Genetic Analysis samples will be provided in the Appendix 7. 
10.4 Future Biomedical Research Samples  
The following samples will be collected for Future Biomedical Research :  
• DNA for future research   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203058] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 63 
CONFIDENTIAL  
10.5 Blood Volume Drawn for Study Assessments  
Table 4: Blood Volume Drawn D uring the Study  
Sample Type  Number 
of Time 
Points  Approximate 
Volume per 
Time Point *  
(mL)  Approximate 
Sample Volume 
Over Course of 
Study  
(mL)  Handling 
Instructions  
Screening laboratory safety tests 
(including hematology, serum chemistry, serology ), FSH (for 
postmenopausal female subjects 
only) and serum pregnancy (for 
female subjects only).  1 11 11 Reliable  
(Local Lab)  
Blood for Planned Genetic Analysis  1 8.5 8.5 Appendix 7 
On-study hematology and serum 
chemistry (this includes serum pregnancy for female subjects only 
when scheduled at the same time)  4 9 36 Reliable  
(Local Lab)  
Blood for serum total and direct 
bilirubin  16 2 32 [COMPANY_003] 
(Central Lab)  
(Appendix 9)  
Blood for serum creatinine  16 2 32 [COMPANY_003] 
(Central Lab)  
(Appendix 9)  
Blood for plasma coproporhyrin  I 
and III  16 2 32 [COMPANY_003] 
(Appendix 9)  
Blood for plasma p- cresol sulfate, 
indoxyl sulfate, and CMPF   16 2 32 TMB/MRL   
(Appendix 9)  
Blood for plasma GDCA -S, 
GCDCA -S, DCA -S, TCDC- S, and 
TCDA -S 16 2 32 Metabolon 
(Appendix 9)  
Blood for free dabigatran and 
midazolam  32 4 128 Appendix 3 
Blood for pi[INVESTIGATOR_2830]  (and 
metabolite) , atorvastatin (and 
metabolites), and rosuvastatin  32 3 96 Appendix 4 
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203059] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 64 
CONFIDENTIAL  
Sample Type  Number 
of Time 
Points  Approximate 
Volume per 
Time Point *  
(mL)  Approximate 
Sample Volume 
Over Course of 
Study  
(mL)  Handling 
Instructions  
Blood for rifampin 10 3 30 Appendix 5 
Blood for protein binding^ 1 3 3 TMB/MRL  
(Appendix 9 ) 
Total Blood Volume for all Subjects except ESRD (mL)→  472.5§  
Total Blood Volume for Subjects with ESRD (mL)→  442.5§  
* Represents the largest collection tube that may be used for this (a smaller tube may be used).  
§ If additional safety, pharmacokinetic , or pharmacodynamic  analysis is necessary or if larger collection tubes 
are required to obtain sufficient plasma/serum for analysis, additional blood may be obtained (up to a 
maximum of 50 mL) . 
^    Protein binding (plasma) assays will be performed on predose samples from Period 1.  
   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203060] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 65 
CONFIDENTIAL  
11 DATA ANALYSIS  
11.1 Pharmacokinetic Parameters  
11.1.1 Plasma  
Pharmacokinetic parameters for all plasma analytes (rifampin, midazolam, dabigatran, 
pi[INVESTIGATOR_2830], pi[INVESTIGATOR_173511], atorvastatin, 4 -OH atorvastatin, 2- OH atorvastatin, and 
rosuvastatin) will be calculated as follows: 
AUC0 -last: Area under the concentration versus time curve, from [ADDRESS_203061] quantifiable (above LLOQ) sample.  
AUC0 -∞: Area under the concentration versus time curve from 0 to infinity after 
single  dosing. 
AUC0 -24: Area under the concentration versus time curve, from 0 to 24  hours after 
dosing (dabigatran and rosuvastatin only). 
CL/F:  Apparent clearance after extravascular administration  (parent only) . 
Cmax:  Maximum observed plasma concentration after the administration of a 
given dose. 
C24: Plasma concentration at 24 hours.  
Tmax:  Time to maximum observed plasma drug concentration.  
t½: (Apparent) terminal half -life. 
Vz/F : Apparent volume of distribution during the terminal phase  (parent only)  
No value for AUC0- ∞, CL/F, Vz/F , and apparent terminal t½, will be reported for cases that 
do not exhibit a terminal log -linear phase in the concentration versus time profile. 
11.1.2 Urine 
Pharmacokinetic parameters for urine dabigatran  and rosuvastatin w ill be calculated as 
follows: 
Ae0-24: Total amount of drug excreted unchanged in the urine over the period of 
24 hours, obtained by [CONTACT_173609].  
CLr: Renal clearance calculated as Ae(t’ -t”)/AUC(t’ -t”) where t’ -t” is the longest 
interval of time during which Ae and plasma AUC are both obtained.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203062] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 66 
CONFIDENTIAL  
fe: Fraction of drug excretion during each collection interval. Obtained by 
[CONTACT_173610] . 
11.2 Statistical Methods  
The statistical analysis of the data obtained from this study will be the responsibility of the 
Data Management and Biometrics  department at Celerion.  
If, after the study has begun, changes are made to the statistical analysis plan stated below, 
then these deviations to the plan will be listed, along with an explanation as to why they occurred, in the Clinical Study Report (CSR). 
Additional statistical analy ses, other than those described in this section, may be performed if 
deemed appropriate.  
11.2.1 Determination of Sample Size  
Source of Variance Estimates:  
There are no available in -house pharmacokinetic data for most substrates in RI subjects, and 
the data publis hed in the literature is limited in its usefulness for sample size planning in that 
relevant parameters are not provided or are not provided on the log scale except for 
Dabigitran. We assumed that the variances for substrates in RI subjects is the same as those 
in healthy subject s. 
Midazolam : 
The estimates of within -subject variability for midazolam AUC0 -∞ were obtained from prior 
[COMPANY_006] studies investigating the effects of a therapeutic agent on the single dose pharmacokinetics of midazolam including MK -0633- 004, MK -0869- 088, MK -1006-003, 
MK-4305- 015, MK -6096- 005, MK -7009- 010, MK -0974- 020, MK -0974- 041, MK -0518-016, 
MK-0524- 051, MK -6186- 004, MK -0364- 010, and MK -0869- 155. The pooled estimate for 
the within -subject standard deviation (SD) for midazolam AUC0- ∞ is 0.1834. From the 
previous microdose study conducted by [CONTACT_173611] s, the within -subject 
coefficient of variation  (CV)  for AUC0 -∞ was 0.31 when midazolam was given with and 
without rifampin.  
Dabigitran : 
In an effort to provide some guidance for the precision and power associated with this study, the published data involving oral d abigitran in RI  subjects have been reviewed 
18. The CV for 
severe RI subjects is 0.61 for AUC0-∞ in this study. In addition, there is 1.5 (mild RI subject 
vs healthy subjects ) to 6.5 (severe RI subject vs healthy subjects ) fold differences in AUC0-
∞ level based on this study. From the previous microdose study conducted by [CONTACT_173611] s, the within- subject CV for AUC0 -∞ was 0.228 when dabigatran was given 
with and without rifampin.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203063] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 67 
CONFIDENTIAL  
Pi[INVESTIGATOR_2830] : 
An estimate of within -subject variability for pi[INVESTIGATOR_173552], MK -7009- 051 in which pi[INVESTIGATOR_173553]. The CV for 
the GMR for AUC0 -∞ from this study w as 0.214. From the previous microdose study 
conducted by [CONTACT_173611] s, the within -subject CV for AUC0 -∞ was 0.[ADDRESS_203064] (mild, moderate, and severe) and healthy subjects in related published 
literature.  
Atorvastatin : 
An estimate of within -subject variability for atorvastatin is derived from earlier [COMPANY_006] 
studies, specifically MK -5172- 032, MK -0431E-212, and MK -0431E- 214. The pooled  
estimate of the within -subject standard deviation of the log AUC0-∞ values is 0.[ADDRESS_203065] CV for AUC0 -∞ was 0.185 when atorvastatin was given with and without 
rifampin.  
Rosuvastatin : 
An estimate of within -subject variability for rosuvastatin is derived from an earlier [COMPANY_006] 
study, MK -7009- 051 in which rosuvastatin was given with and without rifampin. The CV for 
the GMR for AUC0 -∞ from this study was 0.32. From the previous microdose study 
conducted by [CONTACT_173611] s, the within -subject CV for AUC0 -∞ was 0.[ADDRESS_203066] of renal impai rment on the 
pharmacokinetics  of MK -7264 was not chosen to satisfy any a priori statistical requirement. 
This sample size (N= 6 per group) has historically been shown to be sufficient for studies of 
this type and should provide adequate data to support the  planned analyses. Nevertheless, 
estimates of the expected precision of the estimates, based on these sample sizes are presented below.  
Sample Size and Power : 
Six subjects/subjects will be enrolled in each group (i.e., healthy, mild, moderate, severe without dialysis). To evaluate the DDI between each substrate in the microdose cocktail and rifampin, the comparisons will be within subject. The within subject CV varied from 0.1 to 
0.6 for the various groups based on internal and external published data. Clinically meaningful true fold increases in AUC0- ∞  o f  2 -, 3-, 4- and 5- fold were assumed for the 
power calculations. Table 5 below shows the power calculations for the various combinations 
of assumed values for hypotheses, assuming N=6.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203067] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 68 
CONFIDENTIAL  
Table 5: Power Calculations for True Fold Increases  by [CONTACT_173612]  
2 0.1 >0.99 
 0.3 0.83 
 0.6 0.39 
3 0.1 >0.99 
 0.3 >0.99 
 0.6 0.82 
4 0.1 >0.99 
 0.3 >0.99 
 0.6 >0.99 
5 0.1 >0.99 
 0.3 >0.99 
 0.6 >0.99 
11.2.2 Subjects to Analyze  
The decision as to which plasma  samples collected will be assayed for evaluation of 
pharmacokinetics/pharmacodynamics will be collaboratively determined by [CONTACT_173613] -Stage Development. If indicated, these samples may also be assayed and/or pooled for 
assay in an exploratory manner for metabolites and/or additional pharmacodynamic markers. 
The following populations are defined for the analysis and reporting of data. All subjects will 
be reported, and their data analyzed, according to the treatment(s) they actually received.  
All Subjects as Treated:  All subjects who received at least one dose of the investigational 
drug(s). This population will be used for assessments of safety and tolerabili ty. 
Per-Protocol:   The set of data generated by [CONTACT_26377], according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of major protocol violations. Any subjects or data values excluded from analysis will be identified, along with their reason for exclusion, in the CSR. At the end of the study, all subjects who are compliant with the study procedure as aforementioned and have available data will be included in the primary analysis dataset. This population will be used for the pharmacokinetic analyses.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203068] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 69 
CONFIDENTIAL  
11.2.3 Descriptive Statistics  
Non-model based descriptive statistics will be provided for all plasma analytes (rifampin, 
midazolam, dabigatran, pi[INVESTIGATOR_2830], pi[INVESTIGATOR_173511], atorvastatin, 2-OH atorvastatin, 
4-OH atorvastatin, and rosuvastatin) and urine analytes (rosuvastatin and dabigatran)  
pharmacokinetic parameters by [CONTACT_110590]. The following (non -model- based) descriptive 
statistics will be provided: N (number of subjects with non- missing data), arithmetic mean, 
standard deviation, arithmetic percent CV (calculated as [ADDRESS_203069] deviation/arithmetic 
mean), median, minimum, maximum, geometric mean, and geometric percent CV (calculated 
as 100 x sqrt( exp(s2) - 1), where s2 is the observed variance on the natural log- scale).  
11.2.4 Analysis Overview  
[IP_ADDRESS] Primary  Analyses 
Objective 1 : 
This analysis will include Period 1 data only. Separate ANOVA models will be constructed for each substrate in the microdose cocktail. Each model will include the natural logarithm of the AUC0 -∞ data as the dependent variable and a fixed effect term for subject  group (healthy  
subjects , mild, moderate, severe RI  subjects , and ESRD subjects ). AUC0 -∞ will be compared 
between each RI subject group and the healthy subject group by [CONTACT_173614] 95% confidence intervals. Sample SAS code is given below: 
proc mixed data=dataset;  
class group; model endpoint = group /ddfm=kr; lsmeans group / CIalpha = 0.05 run; Similar analyses will be conducted for the following pharmacokinetic parameter s: AUC0 -24, 
AUC0 -last, Cmax, and C24. For the other pharmacokinetic parameters, appropriate summary 
statistics will be provided.  
Objectives 2 to 6 : 
This analysis will include data from Period [ADDRESS_203070] received rifampin in Period 2. A linear 
mixed -effects model will be used and separate models will be constructed for each substrate 
in the microdose cocktail. Each model will include the natural logarithm of the AUC0 -∞ data 
as the dependent variable, with a fixed effect term for treatment (microdose only or microdose+rifampin), subject group (healthy  subjects , mild, moderate, or severe RI subjects  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203071] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 70 
CONFIDENTIAL  
only) and the interaction of the terms. An unstructured covariance matrix w ill be used to 
allow for unequal treatment variances and to model the correlation between the treatment 
measurements within each subject via the REPEATED statement in SAS PROC MIXED.  Kenward and Roger's method will be used to calculate the denominator degrees of freedom for the fixed effects (using the DDFM=KR option in SAS). The pharmacokinetic parameters 
will be compared between the different groups by [CONTACT_173615]. Sample SAS code is given below: 
proc mixed data=dataset;  
class treatment group subject;  
model endpoint = treatment group treatment*group /ddfm=kr; 
repeated treatment / subject=subject type=un;  
run; For each substrate in the microdose cocktail, the GMRs and corresponding 95% confidence 
intervals for the comparison of microdose cocktail + rifampin vs. microdose cocktail alone in 
each group of subjects will be computed from the model. Similar analyses will be conducted for the following pharmacokinetic parameters: AUC0 -24, 
AUC0 -last, Cmax , and C24. For the other pharmacokinetic parameters, appropriate summary 
statistics will be provided.  
Plots with the individual ratios, GMR and 95% confidence intervals will be provided for 
AUC0 -24, AUC0 -last, AUC0 -∞, Cmax, and C24. 
[IP_ADDRESS] Secondary Analyses 
Seco ndary objectives will estimate the effect of rifampin on the single oral dose 
pharmacokinetics (AUC0 -last, Cmax, and C24) using the same statistical models that were 
used to address the primary objectives  2 through 6 . These models will be used to estimate the 
differences with/without rifampin for each substrate. For example, from the model constructed for midazolam, a between treatment comparison of midazolam+rifampin and 
midazolam will be made  for each subject group (except subjects with ESRD). In addition, a 
comparison of the extent of the DDI between rifampin and each of the [ADDRESS_203072] s and each category of RI subjects  (with the 
exception of the ESRD ) will be conducted by [CONTACT_173616] 95% 
confidence intervals. 
A mixed effects model with period as fixed effect and subject as random effect  will be used 
to assess the impact of dialysis on the pharmacokinetic parameters of each of the substrates 
in the microdose cocktail by [CONTACT_173617] [ADDRESS_203073]  subjects.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203074] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 71 
CONFIDENTIAL  
[IP_ADDRESS] Exploratory Analyses for Biomarkers  
The exploratory objectives will be evaluated using the same statistical models that were used 
to address the primary and secondary objectives. Although no formal hypotheses will be tested, these models will be used to estimate the between -group differences amongst each 
substrate/perpetrator combination within a substrate. 
11.3 Safety Evaluation 
The safety will be evaluated by [CONTACT_173618]. Summary statistics for the laboratory safety tests, ECGs, pulse oximetry, 
and/or vital signs may also be computed and provided, as deemed clinically appropriate. 
   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203075] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203076] 
This protocol will be reviewed by [CONTACT_173619], Inc. IRB, and the study 
will not start until the IRB has approved the protocol or a modification thereof. The IRB is 
constituted and operates in accordance with the principles and requirements described in the US Code of Federal Regulations (21 CFR  Part 56). The IRB is compliant with the 
International Conference on Harmonization (ICH). 
12.1.[ADDRESS_203077] of the Study  
This research will be carried out in accordance with the protocol, US Code of Federal 
Regulations, Good Clinical Practices ( GCP ), 21 CFR  Parts  50, 56, and 312, the ethical 
principles set forth in the Declaration of Helsinki, and the ICH harmonized triparti te 
guideline regarding GCP (E6  Consolidated Guidance, April 1996). 
12.1.[ADDRESS_203078] receive the IRB approval/favorable opi[INVESTIGATOR_19349]. The subject should be informed in a timely manner if new information becomes av ailable that may be relevant to the subject’s willingness to continue participation 
in the trial. The communication of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the subject’s dated signature.  
The informed consent will adhere to IRB/Ethics Research Committee (ERC) requirements, applicable laws and regulations and Sponsor requirements. 
12.1.[ADDRESS_203079], answer all of his/her questions, and obtain written informed consent before 
performing any procedure related to the Future Biomedical Research sub -trial. A copy of the 
informed consent will be given to the subject.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203080] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 73 
CONFIDENTIAL  
12.2 Termination of the Study  
Celerion and/or [COMPANY_006] reserve the right to terminate the study in the interest of subject 
welfare.  
12.2.[ADDRESS_203081] of the clinical study. 
The CSR will be audited by [CONTACT_121295] (QA) department and the QA audit 
certificate will be included in the study report.  
All clinical data will undergo a 100%  quality control check prior to clinical database lock. 
Edit checks are then performed for appropriate databases as a validation routine using SAS
® 
to check for missing data, data inconsistencies, data ranges etc. Corrections are made prior to 
database lock.  
Case Report Forms ( CRFs ) are printed off directly from the database. Each CRF is reviewed 
and signed by [CONTACT_737]. 
12.[ADDRESS_203082] data. By [CONTACT_12570], the Investigator acknowledges that his/her 
electronic signature [CONTACT_26408] a written signature. By  [CONTACT_26394]/her electronic signature, the Investigator confirms that all recorded data have been 
verified as accurate.  
Detailed information regarding Data Management procedures will be outlined in Celerion 
Data Management Plan.  
12.[ADDRESS_203083] Access to Source Data/Documents  
Celerion will ensure that the Sponsor, IRB and inspection by [CONTACT_173620]- related sites, source data/documents, and reports 
for the purpose of monitoring and auditing (ICH[E6]  5.1.2 & 6.10). In the event that other  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203084] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203085] to allow 
completion of this study.  Celerion or sites will purchase midazolam 2 mg/mL syrup and rifam pin 300- mg capsules from commercially available supplies. The lot numbers and 
expi[INVESTIGATOR_1659] (where available) of the drugs supplied will be recorded in the final report. 
Records will be made of the receipt and dispensing of the drugs supplied. At the conclusion 
of the study, any unused drugs will be returned to the Sponsor  unless otherwise specified by 
[CONTACT_1034] . If no supplies remain, this fact will be documented in the  pharmacy product 
accountability records.  
12.[ADDRESS_203086] Keepi[INVESTIGATOR_121258]’s [COMPANY_006] library  CRFs will be supplied. 
12.8 Report Format  
According to the ICH Harmonized Tripartite Guideline (Organization of the Common Technical Document for the Registratio n of Pharmaceuticals for Human Use M4 and the 
ICH M2 Expert Working Group), the final report will be written according to the 
ICH E3 Guideline (Structure and Content of Clinical Study Reports). 
12.[ADDRESS_203087] the trial in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of GCP  
(e.g., International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice:  Consolidated Guideline and 
other generally accepted standards of good clinical practice); and all applicable federal, state and local laws, rules and regulations relating to the conduct of the clinica l trial.  
The Code of Conduct, a collection of goals and considerations that govern the ethical and scientific conduct of clinical investigations sponsored by [CONTACT_44873], is provided in Appendix  1. 
The Investigator also agrees to allow monitoring, audits, IRB/ERC review and regulatory 
authority inspection of trial -related documents and procedures and provide for direct access 
to all tr ial-related source data and documents.  
The Investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the Investigator by [CONTACT_1034].  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203088] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 75 
CONFIDENTIAL  
The Investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with GCP  standards and applicable federal, state and local laws, rules and 
regulations; and, for each subject participating in the trial, provide all data, and, upon 
completion or termination of the clinical trial, submit any other reports to the Sponsor as required by [CONTACT_121300]. 
Trial documentation will be promptly and fully disclosed to the S ponsor by [CONTACT_173621], 
copying, review and audit at reasonable times by [CONTACT_121302]. The Investigator agrees t o promptly take any reasonable steps that are 
requested by [CONTACT_14547] a result of an audit to cure deficiencies in the trial documentation and worksheets/case report forms. 
The Investigator must maintain copi[INVESTIGATOR_173554]. This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory authorities and IRBs/ERCs, consent forms, Investigator ’s 
curricula vitae, monitor visit logs, laboratory reference ranges, laboratory certification or quality control procedures and laboratory director curriculum vitae. By [CONTACT_12570], the Investigator agrees that documentation shall be retained until at least [ADDRESS_203089] consult 
with and obtain written approval by [CONTACT_26392]/or subject files.  
ICH GCP guidelines recommend that the Investigato r inform the subject’s primary physician 
about the subject’s participation in the trial if the subject has a primary physician and if the subject agrees to the primary physician being informed. 
The Investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this trial. Persons debarred from conducting or working on clinical trials by [CONTACT_19500]’s trials. The Investigator 
will immediately disc lose in writing to the Sponsor if any person who is involved in  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203090] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203091] 
of the Investigator’s knowledge, threatened. 
In the event the Sponsor prematurely terminates a pa rticular trial site, the Sponsor will 
promptly notify that trial site’s IRB/IEC.  
According to European legislation, a Sponsor must designate an overall coordinating 
Investigator [INVESTIGATOR_8178] a multi- center trial (including multinational). When more than one trial site is 
open in an EU country, [COMPANY_006], as the Sponsor, will designate, per country, a national principal coordinator (Protocol CI), responsible for coordinating the work of the Principal 
Investigators at the different trial sites in that Member State, according to national 
regulations. For a single -center trial, the Protocol CI is the Principal Investigator . In addition, 
the Sponsor must designate a principal or coordinating Investigator [INVESTIGATOR_130987], to the best of his/her knowledge, the report 
accurately describes the conduct and results of the trial [CSR CI]. The Sponsor may consider one or more factors in the selection of the individual to serve as the Protocol CI and or CSR CI (e.g., availab ility of the Protocol/CSR CI during the anticipated review process, thorough 
understanding of clinical trial methods, appropriate enrollment of subject cohort, timely achievement of trial milestones). The Protocol CI must be a participating trial Investiga tor. 
12.10 Publication Policy  
The Sponsor will provide separate guidance on the criteria for publication of clinical trial data when contact[CONTACT_121305]. 
12.11 Privacy Notice 
In order to comply with government regulations governing clinical studies, as  well as 
ICH GCP  3.2.1, [COMPANY_006] & Co., Inc., and its corporate affiliates ("Sponsor"), is required to 
record the name [CONTACT_173635]. The Sponsor is also required to document that each IRB or IEC me ets regulatory and 
ICH GCP requirements by [CONTACT_121306]/IEC members and to make these records available for regulatory agency review upon request by [CONTACT_19496] (ICH GCP  8.2.8).
   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203092] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 77 
CONFIDENTIAL  
13 REFERENCE S 
1. Sun H, Frasseto L, Benet LZ. Effects of renal failure on drug transport and metabolism. 
Pharmacol Therap. 2006;109:1–11. 
2. Prueksaritanont T, et al. Validation of a microdose  probe drug cocktail for clinical drug 
interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 
2017;101(4):519-530. 
3. Midazolam hydrochloride syrup, full prescribing information (electronic monograph) 
published on the Boehringer Ingelhe im/Roxane Laboratories, Inc. website 
(documentrevised: SEP/2012). 
4. Pradaxa® (dabigatran etexilate mesylate) capsules, monograph by [CONTACT_173622], Inc, full prescribing information (electronic monograph / revised 
November 2015) published on the FDA website. 
5. Hankey GJ, Eiklboom JW. Dabigatran Etexilate – A New Oral Thrombin Inhibitor. 
Circulation 2011;123:1436-1450. 
6. NDA 22 -512 for Boehringer Ingelheim GmbH dabigatran etexilate mesylate (Pradaxa®) 
110 and 150 mg capsules.  
7. Lipi[INVESTIGATOR_17133]®  (atorvastatin calcium) tablets, monograph by [CONTACT_4618], full prescribing 
information(electronic monograph / revised 2015) published on the FDA website. 
8. Neuvonen P.J., Niemi M., and Backman J.T., Drug Interactions with Lipid-Lowering 
Drugs: Mechanisms and Clinical Relevance. Clin Pharmacol Ther. 2006; 80(6):565-581. 
9. Livalo® (pi[INVESTIGATOR_173510]) tablets, monograph by [CONTACT_173623], 
full prescribing information (electronic monograph / revised October 2013) published on 
the FDA website.  
10. Crestor® (rosuvastatin calcium) tablets, full prescribing information 
(electronicmonograph) published on the Drugs@FDA website (document revised: 
07/2014). 
11. Martin PD, Mitchell PD, and Schneck DW. Pharmacodynamic effects and 
pharmacokinetics of a new HMG -CoA reductase inhibitor, rosuvastatin, after morning 
and evening administration in healthy volunteers. Br J Clin Pharmacol 2002; 54:472-477. 
12. Zhang W, et al. Role of BCRP 421C. A polymorphism on rosuvastatin pharmacokinetics 
in healthy chinese males. Clin Chim Acta 20 06; 373(1-2):99-103. 
13. NDA 21 -366 for [COMPANY_008] Rosuvastatin Calcium (Crestor®) 5, 10, 20 and 40 mg 
tablets.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203093] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 78 
CONFIDENTIAL  
14. Rifadin® (Rifampin capsules or for injection), monograph by [CONTACT_13225] -Aventis U.S. LLC, 
full prescribing information (electronic monograph / revised Febuary 2013) published on 
the FDA website.  
15. Gurumurthy P, Sarina GR, Jayasankar K, Thyagarajan K, Prabhakar R, Muthusetupathi 
MA, et al. Single dose pharmacokinetic of isoniazid and rifampi[INVESTIGATOR_173555]. Ind J Tub 1992; 39: 221-8. 
16. Acocella G. Clinical pharmacokinetics of rifampi[INVESTIGATOR_173556]. 1978; 
3(2):108-27. 
17. Ellard G.A. Chemotherapy of Tuberculosis for Patients with Renal Impairment. Nephron 
1993;64: 169–181. 
18. Malone RS, Fish DN, Spi[INVESTIGATOR_63724], Childs JM, Peloquin CA. The effect of hemodialysis 
on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med. 1999 
May;159(5 Pt 1): 1580-4. 
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203094] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 79 
CONFIDENTIAL  
Appendix 1: [COMPANY_006]* Code of Conduct for Clinical Trials  
I. Introduction 
A. Purpose  
[COMPANY_006], through its subsidiaries, conducts clinical trials worldwide to evaluate the 
safety and effectiveness of our products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding 
concern in the design of clinical trials. In all cases, [COMPANY_006] clinical trials will be conducted in compliance with local and/or national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.  
B. Scope  
Such standards shall be endorsed for all clinical interventional investigations sponsored by [CONTACT_121308] (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This Code is not 
intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code does not apply to Investigator- initiated trials which 
are n ot under the control of [COMPANY_006]. 
II. Scientific Issues  
A. Trial Conduct  
1. Trial Design  
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis- driven to assess safety, efficacy and/or pharmacokinetic or 
pharmacodynamic indices of [COMPANY_006] or comparator products. Alternatively, [COMPANY_006] 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine subject preferences, etc.  
The design (i.e., subject population, duration, st atistical power) must be adequate 
to address the specific purpose of the trial. Research subjects must meet protocol entry criteria to be enrolled in the trial.  
2. Site Selection  
[COMPANY_006] selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appr opriate 
subjects, adequacy of facilities and staff, previous performance in [COMPANY_006] trials, as well as budgetary considerations. Prior to trial initiation, sites are evaluated by [CONTACT_75396].  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203095] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 80 
CONFIDENTIAL  
3. Site Monitoring/Scientific Integrity  
Trial sites are monitored to assess compliance with the trial protocol and general 
principles of Good Clinical Practice. [COMPANY_006] reviews clinical data for accuracy, completeness and consistency. Data are verified versus source documentation according to standard operating procedures. Per [COMPANY_006] policies and procedures, if fraud, misconduct or serious GCP -non- Compliance are suspected, the issues are 
promptly investigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and data 
disclosed accordingly.  
B. Publication and Authorship  
To the extent scientifically appropriate, [COMPANY_006] seeks to publish the results of trials it conducts. Some early phase or pi[INVESTIGATOR_26346] -generating 
rather than hypothesis testing. In such cases, publication of results may not be appropriate since the trial may be underpowered and the analyses complicated by [CONTACT_121309].  
[COMPANY_006]’s  policy on authorship is consistent with the requirements outlined in the 
ICH-Good Clinical Practice guidelines. In summary, authorship should reflect 
significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named authors must be able to defend the trial results and conclusions. [COMPANY_006] funding of a trial will be acknowledged in publications.  
III. Subject Protection  
A. IRB/ERC review  
All clinical trials will be revie wed and approved by [CONTACT_75398]/ERC before 
being initiated at each site. Significant changes or revisions to the protocol will be approved by [CONTACT_1201]/ERC prior to implementation, except that changes required urgently to protect subject safety and we ll-being may be enacted in anticipation of 
IRB/ERC approval. For each site, the IRB/ERC and [COMPANY_006] will approve the subject informed consent form.  
B. Safety  
The guiding principle in decision- making in clinical trials is that subject welfare is of 
primary importance. Potential subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial designs will take into account the local standard of care. Subjects are never denied access to appropriate medical care based on participation in a [COMPANY_006] clinical trial.  
All participation in [COMPANY_006] clinical trials is voluntary. Subjects are enrolled only after providing informed consent for participation. Subjects may withdraw from a [COMPANY_006]  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203096] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203097] extent 
possible. Unless required by [CONTACT_2371], only the Inves tigator , Sponsor (or representative) 
and/or regulatory authorities will have access to confidential medical records that might identify the research subject by [CONTACT_2300].  
D. Genomic Research  
Genomic Research will only be conducted in accordance with informed consent and/or as specifically authorized by [CONTACT_75399].  
IV. Financial Considerations 
A. Payments to Investigators  
Clinical trials are time - and labor -intensive. It is [COMPANY_006]’s policy to compensate 
Investigator s (or the sponsoring institution) in a f air manner for the work performed 
in support of [COMPANY_006] trials. [COMPANY_006] does not pay incentives to enroll subjects in its trials. However, when enrollment is particularly challenging, additional payments may be made to compensate for the time spent in extra re cruiting efforts.  
[COMPANY_006] does not pay for subject referrals. However, [COMPANY_006] may compensate referring physicians for time spent on chart review to identify potentially eligible subjects.  
B. Clinical Research Funding  
Informed consent forms will disclose that the trial is sponsored by [CONTACT_44873], and that the Investigator or sponsoring institution is being paid or provided a grant for performing 
the trial. However, the local IRB/ERC may wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As noted above, publications resulting from [COMPANY_006] trials will indicate [COMPANY_006] as a source of funding.  
C. Funding for Travel and Other Requests  
Funding of travel by [CONTACT_10670] s and support staff (e.g., to scientific meetings, 
Investigator meetings, etc.) will be consistent with local guidelines and practices 
including, in the U.S., those established by [CONTACT_121310] (AMA).   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203098] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 82 
CONFIDENTIAL  
V.  Investigator Commitment 
Investi gator s will be expected to review [COMPANY_006]’s Code of Conduct as an appendix to the 
trial protocol, and in signing the protocol, agree to support these ethical and scientific 
standards. 
* In this document, "[COMPANY_006]" refers to [COMPANY_006] Sharp & Dohme Corp. and Scheri ng 
Corporation, each of which is a subsidiary of [COMPANY_006] & Co., Inc. [COMPANY_006] is known as MSD outside of the [LOCATION_002] and Canada. As warranted by [CONTACT_74647], [COMPANY_006] also includes affiliates and subsidiaries of [COMPANY_006] & Co., Inc.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203099] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 83 
CONFIDENTIAL  
Appendix 2: Collection and Management of Specimens for Future Biomedical 
Research  
1. Definitions  
a. Biomarker:  A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.
1 
b. Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as related to drug/vaccine response.
2 
c. Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the 
influence of variations in DNA sequence on drug /vaccine response.2 
d. DNA:  Deoxyribonucleic acid.  
e. RNA:  Ribonucleic acid.  
2. Scope of Future Biomedical Research  
The specimens consented and/or collected in this trial as outlined in Section 10.4 will be 
used in various experiments to understand: 
• The biology of how drugs/vaccines work 
• Bioma rkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489] 
• Other pathways drugs/vaccines may interact with  
• The biology of disease 
The specimen(s) may be used for future assay development and/or drug/vaccine 
development. 
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately improve public health through development of novel treatments targeted to populations with the greatest need. All specimens will be used by [CONTACT_121311].  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203100] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 84 
CONFIDENTIAL  
3. Summary of Procedures for Future Biomedical Research  
a. Subjects for Enr ollment 
All subjects enrolled in the clinical trial will be considered for enrollment in the 
Future Biomedical Research sub -trial. 
b. Informed Consent  
Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained during screening for pro tocol enrollment from all subjects or legal guardians, at a trial 
visit by [CONTACT_90094]. Informed consent for Future Biomedical Research should be presented to the subjects on the visit designated in the 
trial flow chart. If delayed, present consent at next possible Subject Visit. Consent forms signed by [CONTACT_173624].   
A template of each trial site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository. 
c. CRF Documentation for Future Biomedical Research Specimens  
Documentation of subject consent for Future Biomedical Research will be captured in 
the electronic Case Report Forms (CRFs). Any specimens for wh ich such an 
informed consent cannot be verified will be destroyed. 
d. Future Biomedical Research Specimen (s) 
Collection of specimens for Future Biomedical Research will be performed as outlined in the trial flow chart. In general, if additional blood speci mens are being 
collected for Future Biomedical Research, these will usually be obtained at a time when the subject is having blood drawn for other trial purposes. 
4. Confidential Subject Information for Future Biomedical Research  
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link subject' clinical information with future test results. In fact little or no research can be conducted without connecting the clinical trial data to the specim en. The clinical data allow specific analyses to be conducted. Knowing subject 
characteristics like gender, age, medical history and treatment outcomes are critical to understanding clinical context of analytical results.  
To maintain privacy of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor has developed secure policies and procedures. All specimens will be single -coded per ICH E15 guidelines as described below.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203101] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 85 
CONFIDENTIAL  
At the clinical trial site, unique codes will be pla ced on the Future Biomedical Research 
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between subject identifiers and this unique code will be held at the trial site. No personal identifiers will appear on the specimen tube. 
5. Biorepository Specimen Usage  
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices. Analyses utilizing the Future Biomedical Research specimens may be performed by [CONTACT_1034], or an additional third party (e.g., a university investigator) 
designated by [CONTACT_1034]. The investigator conducting the analysis will follow the Sponsor’s privacy and confidentiality requirements. Any contracted third party analys es 
will conform to the specific scope of analysis outlined in this sub -trial. Future Biomedical 
Research specimens remaining with the third party after specific analysis is performed will be reported to the Sponsor. 
6. Withdrawal From Future Biomedical Research  
Subjects may withdraw their consent for Future Biomedical Research and ask that their 
biospecimens not be used for Future Biomedical Research. Subjects may withdraw consent at any time by [CONTACT_59554] [INVESTIGATOR_75306]. If medical records for the main trial are still available, the investigator will contact [CONTACT_75355] (clinical.specimen.ma [EMAIL_3449]). 
Subsequently, the subject's specimens will be flagged in the biorepository and restricted 
to main study use only . If specimens were collected from study participants specifically 
for Future Biomedical Research, these specimens will be removed from the biorepository 
and destroyed. Documentation will be sent to the investigator confirming withdrawal 
and/or destruction , if applicable. It is the responsibility of the investigator to inform the 
subject of completion of the withdrawal and/or destruction, if applicable . Any analyses in 
progress at the time of request for withdrawal/destruction or already performed prior to 
the request being received by [CONTACT_90070]. No new analyses would be generated after the request is received.  
In the event that the medical records for the main trial are no longer available (e.g., if the investigator is no longer required by [CONTACT_121275]) or the specimens have been completely anonymized, there will no longer be a 
link between the subject’s personal information and their specimens. In this situation, the request for withdrawal of consent and/or destruction cannot be processed .  
7. Retention of Specimens  
Future Biomedical Research specimens will be stored in the biorepository for potential analysis for up to 20 years from the end of the main study. Specimens may be stored for longer if a regulatory or governmental authority has active questions that are being  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203102] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203103] results are accessible only to the authorized Sponsor representatives and the designated trial administrator research personnel and/or collaborators. Database user authentication is highly secure, and is accomplished using network security policies and practices based on international standards to protect against unauthorized access. 
9. Reporting of Future Biomedical Research Data to Subjects  
No information obtained from exploratory laboratory studies will be reported to the subject, family, or physicians. Principle reasons not to inform or return results to the subject include:  Lack of relevance to subject health, limitations of predictive capability, 
and concerns regarding misinterpretation. 
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to rapi[INVESTIGATOR_173557]. Subjects will not be identified by 
[CONTACT_173625] . 
10. Future Biomedical Research Study Population  
Every effort will be made to recruit all subjects diagnosed and treated on Sponsor clinical trials for Future Biomedical Research.  
11. Risks Versus Benefits of Future Biomedical Research  
The Sponsor has developed strict security, policies and procedures to address subject data privacy concerns. Data privacy risks are largely limited to rare situations involving possible breach of confidentiality. In this highly unlikely situation there is risk that the 
information, like all medical information, may be misused.   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203104] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 87 
CONFIDENTIAL  
12. Questions  
Any questions related to the future biomedical research should be e -mailed directly to 
[EMAIL_1250].  
13. References  
1. National Cancer Institute:  http://www.cancer.gov/dictionary/?searchTxt=biomarker  
2. International Conference on Harmonization:  DEFINITIONS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC DATA AND SAMPLE CODING CATEGORIES - E15; 
http://www.ich.org/LOB/media/MEDIA3383.pdf 
3. Industry Pharmacogenomics Working Group. Understanding the Intent, Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/  
4. Industry Pharmacogenomics Working Group. Pharmacogenomics Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203105] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 88 
CONFIDENTIAL  
Appendix 3: Sample Handling Instructions for Midazolam and Dabigatran Samples 
Supplies and Equipment  
1. Plastic Lavender Topped Vacutainers containing K 2EDTA as the anticoagulant . 
Capable of holding 4 - 5 mL of whole blood.  
2. 25% o-Phosphoric acid: Ricca Chemical Company (585116 or equivalent)   
3. Midazolam tubes: 3.6 mL NUNC Internal Thread Round Bottom Cryotubes (NUNC 
Part #366524).  
4. Dabigatran Tubes:  3.6 mL NUNC Internal Thread Round Bottom Cryotubes (NUNC 
Part #366524) containing 15 µL of 25% o- phosphoric acid per tube (any brand 
25% o- phosphoric acid solution is acceptable) . 
• 15 µL of the acid can be pre -pi[INVESTIGATOR_173558].  
Tubes should be stored upright at room temperature.   
5. Calibrated Adjustable Volume Pi[INVESTIGATOR_6343]:  Suitable for delivering volumes between 10-
200 µL and 100 -1000 µL. 
6. Disposable Plastic Pi[INVESTIGATOR_6343] : Suitable for delivering volumes between 10-200 µL and 
100 -1000 µL. 
7. Refrigerated Centrifuge. Capable of rotating between 1000 -1300 RCF (x g) at 
between 4oC to 10oC for 10 minutes. Note that RCF varies according to the centrifuge 
rotor radius. The formula for computing RCF from rotation speed and centrifuge 
radius is RCF = 11.2r(RPM/1000)2, where r is rotor radius, in cm, and RPM is the 
rotations per minute se tting of the centrifuge. A typi[INVESTIGATOR_173559] (GH -
3.8 model from Beckman) yields 1150 RCF at 2500 RPM, for example. 
8. -65oC to -85oC Sample Storage Freezer . 
Collection of Blood 
For specific time points of sample collection, please refer to the Study Flow Chart. 
Sample Labeling  
1. Whole Blood Samples. Vacutainers containing whole blood should be labeled (non-
barcoded) as appropriate.  
2. Plasma Samples . NUNC tubes containing plasma samples should be labeled with the 
pre-printed barcoded labels  with the  allocation number, day, date and time (hours 
postdose) provided by [CONTACT_1034]. Labels should be placed on the NUNC tubes 
toward the top 30% of the tube in order for the level of plasma in the tube to be  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203106] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 89 
CONFIDENTIAL  
viewed. Only one (1)  layer of label should be placed on the tube (not 2). This is 
critical for the proper functioning of the automated liquid handling station. 
Procedure  
1. Draw approximately 4 mL whole blood into plastic (PET) vacutainer containing 
K2EDTA as the anticoagulant and invert 6 times. The vacutainer should be labeled as 
appropriate (see above).  
2. Immediately after collection, the blood containing tubes should be placed on ice and centrifuged promptly at between 1000 -1300 RCF (x g) at between 4
oC to 10oC for 
10 minutes. Note that RCF varies ac cording to the centrifuge rotor radius. The 
formula for computing RCF from rotation speed and centrifuge radius is RCF  = 11.2r(RPM/1000)
2, where r is rotor radius, in cm, and RPM is the rotations per 
minute setting of the centrifuge.  If the samples cannot be centrifuged immediately, 
the tubes should be kept on ice and centrifuged within 30 minutes of collection. 
Note:  Be sure to account for rotor size variations by [CONTACT_173626] (RPM) for the specific centrifuge to yield between 1000- 1300 RCF (xg) as 
noted in the Supplies and Equipment section. 
3. Immediately after separation of the whole blood, carefully transfer the plasma into 
two tubes with pre -printed barcoded labels.  Transfer 0.6 mL plasma into the tube 
containing 15 µL of 25% O-Phosphoric acid for Dabigatran and the remaining plasma into the Midazolam labeled tube using calibrated pi[INVESTIGATOR_8462] s. Store at -65
oC to -85oC 
until transfer to Pharma Medica Research Inc. on DRY ICE.  
Note:   In the event that the whole blood samples cannot be processed immediately 
the samples should be kept on ice. No more than 60 minutes should elapse between blood draw and the freezing of plasma samples. 
Sample Shippi[INVESTIGATOR_173560], packaging, and/or shippi[INVESTIGATOR_173561] (IATA) regulations relating to the handling and shippi[INVESTIGATOR_173562]. 
1. All shipments will be made in freezer boxes  containing sufficient DRY ICE. 
2. Please include a sample inventory with each shipment.  
3. Samples should be sent at intervals to be determined by [CONTACT_66229]. Shipments should be sent on MONDAY or TUESDAY to assure receipt by [CONTACT_52385].   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203107] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 90 
CONFIDENTIAL  
4. Samples should be shipped to: 
Analytical Laboratory  
Pharma Medica Research Inc.  
[ADDRESS_203108] 
Mississauga, Ontario, Canada L5R 0B7  
Phone  
Fax  
 
Manager, Lab Operations Support 
 
 
Note:  Sample storage for this study is -65
oC to -85oC. 
  
  04VMX7
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203109] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 91 
CONFIDENTIAL  
Appendix 4: Sample Handling Instructions for Pi[INVESTIGATOR_2830], Atorvastatin (and 
metabolites), and Rosuvastatin Samples  
Supplies and Equipment  
1. Plastic Lavender Topped Vacutainers containing K 2EDTA as the anticoagulant . 
Capable of holding 3- 4 mL of whole blood.   
2. 3.6 mL NUNC Internal Thread Round Bottom Cryotubes (NUNC Part #366524). 
3. Calibrated Adjustable Volume Pi[INVESTIGATOR_173563]. Suitable for delivering volumes between 10-
200 µL, 100 -1000 µL, and 1.0 - 10.0 mL. 
4. Disposable Pi[INVESTIGATOR_173564]. Suitable for delivering volumes between 10-200 µL; 
100-1000 µL, and 1.0 – 10.0 mL. 
5. Refrigerated Centrifuge. Capable of rotating between 1000 -1300 RCF (x g) at 
between 4oC to 10oC for 10 minutes. Note that RCF varies according to the centrifuge 
rotor radius. The formula for computing RCF from rotation speed and centrifuge 
radius is RCF = 11.2r(RPM/1000)2, where r is rotor radius, in cm, and RPM is the 
rotations per minute setting of the centrifuge. A typi[INVESTIGATOR_173559] (GH -
3.8 model from Beckman) yields 1150 RCF at 2500 RPM, for example. 
6. -65oC to -85oC Sample Storage Freezer . 
7. Corning Pyrex Reusable Media Storage Bottle (250 mL):  Fisher Scientific Catalog #06-414-1B. To be used for buffer preparation. 
8. Ammonium acetate, certified ≥97%, 500 g; Fisher Scientific Catalog #A637-500 or 
equivalent.  
9. Acetic Acid, Glacial ≥97% (w/w%), 500 mL; Fisher Scientific Catalog #A35 -500 or 
equivalent. 
10. Water Optima, 1L; Fisher Scientific C atalog#W6 -1 or equivalent. 
11. Top loading digital balance capable of weights listed below. 
12. Glass cylinder for measuring liquid volume up to 250 mL. 
Procedures  
Preparation of 1M Ammonium acetate buffer, pH 5 
1. Weigh 19.25g of ammonium acetate.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203110] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 92 
CONFIDENTIAL  
2. Transfer the weighed ammonium acetate to the 250 -mL pyrex storage bottle and 
dissolve with 230 mL of bottled water (Optima). Mix. 
3. Pi[INVESTIGATOR_8459] 8.25 mL of glacial acetic acid into the mixture. Mix.  
4. Store refrigerated (~4 °C) when not in use  for up to 90 days after preparation . Let it 
stand at room temperature and mix before use.  
Sample Labeling  
Whole Blood Samples. Vacutainers containing whole blood should be labeled (non-
barcoded) as appropriate.  
Plasma Samples . NUNC tubes containing buffered plasma samples  should be 
labeled with the pre -printed barcoded labels  with the allocation number, day, date and 
time (hours postdose) provided by [CONTACT_1034]. Labels should be placed on the 
NUNC tubes toward the top 30% of the tube in order for the level of plasma in the tube to be viewed. Only one (1)  layer of label should be placed on the tube (not 2). 
This is critical for the proper functioning of the automated liquid handling station. 
Collection of Blood 
For specific time points of sample collection, please refer to the Study Flow Chart. 
1. Prior to blood draw, prepare the Nunc tube for plasma collection by [CONTACT_21173][INVESTIGATOR_42115] 50 µL 
of 1M ammonium acetate buffer (pH5)  into each tube. 
2. Draw approximately 3 mL whole blood into plastic (PET) vacutainer containing K
2EDTA as the anticoagulant and invert 6 times. The vacutainer should be labeled as 
appropriate (see above).  
3. Immediately after collection, the blood containing tubes should be placed on ice and centrifuged promptly at between 1000 -1300 RCF (x g) at between 4
oC to 10oC for 
10 minutes. Note that RCF varies according to the centrifuge rotor radius. The formula for computing RCF from rotation speed and centrifuge radius is RCF  = 11.2r(RPM/1000)
2, where r is rotor radius, in cm, and RPM is the rotations per 
minute setting of the  centrifuge. If the samples cannot be centrifuged immediately, 
the tubes should be kept on ice and centrifuged within 30 minutes of collection. 
Note:  Be sure to account for rotor size variations by [CONTACT_173626] (RPM) for the specific centrifuge to yield between 1000 -1300 RCF (xg) as 
noted in the Supplies and Equipment section. 
4. Immediately after separation of the whole blood, carefully transfer 1 mL  of the 
plasma using a pi[INVESTIGATOR_173565] a 3.6 mL internally -threaded NUNC cryotube contain ing 
50 µL of 1M ammonium acetate buffer (pH5)  identified with pre -printed barcoded 
labels (see above).   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203111] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 93 
CONFIDENTIAL  
5.  Vortex mix for approximately 10 seconds, and store at -65oC to -85oC until transfer 
to Pharma Medica Research Inc. on DRY ICE.  
Note:   In the event that the whole blood samples cannot be processed immediately 
the samples should be kept on ice. No more than 60 minutes should elapse 
between blood draw and the freezing of plasma samples. 
Sample Shippi[INVESTIGATOR_173566], packaging, and/or shippi[INVESTIGATOR_173561] (IATA) regulations relating to the handling and shippi[INVESTIGATOR_173562]. 
1. All shipments will be made in freezer boxes containing sufficient DRY ICE.  
2. Please include a sample inventory with each shipment.  
3. Samples should be sent at intervals to be determined by [CONTACT_66229]. Shipments should be  sent on MONDAY or TUESDAY to assure receipt 
by [CONTACT_52385].  
4. Samples should be shipped to: 
Analytical Laboratory  
Pharma Medica Research Inc.  
[ADDRESS_203112] Mississauga, Ontario, Canada L5R 0B7  
Phone  
Fax  
 
Manage r, Lab Operations Support 
 
 Note:   Sample storage for this study is -65
oC to -85oC. 
  
  04VMX7
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203113] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 94 
CONFIDENTIAL  
Appendix 5: Sample Handling Instructions for Rifampin Samples  
SAMPLE LABELING  
K2EDTA vacutainer tubes and plasma transfer vials (cryotubes) should be labeled with 
allocation number, period, day, date, and actual time (hours postdose). Bar -coded labels will 
be provided by [CONTACT_173627]. 
Place label toward the top 30% of the cryotube in order for the level of plasma in the tube to 
be viewed. Only one (1) layer of label should be placed on the tube (not 2). This is critical for 
the proper function of the automatic liquid handling station. 
SAMPLE COLLECTION, HANDLING, LABELING, STORAGE, AND SHIPMENT  
Blood samples will be collected in labelled 3 mL blood collection tubes containing K 2EDTA 
as the anticoagulant. The blood- containing tubes should be gently inverted 8 to 10 times and 
placed immediately in an ice water bath. The samples will be maintained in an ice bath 
throughout sample collection and until further processing. Within 240 minutes of collection, 
the blood samples will be centrifuged at 1700 g (approximately 3000 rpm) for approximately 10 minutes and at 4°C (2
oC to 8oC). Samples that are interrupted during centrifugation, 
disturbed during the separation process or exhibit inadequate separation will be re-spun under the same conditions in an attempt to separate the maximum amount of plasma from each sample. The samples will be maintained in an ice bath following centrifugation and until storage in the freezer.  
The plasma from each sample will be aliquoted into separately labelled cryotubes (3. 6 mL 
NUNC Internal Thread Round Bottom Cryotubes [NUNC Part #366524]). Cryotubes are 
immediately frozen or stored temporally on ice and frozen at -15
oC to -30oC within 180 
minutes from start of centrifugation. Plasma samples are stored in a freezer at -15oC to -30oC 
pending shipment. 
At the completion of the clinical portion of the study, the plasma samples will be packed on 
dry ice and sent to the analytical facility. The shipment of the plasma samples will be made in freezer boxes containing sufficient DRY ICE (and labeled as HUMAN S AMPLES:  
NONINFECTIOUS). All shipments will be made on Monday or Tuesday only.  
Clinic personnel will notify the analytical laboratory via e -mail prior to shipment with the 
following information:  
• Date of the shipment  
• Number and type of samples  
• Special h andling requirements and  
• Number of shippi[INVESTIGATOR_35275]  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203114] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 95 
CONFIDENTIAL  
This information will be e -mailed to: 
  
 
In addition, on the day of shipment, please notify inVentiv Health  Clinique  (at the e- mail 
coordinates above) of the shipment as well as the name [CONTACT_173636][INVESTIGATOR_173567]. The shipment will be accompanied by [CONTACT_173628]:  
 inVentiv Health Clinique  
 Attention: Sample Controller  
 2500 rue Einstein  
 Québec (Québec), Canada G1P 0A2  
 Phone:   Fax:    
  04VMX7
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203115] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 96 
CONFIDENTIAL  
Appendix 6: Sample Handling Instructions for Urine Collection  (Dabigatran and 
Rosuvastatin) 
Urine Collection Procedure 
Introduction 
Buffering urine in the urine collection procedure is required.  Buffer must be added to the 
original urine collection container after each void into the container.  Any sample transfers from the original sample container p rior to the addition of buffer must be avoided in that loss 
of drug and metabolite may occur.  Urine weights, rather than volumes, are determined in order to eliminate the need to pour the sample into a graduated cylinder before the addition of the buffer.  
Supplies and Equipment  
1. 24 hour Urine amber collection Jugs (from [COMPANY_003] for the biomarker urine collection) (or 
Nalgene Series 2105 Wide Mouth Bottles  may be used if for PK only).  These bottles are to 
be used for the actual urine collection, and are available in sizes ranging from 250 to 1000 mL.  Thus, the bottle size may be varied depending on the length of the collection interval.   The bottles are available in the [LOCATION_002] from Fisher Scientific.  Their catalog numbers are as follows:  
 30 mL bottle:  #02-893AA 
 60 mL bottle: #02-893BB  250 mL bottle:  #02-893B A list of Nalgene distributors for countries outside of the U.S. may be found on the World 
Wide Web at http://nalgenelab.nalgenunc.com/gen/order.html 
2.  Set of pi[INVESTIGATOR_173568] 0.25 mL and 20 mL. 
3.  4.5 mL NUNC cryotube vials (NUNC #363452 or Fisher #12-565-173N) 
4.  Corning Pyrex Reusable Media Storage Bottle (250 mL):  Fisher Scientific Catalog #06-
414-1B. To be used for buffer preparation. 
5.  Ammonium acetate, certified 97%, 500 g; Fisher Scientific Catalog #A637 -500 or 
equivalent.  6.  Acetic Acid, Glacial 97% (w/w%), 500 mL; Fisher Scientific Catalog #A35 -500 or 
equivalent. 7.  Water Optima, 1L; Fisher Scientific Catalog#W6 -1 or equivalent.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203116] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 97 
CONFIDENTIAL  
8.  Top loading digital balance capable of weights listed below. 
9.  Glass cylinder for measuring liquid volume up to 250 mL. 
 
Preparation of 1M Ammonium acetate buffer, pH 5 (Prepare fresh at the start of the 
study)  
1.  Weigh 19.25g of ammonium acetate. 
2. Transfer the weighed ammonium acetate to the 250 -mL pyrex storage bottle and dissolve 
with 230 mL of bottled water (Optima). Mix. 
3. Pi[INVESTIGATOR_8459] 8.25 mL of glacial acetic acid into the mixture. Mix.  
4.   Store refrigerated (~4°C) when not in use  for up to [ADDRESS_203117] the weight of the capped collection bottle 
and remove the biomarker aliquots (see Appendix 10),  then determine and record the weight 
of the capped collection bottle containing the pharmacokinetic urine specimen.  
5.  Subtract the weight of the empty bottle from the weight of the bottle containing the specimen in order to determine the weight of the specimen.  For additional collections within the interval, record the current weight and subtract the previous weight. 
6.  Record the weight of the specimen. 7.  Calculate the volume of 1M ammonium acetate buffer, pH 5 solution that needs to be 
added to the specimen.  The volume (mL) of buffer solution that needs to be added to the sample is calculated by [CONTACT_173629] 0.05.  For 
example, a specimen weighing 500 grams requires 25 mL of buffer solution to be added to it. 
8.  Add the calculated volume of buffer solution to the specimen after each void.  The 
volume of buffer solution added to the specimen should also be recorded.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203118] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 98 
CONFIDENTIAL  
Note that if urine collection volumes exceed 1 L for any given interval, separate additions of 
buffer (to each container within a collection interval) are to be completed as des cribed 
above, and the separate collections are to be combined after the solutions are mixed thoroughly. 
9. Cap the specimen bottle and shake the sample well.  
10. During each collection interval, s eparate collection  voids following addition of buffer 
are to be combined into a pooling container and stored at 4
oC. 
11. At the end of each collection interval, transfer a 3 mL aliquot of the buffer treated 
specimen into two  pre-labeled 4.5 mL NUNC tubes. 
12. The sample aliquots should be frozen at -65oC to -85oC prior to shipment on dry ice to 
Pharma Medica Research Inc. 
Sample Shippi[INVESTIGATOR_173569], packaging, and/or shippi[INVESTIGATOR_173561] (IATA) regulations relating to the handling and shippi[INVESTIGATOR_173562]. 
1.  All shipments will be made in freezer boxes containing sufficient DRY ICE. 
2. Please include a sample inventory with each shipment.  
3. Samples should be sent at intervals to be determined by [CONTACT_173630].  Shipments should be sent on MONDAY or TUESDAY to assure receipt by [CONTACT_52385].  
4. Samples should be shipped to: 
Analytical Laboratory  
Pharma Medica Research Inc.  
[ADDRESS_203119]  
Mississauga, Ontario, Canada L5R 0B7  
Phone  
Fax  
 
Manager, Lab Operations Support 
 
 
Note:   Sample storage for this study is -65
oC to -85oC.   
 
  
  04VMX7
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203120] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 99 
CONFIDENTIAL  
Appendix 7: PAXgeneTM Blood for DNA Analysis 
 
PAXge ne™ BLOOD F OR DNA ANALYSIS 
SPECIMEN COLLECTION PROCEDURE  
 
 
SPECIMEN COLLECTION NOTES* SCP -124-00  
 
*NOTE :  Refer to protocol flow chart or Specimen Collection Overview Chart for 
scheduled collection time points. 
 *NOTE :  Collection of specimens from vascular access devices and heparin or saline 
locks is not recommended due to the potential for specimen contamination. This 
specimen should be collected as a peripheral blood draw. 
 
Supplies and Materials (per patient, per time point)  
 
Provided to the Instituti on 
• Requisition for m/card 
• "PAXge ne Blood DNA" labe ls 
• One 8.5 mL PA Xgene™ Blood D NA coll ection tube (Cat#761115) 
 
Precautions  
 
* SAFETY PRECAUTION:  Contents of the PAXgene™ tube are irritating to skin. 
Wear disposable gloves, safety glasses or goggles and a laboratory coat and follow standard laboratory safety procedures while working with these tubes. If inhaled, supply fresh air; consult doctor in case of complaint s. If skin contact, immediately wash 
with water and soap, and rinse thoroughly. If contents make eye contact, rinse opened eye for 15 minutes under running water, then consult a doctor. If swallowed, immediately call a doctor.  
 
Required Equipment  
 
• Freezer for -20oC for PAXgene™ tube storage (For storage exceptions/monthly batch 
shipments). 
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203121] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203122] ace patient-spec ific label on the PA Xgene Blood DNA tube. 
 
2. If required :  Fill out the requis ition form/card appropriate ly (ensure that you 
follow specif ic processing in struc tions pe r the p rotocol specif ic Labora tory Procedure 
Manua l). 
 
Preparation  
 
1. Ensure the p atient has signe d the appropria te IRB/ ERC -approve d consent for 
gene tic specimen coll ection prior to  collecting  the specimen. 
 
2. Ensur e the P AXge ne™ Blood DNA coll ection tubes ar e at room t emperature prior 
to collecting  blood. 
 
*NOTE:   Do not use tubes after the expi[INVESTIGATOR_173570] l. 
 
3. The P AXge ne™ Blood DNA coll ection tubes should not be  the fi rst tubes drawn 
during v enipunc ture. It s hould be  the last tube  collected. 
 
Specimen Collection  
 
1. Collect blood into each P AXge ne™ Blood DNA coll ection tube vi a your 
institution 's recommended standard proce dure for venipunc ture. 
 
• Ensur e that the blood has stopped f lowing into the tube before removing 
the tube from the holder. 
• Each tube holds approximate ly 8.5 mL of blood. 
• Under-filling  of the tubes could result in a n incorrect blood- to-additive 
ratio and may lead to  poor pe rformance (e.g. poor qua lity or low qua ntity) 
 
2. Immediate ly after co llection, complete ly and gently invert the tube 10 times to 
mix unifor mly. 
 
 
 
  
*NOTE:   After each  tube is collec ted, it is CRIT ICAL to gently invert PAX gene™ 
10 times to ensure proper mixing  of blood  & PAX gene™ proprietary reagen t.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203123] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 101 
CONFIDENTIAL  
 
Specimen Processing & Handling  
 
1. W ithin 5-[ADDRESS_203124] plastic  
rack at ambient te mperature (18-25°C ). 
 
2. Tubes must be shipped within 24 hrs of collec tion to the laboratory at ambient 
temperature. 
 
Storage Exceptions (special circumstances only ) 
 
If storing specimens for batch shipment :  Specimen tubes MUST  be transf erred to 
a -20° C freeze r, in a wire or hard plastic rack in the upright position, after collection . 
Specimen t ubes may be stored frozen upright  at -20°C for no longer than 4 weeks  
at -20ºC. Tubes s tored at - 20°C mu st be shipped on  dry ice to  the Laboratory.  
 
*NOTE :  Any storage time and temperature excursions must be documented and 
communicated upon specimen shipment within the shipment inventory documents. 
 
*NO TE:  Frozen PAXg ene™ Blood DNA collection tubes are subject to breakage on 
impact. To reduce the risk of breakage during handling and shipment, frozen tubes 
should be treated in the same manner as glass tubes. If freezing is required, a wire or 
hard plastic rack should be used ( NO STYROFOAM ) as the tubes may cr ack. 
 
 
Packaging and Shippi[INVESTIGATOR_007]  
 
1. It is the responsibility of the primary investigator to ensure that all staff personnel 
who will be handling, packaging, and/or shippi[INVESTIGATOR_173571].  
2. F ollow packing and shippi[INVESTIGATOR_173572]. 
 
3. Contact [CONTACT_11675][INVESTIGATOR_173573]/forms required for shipment.  
4. Ship to the Laboratory within 24 hr of the blood draw. 
 
5. Shippi[INVESTIGATOR_173574]  – Select overnight or priority delivery and ensure that shipments 
are received at the destination vendor Monday through Friday, except on U.S. 
holidays. Shipments can be received on Saturday with advanced notification. Contact 
[CONTACT_173631][INVESTIGATOR_173575].  
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203125] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 102 
CONFIDENTIAL  
*NOTE:  For storage exceptions where ambient shipment was not possible, and 
specimens were frozen ( -20°C), always ship frozen specimens on DRY ICE. 
 
Shippi[INVESTIGATOR_86894]:  
BioProcessing Solutions Alliance  
Attn:  CommStaff  
Nelson Biological Laboratories  
[ADDRESS_203126], New Jersey [ZIP_CODE], [LOCATION_003] 
Tel.:   
Email:   
 
  
  04VMX7
[COMPANY_003]
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203127] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 103 
CONFIDENTIAL  
Appendix 8: Prohibited and Allowed Medications for Subjects with RI  
Systemically absorbed drugs specifically prohibited in the exclusion criteria are not allowed 
during the ongoing trial. Listed below are some specific restrictions for concomitant therapy use during the course of the trial. If there is  a clinical indication for one of these or other 
medications specifically prohibited during the trial, discontinuation from trial therapy may be required. The Investigator should discuss any questions regarding this with the Sponsor Clinical Monitor. The final decision on any supportive therapy rests with the Investigator and/or the subject's primary physician. However, the decision to continue the subject on trial therapy requires the mutual agreement of the Investigator, the Sponsor and the subject. 
The f ollowing medications/therapi[INVESTIGATOR_173576]:  
Strong and moderate CYP3A/P -gp inhibitors, including but not limited to:  
• Antibiotics: clarithromycin, erythromycin, telithromycin  
• Antifungals: itraconazole, ketoconazole, voriconazole 
• Antihy pertensives: nifedipi[INVESTIGATOR_050] 
• Nefazodone 
Strong and moderate CYP3A/P- gp inducers, including but not limited to:  
• Anti-infectives: nafcillin, rifampin  
• Anticonvulsants: carbamazepi[INVESTIGATOR_050], phenytoin, phenobarbital 
• Bosentan  
• Modafinil 
• St. John's wort  
OATP inhibitors, including but not limited to:  
• Immunosuppressants: cyclosporine 
• Anti-infectives: rifampin, ritonavir, atazanavir, saquinavir, tipranavir, lopi[INVESTIGATOR_054] 
• Diabetes agents: glibeclamide, glyburide  
• Lipid lowering agents: gemfibrozil 
• Eltrombopag 
• Lapatinib  
All HMG -CoA reductase inhibitors (statins)  
In general, CYP3A4 substrates with narrow therapeutic ranges (e.g., warfarin, amiodarone,  
flecainide, propafenone, quinidine, fentanyl, sildenafil or tadalafil when used for the  
treatment of pulmonary arterial hypertension) are not prohibited but their levels have the  
potential to be increased by [CONTACT_3450] 30%. Therefore, subjects taking these  medications 
should be monitored closely or dose adjusted appropriately.  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203128] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203129] study drug administration and is anticipated to remain stable during the study.  
• Proton Pum p Inhibitors  
Note:  Proton pump inhibitors  must be withheld [ADDRESS_203130] dosing. 
• Anti -hypertensive agents , including mono- or combination therapy with an 
angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, 
a betablocker, a calcium -channel blocker or a diuretic (e.g., lisinopril, ramipril, 
candesartan, irbesartan, olmesartan, hydrochlorothiazide, furosemide, or nitrates). 
Note:  Diuretics must be withheld [ADDRESS_203131] 
dosing. 
• Medications for treatment of diabetes  such as insulin, sulfonylureas (e.g., 
tolbutamide, glipi[INVESTIGATOR_7130], glimepi[INVESTIGATOR_14956], metformin, saxagliptin, sitagliptin), meglitinides 
(e.g., repaglinide, nateglinide), thiazolidinediones, dipeptidyl peptidase- 4 inhibitors, 
and glucagon- like peptide -1 analogs.  
• Iron . 
• Vitamin D  
• Thyroid hormone replacement . 
• Acetaminophen (up to 2 g per 24 -hour period) . 
• Phosphate binders containing aluminum, calcium or lanthanum salts; iron 
supplements or other metal catio ns; antacids; or multivitamins containing iron 
or zinc.   
Note:  These drugs  must be withheld [ADDRESS_203132] 
dosing.  
   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203133] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 105 
CONFIDENTIAL  
Appendix 9: Specimen Collection Procedure – Plasma and Serum  Biomarkers  
STANDARD & K2EDTA P  L AS M A  
SPECIMEN C O L L E C T I ON PROCEDURE  
 
 
SPEC IMEN COLLECTION NOT ES*                           SCP107- 00 
 
*NOTE : Refer to protocol flow chart for sche duled collect ion time poin ts. 
 
*NOTE:  Collection of specimens from a vascular access device or heparin / saline 
locks is not recommended due to the potential for specimen contamination.  This 
specimen should be collected as a peripheral blood draw. 
 The collection procedures below are for the following collections: 
 
Sample Type  (Per Tube)  Approximate Volume per 
Time Point *  
(mL)  Shippi[INVESTIGATOR_173577]  2 [COMPANY_003]  
Blood for serum creatinine  2 [COMPANY_003]  
Blood for plasma coproporhyrin  I and III  2  [COMPANY_003]  
Blood for plasma p -cresol sulfate, indoxyl sulfate, 
and CMPF   2 TMB/MRL  
Blood for plasma GDCA -S, GCDCA- S, DCA- S, 
TCDC- S, and TCDA -S 2 Metabolon  
Blood for protein binding^ 3 TMB/MRL  
 
 
Supplies and Material s (per pat ient, per time point)  
 
Provi ded to the Insti tution for total and direct bilirubin , creatinine , 
and coproporhyrin I and III  (kits from [COMPANY_003]):  
• Requisition forms  
• Requisition forms for K 2EDTA Plasma  
• Shipment notification forms  
• Supply re -order forms  
• Shippi[INVESTIGATOR_173578]  
• K2EDTA Vacutainer collection tubes   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203134] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 106 
CONFIDENTIAL  
• Transfer pi[INVESTIGATOR_6343]  
• 15mL amber polypropylene conical tubes  
• 2.0mL amber or regular Eppendorf microcentrifuge tubes  
• Preprinted return air bills  
• Collection Flow Charts  
 
*NOTE : Kits and materials provided by [CONTACT_173632]. Laboratory manuals, instructions, and collection flow charts should be followed.   
 
*NOTE : For int ernational shipment s, [COMPANY_006] approved couri ers must be used.  
The s elected courier w ill provide t he air bill and customs documenta tion 
at the time your packa ge is pic ked up. 
 
Insti tution to procure for (p-cresol sulfate, indoxyl sulfate, and 
CMPF), ( GDCA-S, GCDCA-S, DCA- S, TCDC-S, and 
TCDA-S), and protein binding:  
• K2EDTA Vacutainer collection tubes  
• Transfer pi[INVESTIGATOR_6343]  
• 15mL polypropylene conical tube  
• Appropriate number of 2.0mL Eppendorf microcentrifuge tubes  
• Other supplies as needed, per site decision 
 
Required Equipment  
 
• Refrigerated centrifuge (4 º C) 
 
Labeling  
 
 
• Place patient- specific labe ls on the 15mL collection tube and the 2mL microcentrifuge 
tubes 
 
 
• If applicable, fill out the requisition form/ card appropriatel y (ensure that 
you follow specific proce ssing  instruc tions per t he protocol specific  Labora tory 
Procedur e Manual ). 
 
 
Specimen Collection  
 
 
 
Total and direct bilirubin , creatinine , (p-cresol sulf ate, indoxyl sulfate, 
and CMPF), ( GDCA-S, GCDCA- S, DCA-S, TCDC-S, and 
TCDA-S), and protein binding :  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203135] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 107 
CONFIDENTIAL  
 
For all subjects, blood samples will be collected in 2 mL K2EDTA Vacutainer  
tubes blood collection tubes containing no additive at scheduled time points as 
delineated in the Study Events Flow Chart ( Section  6). 
 
Coproporhyrin I and III:   
 
Patients should sit in a room with low fluorescent lighting for all biomarker and PK 
blood draws.  Lighting should be as low as possible but light enough for the 
collection to be done safely and effectively.   
 
CPI/CPI[INVESTIGATOR_173579]. Exposure to ambient light should be minimized to the greatest extent possible during sample collection and processing.  Precautions will include covering collection and processing tubes with aluminum foil. 
 
•  Collect 2mL of whole blood in the pre -labeled K 2EDTA Vacutainer.  The p re-
labeled K 2EDTA Vacutainer  tubes for Coproporhyrin I/III should be covered in 
aluminum foil.  Fill the collection tube completely or until blood flow stops to 
ensure adequate anticoagulant/blood ratios. 
 
*NOTE : Allow vacuum to be exhausted prior to removing vacutainer from needle. 
To prevent backflow of chemical additives from the vacutainer, keep the height of the vacutainer at or below the level of the blood draw site and do not allow the 
contents of the vacutainer to contact [CONTACT_173633].    
 
 
• After colle ction, gently inver t the K2EDTA Vacuta iner tube  10 times to ensure 
proper mixing of anti-coagulant additive . 
 
 
 
Specimen Proce ssing & Handling  
 
 
Total and direct bilirubin , creatinine , (p-cresol sulf ate, indoxyl sulfate, 
and CMPF), ( GDCA-S, GCDCA- S, DCA-S, TCDC-S, and 
TCDA-S), and protein binding:  
 
Following blood collection, each blood sample will be gently inverted 5 times and samples will be allowed to clot at room temperature (for at least 60  minutes).  
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203136] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 108 
CONFIDENTIAL  
Within 60- 90 minutes of collection, the content of the tubes will then be 
centrifuged (approx imately at 1100 -1300 x g for 10  minutes) under refrigeration at 
a temperature of 4°C to separate the serum.  
 
Aliquot serum in a cryo/transfer tube (or equivalent).  
Coproporhyrin I and III:   
 
Processing should occur  in a room with low fluorescent lighting for all biomarker 
and PK samples.  Lighting should be as low as possible but light enough for the 
procedures to be done effectively.   
 
CPI/CPI[INVESTIGATOR_173579]. Exposure to ambient light should be minimize d to 
the greatest extent possible during sample collection and processing.  Precautions will include covering collection and processing tubes with aluminum foil. 
 
*NO TE: The K
2EDTA Vacutainer tubes should be processed immediately, or 
within [ADDRESS_203137] the tubes on ice until centrifugation.  
 
• Centrifuge the K 2EDTA Vacutainer   in a r efrigerated at 4°C the K 2EDTA 
Vacutainer for 10 minutes at 1,300 x g. 
 
 
 *NO TE: The RCF (Relative centrifugal force) varies according to the 
centrifuge rot or radius.  The f ormula f or computing RCF from rota tion speed 
and centrifuge radius is RCF = 11.2r ( RPM/1000)2, wher e r is rotor radius, in 
cm, and RPM is the rota tions pe r minut e setting of the centrifuge. 
 
 
• Without disturbi ng the bottom red blood cell layer, slowly and carefully 
collect t he plasma from the top layer of t he tube (approx imatel y 1/2 the original 
blood volume) usi ng a transfer pi[INVESTIGATOR_173580], and transfer the plasma into a pre-
labelled 15mL polypropylene collection tube.  Discard the remaining red blood 
cell layer appropriately.  
*NOTE: Do not try to remove all the possible plasma.  Stay about [ADDRESS_203138] 
from the red blood layer to avoid contamination of plasma with the red bl ood 
cell layer at the bottom of the tube.  
 
• Mix the plasma in the foil covered 15mL collection tube by [CONTACT_8536] 5- 6 times, 
and then transfer equal volumes to the two (2) pre-labelled 2mL microcentrifuge 
tubes. 
 
All pla sma aliquots  MUST be frozen  upright immed iately at -80oC or lower and 
mainta ined in the frozen state duri ng shipment.  Please protect from ligh t. 
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203139] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 109 
CONFIDENTIAL  
 
Specimen Storage (All samples)  
 
 
• The specimens can e ither be store d frozen over night at the s ite at -80oC or 
lower  and then shipped nex t day or store d at -80oC or lower  to accommodate 
batch shipment (e.g. wee kly or monthly). 
 
• Avoid any freeze- thaw cycles  
 
• Any temperature excursions should be documented and communicated upon 
specimen shipment within the shipment inventory documents. 
 
Reminder:  CPI/CPI[INVESTIGATOR_173579]. Exposure to ambient light should be 
minimized to the greatest extent possible during sample collection and processing.  Precautions will include covering collection and processing tubes with aluminum foil. 
 
 
Packaging and Shippi[INVESTIGATOR_007] (All samples)  
 
 
 
1. It is the responsibility of the primary investigator to ensure that all staff personnel 
who will be handling, packaging, and/or shippi[INVESTIGATOR_173581]. 
2. Contact [CONTACT_11675][INVESTIGATOR_173573]/forms required for shipment. 
3. Follow packing and shippi[INVESTIGATOR_173582]/or shippi[INVESTIGATOR_173583].  
4. All shipments should be made in freezer boxes containing sufficient DRY ICE, and 
labeled as HUMAN SAMPLES: NONINFECTIOUS  
*NOTE : The packaging and shippi[INVESTIGATOR_173584]/or 
shippi[INVESTIGATOR_173585].  
5. Include a specimen inventory form with each shipment.  
6. Shipments should be sent on a MONDAY or TUESDAY only to assure rec eipt by 
[CONTACT_52385].   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203140] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 110 
CONFIDENTIAL  
7. Ship  pre-labelled 2mL microcentrifuge tubes  appropriately to all of the following 
addresses:  
Address I  (plasma p- cresol sulfate, indoxyl sulfate, and CMPF ) and protein 
binding: 
 
TMB/  [COMPANY_006] Research Laboratories  
KW015C-C302-[ADDRESS_203141] Kenilworth, NJ [ZIP_CODE] 
 
 
 Address II  (plasma coproporhyrin I/ III, serum total and direct bilirubin, and 
serum creatinine): [COMPANY_003]   
Central Labs Attn:  
[ADDRESS_203142]  
Highland Heights, KY [ZIP_CODE]  Address III  (GDCA -S, GCDCA-S, DCA-S, TCDC -S, and TCDA -S): 
 
Metabolon [ADDRESS_203143]  Morrisville, NC [ZIP_CODE] [LOCATION_002] 
 
   
  04VMX7
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203144] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 111 
CONFIDENTIAL  
Appendix 10: Sample Handling Instructions for Urine Collection (Biomarkers)  
URINE:  
SPECIMEN COLLECTION PROCEDURE  
 
SPECIMEN COLLECTION NOTES*                          SCP108 -00 
 
*NOTE : Refer to the protocol flow chart for scheduled collection time points.  
The collection procedures below are for the following collections: 
 
Urine Biomarker Sample Type  Number of 
Samples (Aliquots)  Shippi[INVESTIGATOR_173586]  I and III  2 [COMPANY_003]  
Urine  p-cresol sulfate, indoxyl sulfate, and 
CMPF   1 TMB/MRL  
 
Supplies and Materials (per patient, per time point)  
 
 
Provided to the Institution:  
 
• 24 hour Urine amber collection jugs  (should be also used for PK urine collection if possible)  
• 120mL amber Urine collection cups  
• 15mL amber polypropylene conical tubes  
• 2.0mL amber Eppendorf microcentrifuge tubes (for urine coproporhyrin I/III) 
• Boxes for storage of the 2.0 mL microcentrifuge tubes 
 
*NOTE : Kits and materials provided by [CONTACT_173632] .  Laboratory manuals, instructions, and 
collection flow charts should be followed.   
 
Required Equipment (provided by [CONTACT_977])  
 
• 2.0mL Eppendorf microcentrifuge tubes (for urine p- cresol sulfate, indoxyl sulfate, and 
CMPF)  
• -70oC or lower freezer for sample storage 
• Restroom with a toilet for the donor to have privacy while providing the urine specimen (single toilet restroom preferred)  
• Source of water for washing hands 
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203145] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page [ADDRESS_203146] one on each of the polypropylene centrifuge tube s, and the 2.0mL 
microcentrifuge tubes.  
2. Fill out the Central Laboratory requisition form/card or [COMPANY_006] Inventory Form appropriately. 
 
Specimen Collection  
 
Patients should sit in a room with low fluorescent lighting for all biomarker and PK urine 
collections .  Lighting should be as low as possible but light enough for the collection to 
be done safely and effectively.   
 CPI/CPI[INVESTIGATOR_173579]. Exposure to ambient light should be minimized to the 
greatest extent possible during sample collection and processing.  Precautions will 
include covering collection and processing tubes wi th aluminum foil.  
 
 
The labeled amber urine collection cup will have been provided to patient with verbal instructions 
on collecting ( also see Appendix 6).   
 
NOTE:  The amber collection tube will be used for collection of all urine and further processed 
and aliquoted for PK and biomarkers.   
 
Specimen Processing & Handling  
 
Processing should occur  in a room with low fluorescent lighting for all biomarker and PK 
processing.  Lighting should be as low as possible but light enough for the procedures to 
be done effectively.   
 
CPI/CPI[INVESTIGATOR_173579]. Exposure to ambient light should be minimized to the 
greatest extent possible during sample collection and processing.  Precautions will 
include covering collection and processing tubes with aluminum foil  if they are not 
provided as amber. 
 
 
*NOTE : Begin processing immediately after collection, or within maximum of 30   minutes of 
collection. Keep samples on ice at all times until frozen.  Freeze samples at -70oC or lower  
immediately after processing.  
 
  
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203147] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 113 
CONFIDENTIAL  
1. From the urine collected at time points in the flow chart, before PK processing with buffer, 
transfer 1.0mL of urine to each the pre-labelled 2.0mL microcentrifuge tubes ( two amber for 
[COMPANY_003] and one non- amber for [COMPANY_006]). 
 
2. Transfer all urine samples in upright position to the provided boxes for -80oC or lower freezer 
storage until shipment on dry ice.  
3. Discard any remaining urine per site guidelines.  
 
Specimen Storage  
 
1. Store the specimens in at -80oC or lower until shipment to [COMPANY_006] / Central Laboratory 
on DRY ICE.  
2. Any temperature excursions should be documented and communicated upon specimen shipment within the shipment inventory documents. 
 
*NOTE : Frozen tubes are subject to breakage on impact. To reduce the risk of  
breakage during handling and shipment, please package appropriately (i.e. place storage tubes 
in appropriately sized sample box). 
 
 
1. It is the responsibility of the primary investigator to ensure that all staff personnel 
who will be handling, packaging, and/or shippi[INVESTIGATOR_173587]. 
2. Contact [CONTACT_11675][INVESTIGATOR_173573]/forms required for shipment. 
3. Follow packing and shippi[INVESTIGATOR_173582]/or shippi[INVESTIGATOR_173583].  
4. All shipments should be made in freezer boxes containing sufficient DRY ICE, and 
labeled as HUMAN SAMPLES: NONINFECTIOUS  
*NOTE : The packaging and shippi[INVESTIGATOR_173584]/or 
shippi[INVESTIGATOR_173585]. 
5. Include a specimen inventory form with each shipment.  Packaging and Shippi[INVESTIGATOR_007]   
  04VMX7
MK-0000  [COMPANY_006] Protocol No.:  MK-0000-386-[ADDRESS_203148] No.:  CA21005 
[COMPANY_006]   
 
CA21005_(MK-0000-386-02)_Amendment_2_Protocol_26Feb2018 Page 114 
CONFIDENTIAL  
6. Shipments should be sent on a MONDAY or TUESDAY only to assure receipt by 
[CONTACT_52385].  
7. Ship pre -labelled 2.0mL microcentrifuge tubes (one non- amber for TMB/ [COMPANY_006] and 
two amber for [COMPANY_003]) to both of the following addresses: 
 
Address I  (urine p-cresol sulfate, indoxyl sulfate, and CMPF): 
 
TMB/ [COMPANY_006] Research Laboratories 
KW015C-C302-[ADDRESS_203149] Kenilworth, NJ [ZIP_CODE] 
 
 
 Address II  (urine coproporhyrin I/ III): 
[COMPANY_003]  
Central Labs Attn:  
[ADDRESS_203150]  
Highland Heights, KY [ZIP_CODE] 
 
 
 
 
 
  
  04VMX7
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]